0001628280-21-009306.txt : 20210506 0001628280-21-009306.hdr.sgml : 20210506 20210506161411 ACCESSION NUMBER: 0001628280-21-009306 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 21897923 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 10-Q 1 auph-20210331.htm 10-Q auph-20210331
false2021Q1000160062012-3100016006202021-01-012021-03-31xbrli:shares00016006202021-05-06iso4217:USD00016006202021-03-3100016006202020-12-310001600620us-gaap:LicenseMember2021-01-012021-03-310001600620us-gaap:LicenseMember2020-01-012020-03-310001600620us-gaap:ProductMember2021-01-012021-03-310001600620us-gaap:ProductMember2020-01-012020-03-3100016006202020-01-012020-03-310001600620us-gaap:RetainedEarningsMember2020-01-012020-03-31iso4217:USDxbrli:shares0001600620us-gaap:CommonStockMember2020-12-310001600620us-gaap:AdditionalPaidInCapitalMember2020-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001600620us-gaap:RetainedEarningsMember2020-12-310001600620us-gaap:CommonStockMember2021-01-012021-03-310001600620us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001600620us-gaap:RetainedEarningsMember2021-01-012021-03-310001600620us-gaap:CommonStockMember2021-03-310001600620us-gaap:AdditionalPaidInCapitalMember2021-03-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001600620us-gaap:RetainedEarningsMember2021-03-310001600620us-gaap:CommonStockMember2019-12-310001600620us-gaap:AdditionalPaidInCapitalMember2019-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001600620us-gaap:RetainedEarningsMember2019-12-3100016006202019-12-310001600620us-gaap:CommonStockMember2020-01-012020-03-310001600620us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001600620us-gaap:CommonStockMember2020-03-310001600620us-gaap:AdditionalPaidInCapitalMember2020-03-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001600620us-gaap:RetainedEarningsMember2020-03-3100016006202020-03-31auph:segmentauph:reportingUnitxbrli:pure0001600620auph:SpecialtyPharmacyOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001600620auph:SpecialtyPharmacyTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001600620us-gaap:AccountingStandardsUpdate201815Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001600620auph:CashableGuaranteedInvestmentCertificatesMember2021-03-310001600620auph:CashableGuaranteedInvestmentCertificatesMember2020-12-310001600620auph:ShortTermCorporateDebtSecuritiesMember2021-03-310001600620auph:ShortTermCorporateDebtSecuritiesMember2020-12-310001600620us-gaap:CommercialPaperMember2021-03-310001600620us-gaap:CommercialPaperMember2020-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2021-03-310001600620us-gaap:USTreasuryBillSecuritiesMember2020-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2021-03-310001600620us-gaap:USTreasuryBondSecuritiesMember2020-12-310001600620auph:YankeeBondMember2021-03-310001600620auph:YankeeBondMember2020-12-310001600620us-gaap:CorporateBondSecuritiesMember2021-03-310001600620us-gaap:CorporateBondSecuritiesMember2020-12-310001600620us-gaap:PatentsMember2021-01-012021-03-310001600620us-gaap:PatentsMember2021-03-310001600620us-gaap:IntellectualPropertyMember2021-01-012021-03-310001600620us-gaap:IntellectualPropertyMember2021-03-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2021-01-012021-03-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2021-03-310001600620us-gaap:PatentsMember2020-01-012020-12-310001600620us-gaap:PatentsMember2020-12-310001600620us-gaap:IntellectualPropertyMember2020-01-012020-12-310001600620us-gaap:IntellectualPropertyMember2020-12-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2020-01-012020-12-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2020-12-3100016006202020-01-012020-12-310001600620us-gaap:ConstructionInProgressMember2021-03-310001600620us-gaap:ConstructionInProgressMember2020-12-310001600620us-gaap:LeaseholdImprovementsMember2021-03-310001600620us-gaap:LeaseholdImprovementsMember2020-12-310001600620us-gaap:OfficeEquipmentMember2021-03-310001600620us-gaap:OfficeEquipmentMember2020-12-310001600620us-gaap:ComputerEquipmentMember2021-03-310001600620us-gaap:ComputerEquipmentMember2020-12-31utr:sqft0001600620auph:VictoriaBritishColumbiaMember2020-12-310001600620auph:VictoriaBritishColumbiaMember2021-03-310001600620auph:VictoriaBritishColumbiaMember2020-08-310001600620auph:RockvilleMarylandMember2021-03-31auph:extension_option0001600620auph:RockvilleMarylandMember2021-01-012021-03-310001600620auph:RockvilleMarylandMember2020-12-310001600620auph:RockvilleMarylandMember2020-01-012020-12-310001600620auph:RockvilleMarylandMember2020-03-1200016006202021-02-012021-02-280001600620us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel1Member2021-03-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:DemandDepositsMember2021-03-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:DemandDepositsMember2021-03-310001600620us-gaap:DemandDepositsMember2021-03-310001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-03-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-03-310001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-03-310001600620us-gaap:MoneyMarketFundsMember2021-03-310001600620us-gaap:FairValueInputsLevel1Member2021-03-310001600620us-gaap:FairValueInputsLevel2Member2021-03-310001600620us-gaap:FairValueInputsLevel3Member2021-03-310001600620us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:DemandDepositsMember2020-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:DemandDepositsMember2020-12-310001600620us-gaap:DemandDepositsMember2020-12-310001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001600620us-gaap:MoneyMarketFundsMember2020-12-310001600620us-gaap:FairValueInputsLevel1Member2020-12-310001600620us-gaap:FairValueInputsLevel2Member2020-12-310001600620us-gaap:FairValueInputsLevel3Member2020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-172020-12-170001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-170001600620us-gaap:LicenseAgreementTermsMembersrt:MinimumMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-170001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMembersrt:MaximumMember2020-12-170001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-012020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2021-01-012021-03-310001600620us-gaap:PerformanceSharesMembersrt:OfficerMember2021-03-310001600620us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001600620us-gaap:WarrantMember2021-01-012021-03-310001600620us-gaap:WarrantMember2020-01-012020-03-310001600620us-gaap:PerformanceSharesMembersrt:OfficerMember2020-10-232020-10-230001600620us-gaap:PerformanceSharesMembersrt:OfficerMember2021-03-182021-03-180001600620us-gaap:PerformanceSharesMembersrt:OfficerMember2021-01-012021-03-310001600620us-gaap:PerformanceSharesMembersrt:OfficerMember2020-01-012020-03-310001600620us-gaap:PerformanceSharesMembersrt:OfficerMember2020-12-310001600620us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001600620us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001600620us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001600620us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001600620us-gaap:InventoriesMember2021-01-012021-03-310001600620us-gaap:InventoriesMember2020-01-012020-03-310001600620srt:AffiliatedEntityMemberauph:MilestonePaymentMemberauph:ILJINMember2021-01-012021-03-310001600620us-gaap:OtherLiabilitiesMemberauph:ILJINMember2021-03-310001600620us-gaap:OtherLiabilitiesMemberauph:ILJINMember2020-12-310001600620auph:LegalFeesMembersrt:ManagementMember2020-01-012020-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________________________________
FORM 10-Q
_____________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_____________ to ________________
Commission file number: 001-36421
__________________________________________
Aurinia Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
__________________________________________
Alberta, Canada
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification Number)
#1203-4464 Markham Street
Victoria, British Columbia V8Z 7X8
46-4129078
(Address of principal executive offices)
(250) 708-4272
Registrant’s telephone number, including area code
_____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x 
Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of May 6, 2021, the registrant had 128,156,427 of common shares outstanding.
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common shares, no par valueAUPHThe Nasdaq Global Market LLC
Common Shares, no par valueAUPToronto Stock Exchange


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
TABLE OF CONTENTS
Page


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
March 31, 2021December 31, 2020
(unaudited)
ASSETS
Current assets
Cash and cash equivalents$156,591 $272,350 
Short-term investments191,668 125,979 
Accounts receivable, net1,187 — 
Inventories, net15,936 13,927 
Prepaid expenses and other current assets6,864 7,171 
Total current assets372,246 419,427 
Non-current assets
Long-term investments12,603 24,380 
Other non-current assets11,856 247 
Property and equipment, net4,758 4,786 
Acquired intellectual property and other intangible assets, net9,854 9,332 
Right-of-use assets5,761 5,489 
Total assets417,078 463,661 
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities17,694 24,797 
Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively)
2,382 6,412 
Operating lease liabilities1,075 788 
Total current liabilities21,151 31,997 
Non-current liabilities
Other non-current liabilities17,893 16,295 
Operating lease liabilities7,806 7,619 
Total liabilities46,850 55,911 
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY
Common shares - no par value, unlimited shares authorized, 128,121 and 126,725 shares issued and outstanding as at March 31, 2021 and December 31, 2020, respectively
952,673 944,328 
Additional paid-in capital43,889 39,383 
Accumulated other comprehensive loss(799)(805)
Accumulated deficit(625,535)(575,156)
Total shareholder’s equity370,228 407,750 
Total liabilities and shareholders’ equity$417,078 $463,661 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
Three months ended
March 31,
20212020
unaudited
Revenue
Product revenue, net$884 $— 
License revenue30 30 
Total revenue914 30 
Operating expenses:
Cost of sales48 — 
Selling, general and administrative39,282 11,053 
Research and development9,833 13,835 
Amortization of intangible assets523 286 
Other expense, net1,771 1,916 
Total cost and operating expenses51,457 27,090 
Loss from operations(50,543)(27,060)
Interest income172 890 
Net loss before income taxes(50,371)(26,170)
Income tax expense (benefit)8 (238)
Net loss$(50,379)$(25,932)
Other comprehensive loss:
Unrealized gain on available-for-sale securities, net of tax of $nil
6 — 
Comprehensive loss(50,373)(25,932)
Basic and diluted loss per share$(0.40)$(0.23)
Weighted-average common shares outstanding used in computation of basic and diluted loss per share127,401 112,209 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
Common Shares
(unaudited)SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at January 1, 2021126,725 $944,328 $39,383 $(805)$(575,156)$407,750 
Shares issued on exercise of stock options877 7,619 (2,620)— — 4,999 
Exercise of warrants519 726 (695)— — 31 
Share-based compensation— — 7,821 — — 7,821 
Other comprehensive income— — — 6 — 6 
Net loss— — — — (50,379)(50,379)
Balance at March 31, 2021128,121 $952,673 $43,889 $(799)$(625,535)$370,228 
Balance at January 1, 2020111,798 $746,487 $25,394 $(805)$(472,476)$298,600 
Shares issued on exercise of stock options688 4,450 (1,530)— — 2,920 
Exercise of warrants1 3 (1)— — 2 
Shared-based compensation— — 3,496 — — 3,496 
Net loss and comprehensive loss for the period— — — (25,932)(25,932)
Balance at March 31, 2020112,487 $750,940 $27,359 $(805)$(498,408)$279,086 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

Three Months Ended
March 31,
20212020
unaudited
Cash flows used in operating activities:
Net loss$(50,379)$(25,932)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of property and equipment165 12 
Amortization of acquired intellectual property and other intangible assets523 286 
Share-based compensation expense7,821 3,496 
Other, net(2,111)870 
Net changes in operating assets and liabilities
Accounts receivable(1,187)— 
Inventories(2,009)— 
Prepaid expenses and other current assets308 (2,661)
Non-current assets229 — 
Right of use assets(272)(5,764)
Accounts payable and accrued liabilities(7,103)1,234 
Lease liabilities474 5,851 
Net cash used in operating activities (53,541)(22,608)
Cash flows used in investing activities:
Purchase of short-term investments(115,168)(11,913)
Proceeds from maturities of short-investments60,940 —
Purchases of equipment(136)(79)
Upfront lease payment(11,838)— 
Internal use-software implementation costs(1,039)(86)
Capitalized patent costs(6)(48)
Net cash used in investing activities (67,247)(12,126)
Cash flows from financing activities
Proceeds from exercise of stock options4,999 2,920 
Proceeds from exercise of warrants30 2 
Net proceeds from issuance of common shares— — 
Net cash provided by financing activities 5,029 2,922 
Net decrease in cash and cash equivalents(115,759)(31,812)
Cash and cash equivalents, beginning of period272,350 306,019 
Cash and cash equivalents, end of period$156,591 $274,207 
Supplemental cash flow information
Cash received for interest$425 $891 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1.Organization and Description of Business
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company has developed LUPKYNISTM, an investigational drug, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program.
On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN.
Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle, Rockville, Maryland, United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are currently listed and traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH and on the Toronto Stock Exchange (TSX) under the symbol AUP.
2.Basis of Presentation
The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2021 have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.
The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief operating decision maker (CODM), the chief executive officer, makes decisions based on the Company as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.
These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.
5


We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. Taking into consideration the Company's cash and cash equivalents of $156.6 million and short term investments of $191.7 million as of March 31, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued.
3.Summary of Significant Accounting Policies
Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Critical Accounting Estimates: The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial liabilities;
•Share-based compensation;
•Intangible assets; and
•Income taxes.
Concentration of Credit Risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.

The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two specialty pharmacies accounted for approximately 59% and 37% of the Company's total revenues. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the
6

status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
Investments: The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 320, Investments — Debt Securities. Investments classified as held to maturity are carried at fair value which is approximately equal to amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income (expense) is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method.
Revenue Recognition: Pursuant to Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.
More specifically, these adjustments include the following:
Prompt pay discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Customer fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&A) expense.
Government rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.
7

Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
Co-payment assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
License, Collaboration and Other Revenues
The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Manufacturing supply services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.
Milestone payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-
8

evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.
Research, Development and/or Manufacturing Services. The Company’s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.
Cost of sales: Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.
Research and development costs: Research and development costs are accounted for in accordance with ASC Topic 730, Research and Development, (ASC 730) and are expensed as incurred. Research and development costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers.
Selling, general and administrative expenses: The Company's selling, general and administrative (SG&A) expense includes commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These selling, general and administrative costs include: corporate facility operating expenses and allocated depreciation; commercial, marketing and operations in support of LUPKYINIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense selling, general and administrative expenses as they are incurred.
The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to specialty pharmacies, and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in selling, general and administrative expenses.
Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of March 31, 2021, accounts receivable, net are $1.2 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of March 31, 2021 and March 31, 2020.
Recently adopted accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The adoption of the standard as of January 1, 2020 did not have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement. Topic 820 requires to disclose transfers into and out of Level 3 of the
9

fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements, resulting in capitalized costs of $1.7 million in 2020.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.
4.    Investments
As of March 31, 2021 and December 31, 2020, the Company had $191.7 million and $12.6 million and $126.0 million and $24.4 million of short and long-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of March 31, 2021, the Company classifies its investments as debt securities of which $89.1 million are held to maturity and $115.2 million are available-for-sale. As of December 31, 2020, $150.4 million were classified as held to maturity and $nil were available-for-sale.
(in thousands)March 31, 2021December 31, 2020
Cashable Guaranteed Investment Certificate (GIC)$2,502 $2,000 
Corporate Bond41,524 40,372 
Commercial Paper133,907 67,747 
Treasury Bill5,910 7,999 
Treasury Bond5,021 5,045 
Yankee Bond2,804 2,816 
Total short-term investments191,668 125,979 
Corporate Bonds - total long-term investments12,603 24,380 
Total investments$204,271 $150,359 

10

Currently the Company does not intend to sell investments that are classified as held-to-maturity and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of March 31, 2021 and December 31, 2020, accrued interest receivable from the investments were $0.4 million and $0.5 million, respectively. As of March 31, 2021, the Company had $6 thousand unrealized gains on available-for-sale securities, net of tax, which are included as a component of comprehensive loss. The Company's investments as of March 31, 2021 mature at various dates through June 2022.

5.    Inventories

Inventories are valued under a standard costing technique on a first-in, first out (FIFO) basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For our product LUPKYNIS, the Company commenced capitalization of inventory once FDA approval was deemed to be probable, which occurred during the third quarter of 2020. Capitalized costs of inventories for LUPKYNIS mainly includes third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.

The components of inventory as of March 31, 2021 and December 31, 2020 are as follows:
(in thousands)March 31, 2021December 31, 2020
Work in process$14,367 $13,927 
Finished goods1,569 — 
Total inventories$15,936 $13,927 


6.Prepaid Expenses and Other Current Assets

The following table summarizes prepaid expenses and other current assets.

(in thousands)March 31, 2021December 31, 2020
Prepaid assets$4,139 $3,701 
Prepaid insurance939 2,054 
Other current assets1,180 1,018 
Prepaid deposits606 398 
Total prepaid expenses and other current assets$6,864 $7,171 

7.Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
March 31, 2021
(in thousands)Weighted Average
Life (in years)		Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents11$1,657 $(1,229)$428 
Acquired intellectual property and reacquired rights1115,126 (8,028)7,098 
Internal-use software implementation costs32,713 (385)2,328 
11$19,496 $(9,642)$9,854 
11

December 31, 2020
(in thousands)Weighted Average
Life (in years)		Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents11$1,651 $(1,203)$448 
Acquired intellectual property and reacquired rights1115,126 (7,770)7,356 
Internal-use software implementation costs31,675 (147)1,528 
11$18,452 $(9,120)$9,332 
Amortization expense for the three-month periods ended March 31, 2021 and March 31, 2020 was $0.5 million and $0.3 million, respectively.
8.    Property and Equipment, net
Property and equipment as of March 31, 2021 and December 31, 2020 are as follows:
(in thousands)March 31, 2021December 31, 2020
Construction in progress$279 $4,467 
Leasehold improvements2,951 34 
Office equipment and furniture1,604 83 
Computer equipment270 381 
5,1044,965
Less accumulated depreciation(346)(179)
Property and equipment, net$4,758 $4,786 

Depreciation expense for the three-month periods ended March 31, 2021 and March 31, 2020 was $0.2 million and $nil, respectively, which is included in selling, general and administrative expenses in the condensed consolidated statements of operations.
9.    Lease Obligations
Victoria, British Columbia
During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of March 31, 2021, the Company had $0.4 million right-of-use assets (ROU asset) and $0.4 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in selling, general and administrative expense in the condensed consolidated statement of operations. The incremental borrowing rate applied to the lease liabilities was 4.08% based on financial position, geographical region and terms of leases.
12

During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The lease term is expected to begin in 2022. The present value of the minimum lease payments for this lease are $3.3 million. As of March 31, 2021, there has been no accounting recognition associated with this lease, as the Company has not been granted access to the building.
Rockville, Maryland Lease
During March 2020, the Company entered into a lease for its commercial office in Rockville, Maryland. The lease has a remaining term of approximately 11 years and has an option to extend for two five-year periods after the 11 years has elapsed and an option to terminate after seven years. As of March 31, 2021, the Company had a right-of-use asset of $5.4 million and lease liability of $8.5 million included in the condensed consolidated balance sheets. As of December 31, 2020, the Company had a right of use asset of $5.5 million and lease liability of $8.4 million included in the condensed consolidated balance sheets. During 2020, the Company received reimbursements for tenant leasehold improvements by the landlord in the amount of $2.3 million for the Maryland lease. The Company recorded these leasehold improvement incentives as additions to the lease liability and construction in progress. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta Canada
During the fourth quarter of 2020, the Company entered into an agreement to lease premises in Edmonton, Alberta, commencing on October 1, 2020 and ending September 30, 2021. The lease agreement is considered a short-term lease as the term is twelve months. The Company recognizes short-term leases on a straight-line basis and did not record a related lease asset or liability for the Edmonton lease. The Company recognized short-term rent expense for this lease, which is included in selling, general and administrative expense in the condensed consolidated statement of operations.
The following table provides supplemental balance sheet information related to the operating lease ROU asset and lease liabilities:
(in thousands)Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Assets
Operating lease right of-use assetsRight-of-use assets$5,761 $5,489 
Liabilities
Current operating lease liabilitiesCurrent operating lease liabilities1,075 $788 
Non-current operating lease liabilitiesNon-current operating lease liabilities7,806 7,619 
Total lease liabilities$8,881 $8,407 
13


Beginning January 1, 2021 the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs for the three-month periods ended March 31, 2021. The following provides a summary of the components of leasing costs and rent for the three-month periods ended March 31, 2021 and March 31, 2020.
(in thousands)Consolidated Statement of OperationsMarch 31,
2021		March 31,
2020
Operating lease costs
Operating lease costsSelling, general and administrative$261 $65 
Short-term lease costs
Office BuildingSelling, general and administrative7 76 
Variable lease costs
Office buildingSelling, general and administrative41 1 
Total rent expense$309 $142 
The following table represents the weighted-average remaining lease term and discount rate as of March 31, 2021:
As of March 31, 2021
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases10.055.18%
The following table provides a summary of lease liability maturities for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2021$484 
20221,144 
20231,061 
20241,085 
20251,110 
Thereafter6,773 
Total future minimum lease payments 11,657 
Less: lease imputed interest(2,776)
Total future minimum lease payments$8,881 
Finance Lease
On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
Upon completion of the monoplant, the Company will have the right to maintain unobstructed use of the monoplant by paying a quarterly fixed facility fee. The first capital expenditure payment was made in February 2021 of $11.8 million which was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be the beginning of 2023.
14

The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $91.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.
10.Accounts Payable and Accrued Liabilities
The following table summarizes the Company's accounts payable and accrued liabilities.

(in thousands)March 31, 2021December 31, 2020
Trade payables$2,182 $2,635 
Other accrued liabilities9,727 10,855 
Employee accruals5,785 11,307 
Total accounts payable and accrued liabilities$17,694 $24,797 


11.Non-current Liabilities

The Company recorded other non-current liabilities of $17.9 million and $16.3 million as of March 31, 2021 and December 31, 2020, respectively. The balance as of March 31, 2021 and December 31, 2020 primarily included royalty obligations that are the result of a resolution of the board of directors of the Company dated March 8, 2012 whereby certain executive officers at that time were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events.
12.Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short and long-term investments that are valued through third-party pricing services that use verifiable observable market data.
There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.
15

The following tables present the financial assets measured at fair value on a recurring basis:
March 31, 2021
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$110,050 $— $— $110,050 
Short-term highly liquid investments46,511 30 — 46,541 
Investments133,907 70,364 204,271 
$290,468 $70,394 $— $360,862 
December 31, 2020
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$130,807 $— $— $130,807 
Short-term highly liquid investments141,543 — — 141,543 
Investments69,746 80,613 — 150,359 
$342,096 $80,613 $— $422,709 

13.License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS for the treatment of adult patients with active LN in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.

As part of the agreement, Aurinia received an upfront cash payment of $50.0 million for the license agreement, and has the potential to receive up to $50.0 million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, a supply agreement will be negotiated in the future.

The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional intellectual property (IP) that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0 million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.

The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.

As of March 31, 2021 there has been no additional consideration earned or received since the upfront payment of $50.0 million in the quarter ended December 31, 2020.
16

14.Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Common shares that could potentially dilute basic net loss per common share in the future that could be issued from the exercise of stock options and warrants were not included in the computation of the diluted loss per common share for the three-month periods ended March 31, 2021 and March 31, 2020 because to do so would be anti-dilutive. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
March 31,
(in thousands, except per share data)20212020
Net loss$(50,379)$(25,932)
Weighted average common shares outstanding127,401 112,209 
Net loss per common share (expressed in $ per share)$(0.40)$(0.23)
The outstanding number and type of securities in the following table would potentially dilute basic loss per common share in the future and therefore, were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive).
Three months ended
March 31,
(in thousands)20212020
Stock options14,771 9,685 
Warrants1,014 1,690 
15,785 11,375 

15.Share-based Compensation
The Company's Equity Incentive Plan (the Plan) was adopted and approved in 2012 and re-approved in May 2014. The Plan was amended as to Section 2.2 by the shareholders of the Company in June 2016 and amended and restated in June 2020. The purpose of the Plan is to advance the interest of the Company by encouraging equity participation in the Company through the acquisition of common shares. As of March 31, 2021 and December 31, 2020, 128.1 million and 126.7 million, common shares were issued and outstanding, resulting in a maximum of 16.0 million and 15.8 million, respectively, options available for issuance under the Plan.

Stock Options

The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average
17

assumptions were used to estimate the fair value of the options granted during the three-month periods ended March 31, 2021 and March 31, 2020:
March 31, 2021March 31, 2020
Annualized volatility66 %43%
Risk-free interest rate0.28 %1.20%
Expected life of options in years4.0 years3.0 years
Estimated forfeiture rate8.9 %13.0%
Dividend rate0.0 %0.0%
Fair value per common share option$6.72 $5.44 

Performance Awards
On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each performance award which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The Company recorded approximately $0.2 million and $nil of share-based compensation expense related to executive performance awards during the three months ended March 31, 2021 and March 31, 2020, respectively.

The following table summarizes the equity award activity during the three months ended March 31, 2021:

March 31, 2021
Number of shares (in thousands)Weighted average exercise price $
Outstanding - Beginning of Period14,486 11.35 
Granted1,392 13.62 
Exercised(877)5.65 
Forfeited(230)12.33 
Outstanding - End of Period14,771 12.94 
Vested and expected to vest - End of Period897 13.11 
Options exercisable - End of Period5,014 8.15 
Compensation Expense
The Company recognized share-based compensation expense for the three-month periods ended March 31, 2021 and March 31, 2020 as follows:
(in thousands)March 31, 2021March 31, 2020
Research and development$1,074 $1,217 
Selling, general and administrative6,641 2,279 
Capitalized under inventories106 — 
Share-based compensation expense$7,821 $3,496 
At March 31, 2021, there was $36.6 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.

16.Income Taxes

The effective tax rates for the three months ended March 31, 2021 and March 31, 2020 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company
18

recognized an income tax expense of $8 thousand for the three months ended March 31, 2021 and an income tax benefit of $0.2 million for the three months ended March 31, 2020. The expense recognized for the three months ended March 31, 2021 was a result of income in a certain jurisdiction. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions. The tax benefit recognized for the three months ended March 31, 2020 was a result of a discrete tax benefit recorded in the U.S. pursuant to certain tax provisions provided under the CARES Act. The CARES Act permits the Company to carry back net operating losses to offset taxable income generated in the five preceding years, some of which were taxed at a federal income tax rate higher than the current enacted rate.
17.Related Party Transactions
ILJIN is considered to be a related party due to their equity ownership of over 5%. The outstanding related party amount payable to ILJIN is the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the period ended March 31, 2021, Aurinia paid $4.0 million upon achievement of specific milestones. The amount payable to ILJIN of $2.0 million and $6.0 million as of March 31, 2021 and December 31, 2020 was recorded in other current liabilities and non-current liabilities, respectively.
Stephen P. Robertson was a partner at Borden Ladner Gervais (BLG) and acted as our corporate secretary through October 2020. We incurred legal fees in the normal course of business to BLG of $63 thousand for the quarter ended March 31, 2020 and did not incur similar fees in 2021. We had no ongoing contractual or other commitments as a result of engaging Mr. Robertson to act as our corporate secretary and Mr. Robertson received no additional compensation for acting as the corporate secretary. On November 2, 2020 we announced the appointment of Stephen Robertson as our Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.
18.Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's commitments and contingencies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Manufacturing Commitments
We have various manufacturing agreements to support our commercial and clinical product supply requirements.

We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial and clinical drug substance requirements. We have firm orders with Lonza, with remaining total non-cancellable future commitments of approximately $25.4 million through 2023. If we terminate certain firm orders with Lonza without cause, we will be required to pay for drug substance scheduled for manufacture under our arrangement.

19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report. The information in this discussion contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, which are subject to the “safe harbor” created by those sections, as well as “forward-looking information” as defined in applicable Canadian securities laws. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our belief that it has sufficient financial resources to fund its current plans for at least the next 12 months; and our potential to receive certain payments and royalties under its agreement with Otsuka . In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “propose,” “intend,” “continue,” “potential,” “possible,” “foreseeable,” “likely,” “unforeseen” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third party studies and reports; that our intellectual property rights are valid and do not infringe the intellectual property rights of third parties; our assumptions relating to the capital required to fund operations for the next 12 months; the assumption that our current good relationships with its suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading “Risk Factors” in Part I, Item 1A of our 2020 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 24, 2021 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Overview
Aurinia is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. We have commercially launched LUPKYNIS in the United States for the treatment of adult patients with active LN, and continue to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program.
On January 22, 2021, the FDA approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN. As a condition of approval, we are required to conduct two pediatric studies (with reports due in 2025 and 2031), a milk only lactation study (with a report due in 2026), a drug-drug interaction study (with a report due in 2023) and submit a final study report on our AURORA-2 continuation study (by March 2022).
In addition, we plan to prepare a marketing authorization application (MAA) to be filed with the European Medicines Agency (EMA) by our partner Otsuka during the first half of 2021 seeking approval for the use of LUPKYNIS for the treatment of adult patients with active LN in the European Union, which includes Norway, Iceland and Liechtenstein.
LUPKYNIS is a calcineurin inhibitors (CNI) immunosuppressant, that has the potential to improve near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids, the current standard of care for LN (although not currently approved as such). By inhibiting calcineurin, LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. LUPKYNIS also potentially stabilizes podocytes, which can protect against proteinuria. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The mechanism of action of LUPKYNIS has been validated with certain earlier generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications,
20

including uveitis, keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that LUPKYNIS possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation.
Earlier generation CNIs have demonstrated efficacy for a number of conditions, including transplant and other autoimmune diseases; however, side effects exist which can limit their long-term use and tolerability. Some clinical complications of earlier generation CNIs include hypertension, hyperlipidemia, diabetes, and both acute and chronic nephrotoxicity.
Based on published data, we believe the key potential benefits of LUPKYNIS in the treatment of adult patients with active LN versus marketed CNIs include:
•increased potency compared to cyclosporine A, allowing for lower dosing requirements and potentially fewer off target effects;
•limited inter and intra patient variability, allowing for easier dosing without the need for monitoring blood levels for therapeutic drug monitoring;
•less cholesterolemia and triglyceridemia than cyclosporine A; and
•limited incidence of glucose intolerance and diabetes at therapeutic doses compared to tacrolimus.

Recent Developments

On Friday, January 22, 2021, the FDA approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN. On Monday, January 25, 2021, we received our first patient start form and completed our first commercial sale within the same week.

Impact of COVID-19 Pandemic

In the event of a prolonged disruption related to the COVID-19 pandemic, there could be detrimental impact to our ongoing and future clinical trials, our ongoing commercial launch and future commercialization activities for LUPKYNIS, and our ability to access capital markets. For further information, refer to Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020.
Critical Accounting Policies and Significant Judgments and Estimates
The preparation of our unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the revenues and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are relevant under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We discussed accounting policies and assumptions that involve a higher degree of judgment and complexity in Note 2 to our consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and any updates in Item 1. Note 3 from our Summary of Significant Accounting Policies.
There have been no material changes to our critical accounting policies and estimates as compared to those disclosed in our Annual Report.
We believe that of our critical accounting policies, the most significant areas involving critical estimates, judgments and assumptions used in the preparation of our consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial liabilities;
•Share-based compensation;
•Intangible assets; and
•Income taxes.
21

Results of Operations
Comparison of the Three Months Ended March 31, 2021 and March 31, 2020
The following table sets forth our results of operations for the three months ended March 31, 2021 and March 31, 2020.
Three Months Ended March 31,
20212020Change
(in thousands)
Revenue
Product revenue, net$884 $— 884 
License revenue30 30 — 
Total revenue914 30 884 
Operating expenses:— 
Cost of sales48 — 48 
Selling, general and administrative39,282 11,053 28,229 
Research and development9,833 13,835 (4,002)
Amortization of intangible assets523 286 237 
Other expense, net1,771 1,916 (145)
Total cost and operating expenses51,457 27,090 24,367 
Loss from operations(50,543)(27,060)(23,483)
Interest income172 890 (718)
Net loss before income taxes(50,371)(26,170)(24,201)
Income tax expense (benefit)8 (238)246 
Net loss$(50,379)$(25,932)(24,447)
Revenues
Total revenue was $0.9 million and $30 thousand for the three months ended March 31, 2021 and March 31, 2020.
Product Revenue, net
Product revenue, net was $0.9 million and $nil for the three months ended March 31, 2021 and March 31, 2020. The increase was primarily the result of $854 thousand for product revenue, net of adjustments for LUPKYNIS following FDA approval in January 2021.
Cost of Sales
Cost of sales were $48 thousand and $nil for the three months ended March 31, 2021 and March 31, 2020, respectively. The increase was the result of commercial sales of LUPKYNIS and drug substance. Gross margin for the three months ended March 31, 2021 was approximately 95%.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased to $39.3 million for the three months ended March 31, 2021 compared to $11.1 million for the three months ended March 31, 2020. Selling, general and administrative expenses consisted of the following:
22

Three Months Ended March 31,
(in thousands)20212020
Salaries, incentive pay and employee benefits$19,194 $3,578 
Professional fees and services8,717 3,859 
Share-based compensation expense6,641 2,279 
Other public company costs, facility costs, insurance, information technology, amortization of property and equipment3,282 1,042 
Travel, trade shows and sponsorships1,448 295 
$39,282 $11,053 
The primary drivers for the increase in selling, general and administrative spend were an increase in salaries, incentive pay and employee benefits and share-based compensation expense related to the expansion of the commercial team. The increase was also due to administrative functions to support the launch of LUPKYNIS and professional fees for activities such as patient assistance programs, consulting, recruiting, legal, market research and finance and insurance. Following FDA approval, approximately $2.0 million of salaries and expenses have been allocated to selling, general and administrative expense related to post approval support of LUPKYNIS.
Research and Development Expenses
Research and development (R&D) expenses were $9.8 million and $13.8 million for the three months ended March 31, 2021 and March 31, 2020, respectively. R&D consisted of the following:
Three Months Ended March 31,
(in thousands)20212020
Contract research organizations (CRO) and third party clinical trial expenses$4,632 $8,012 
Clinical supply and distribution1,232 2,409 
Salaries, incentive pay and employee benefits3,024 1,928 
Share-based compensation expense1,074 1,217 
Travel, insurance, patent annuity fees, legal fees and other(129)269 
$9,833 $13,835 
The primary drivers for the decrease in R&D spend during the three months ended March 31, 2021 were lower CRO expenses and other third party clinical trial expenses together with a decrease in clinical supply and distribution costs following the approval of LUPKYNIS, including a reduction in NDA preparation costs, capitalization of supply costs following approval, and termination of the dry eye trial during the fourth quarter of 2020. The decrease was partially offset by an increase in salaries, incentive pay and employee benefits. Following FDA approval, approximately $2.0 million of salaries and expenses have been allocated to SG&A related to post approval support of LUPKYNIS.
Other Expenses, net
Other expenses, net was $1.8 million and $1.9 million for the three months ended March 31, 2021 and March 31, 2020, respectively. For the three months ended March 31, 2021, other expense relates primarily to the increase in royalty obligation due to the passage of time. For the three months ended March 31, 2020, the expense relates primarily to foreign exchange loss related to the Company’s Canadian denominated bank accounts due to a significant decrease in the Canadian dollar against the U.S. dollar and an increase in the royalty obligation due to the passage of time and increase in discount rate.
Liquidity and Capital Resources
As of March 31, 2021, we had cash and cash equivalents of $156.6 million and short-term investments of $191.7 million compared to cash and cash equivalents of $272.4 million and short-term investments of $126.0 million at December 31, 2020. Cash and cash equivalents and short-term investments are primarily held in U.S. dollars. As of March 31, 2021 and December 31, 2020, we had working capital of $351.1 million and $387.4 million, respectively.
23

We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. Taking into consideration the cash and cash equivalents and short term investments balance as of March 31, 2021, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, including our FDA related post approval commitments, manufacturing commercial drug supply, conducting our planned R&D programs and funding our supporting corporate and working capital for at least the next 12 months.

Sources and Uses of Cash
The following table summarizes our cash flows for the three months ended March 31, 2021 and March 31, 2020:
Three Months Ended March 31,
(in thousands)20212020
Net cash (used in) provided by:
Operating activities$(53,541)$(22,608)
Investing activities(67,247)(12,126)
Financing activities5,029 2,922 
Net change in cash and cash equivalents$(115,759)$(31,812)

Cash used in operating activities during the three months ended March 31, 2021 was $53.5 million, an increase of $30.9 million from cash used in operating activities of $22.6 million during the three months ended March 31, 2020 due to continued support of commercialization efforts in addition to a one-time payment to a related party upon achievement of specific milestones. In the prior year, the Company was still in the development phase of LUPKYNIS and as a result, did not incur any material related selling expenses.
Cash used in investing activities during the three months ended March 31, 2021 was $67.2 million compared to cash used in investing activities of $12.1 million during the three months ended March 31, 2020. Investing activities during the three months ended March 31, 2021 consisted primarily of $115.2 million for purchases of investments offset by $60.9 million of proceeds of maturities of investments. Cash used in investing activities of $12.1 million for the three months ended March 31, 2020 was primarily attributable to purchases of short-term investments.
Cash provided by financing activities during the three months ended March 31, 2021 was $5.0 million compared to cash provided by financing activities of $2.9 million during the three months ended March 31, 2020. The increase was primarily due to the proceeds of stock options exercised.
Off‑Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off‑balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.
Contractual Obligations
There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.
Item 3. Quantitative and Qualitative Disclosures About Market Risks
24

Our activities can expose us to market risks which include foreign currency risk and interest rate risk. Risk management is carried out by management under policies approved by our board of directors. Our overall risk management program seeks to minimize adverse effects on our financial performance.
Interest rate risk
Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis. Our investment portfolio includes cash and cash equivalents and investments that earn interest at market rates. Our investments held during the year were comprised of bonds and commercial paper with a maturity of less than two years. Accounts receivable, accounts payable and accrued liabilities bear no interest. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.
Foreign currency risk
We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, which could affect our operating and financial results.
A 10% increase of the U.S. dollar would have increased the net loss by $0.3 million assuming all other variables remained constant. An assumed 10% weakening of the U.S. dollar would have had an equal but opposite effect to the amounts shown above assuming all other variables remained constant.
Credit risk
Our exposure to credit risk generally consists of cash and cash equivalents, investments and receivables. We place our cash and cash equivalents with what we believe to be highly rated financial institutions and invest the excess cash in highly rated investments. Our investment policy limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer. The creditworthiness of our customers is monitored and we have internal policies regarding customer credit limits to mitigate credit risk with customers.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of March 31, 2021, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
During the three months ended March 31, 2021, in connection with the approval and commercial availability of LUPKYNIS, we designed and implemented new procedures and controls around our product net sales and inventory processes. No other change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

25

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
There are no material developments in respect of previously disclosed litigation to report.
Item 1A. Risk Factors.
Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
Item 6. Exhibits.
The following exhibits are filed as part of this report:
26

Exhibit
Number		Description
31.1*
31.2*
32.1**
32.2**
3.1
3.2
3.3
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith
**Furnished herewith

27

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AURINIA PHARMACEUTICALS INC.
May 6, 2021By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer, Director
(Principal Executive Officer)
May 6, 2021By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)
28
 EX-31.1 2 auph-20210331xexx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Peter Greenleaf, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:May 6, 2021By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 auph-20210331xexx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph Miller, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:May 6, 2021By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 4 auph-20210331xexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:May 6, 2021By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 5 auph-20210331xexx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:May 6, 2021By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-101.SCH 6 auph-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2205201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2107104 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2110105 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2113106 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2116107 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2120108 - Disclosure - Property, Plant and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2321305 - Disclosure - Property, Plant and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2422408 - Disclosure - Property, Plant and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 2123109 - Disclosure - Lease Obligations link:presentationLink link:calculationLink link:definitionLink 2324306 - Disclosure - Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 2425409 - Disclosure - Lease Obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) link:presentationLink link:calculationLink link:definitionLink 2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2129110 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2132111 - Disclosure - Non-current Liabilities link:presentationLink link:calculationLink link:definitionLink 2433414 - Disclosure - Non-current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2134112 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2335308 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2137113 - Disclosure - License and Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 2438416 - Disclosure - License and Collaboration Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2139114 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 2340309 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2441417 - Disclosure - Net Loss per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2143115 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2344310 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2445419 - Disclosure - Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2446420 - Disclosure - Share-based Compensation - Performance Shares Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2447421 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2448422 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2149116 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2450423 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2151117 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 2452424 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2153118 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 2454425 - Disclosure - Commitment and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 auph-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 auph-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 auph-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Area of property (in sqft) Area of Real Estate Property Granted Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Assets Operating Lease, Assets And Liabilities, Assets, Lessee [Abstract] Operating Lease, Assets And Liabilities, Assets, Lessee Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Related Party [Axis] Related Party [Axis] Unrealized gains on available-for-sale securities Debt Securities, Available-for-sale, Unrealized Gain (Loss) Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Payables and Accruals [Abstract] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Vested, Weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Tiered royalty percentages on future sales Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Level 3 Fair Value, Inputs, Level 3 [Member] Proceeds from maturities of short-investments Proceeds from Sale and Maturity of Marketable Securities Expenses from related party Related Party Transaction, Expenses from Transactions with Related Party Proceeds from exercise of warrants Proceeds from Warrant Exercises Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Security Exchange Name Security Exchange Name Loss from operations Operating Income (Loss) Total current liabilities Liabilities, Current Accounts receivable, net Accounts Receivable [Policy Text Block] Performance Shares Performance Shares [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) Outstanding, Weighted average exercise price - End of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Commitments and contingencies (Note 18) Commitments and Contingencies Minimum finance lease liability payments due Finance Lease, Liability, Payment, Due ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Entity Address, State or Province Entity Address, State or Province Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Due to related party, current Due to Related Parties, Current Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Right-of-use assets Operating Lease, Right-of-Use Asset 2022 Lessee, Operating Lease, Liability, to be Paid, Year One SHAREHOLDER’S EQUITY Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vested and expected to vest - End of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Customer [Axis] Customer [Axis] Total lease costs Total rent expense Lease, Cost Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other non-current liabilities Other non-current liabilities Other Liabilities, Noncurrent Capital expenditure payments Finance Lease, Principal Payments Treasury Bond US Treasury Bond Securities [Member] Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Payments to related party Related Party Transaction, Amounts of Transaction Inventories, net Total inventories Inventory, Net Total revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Investments Investment, Policy [Policy Text Block] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Concentration risk Concentration Risk, Percentage Geographical [Domain] Geographical [Domain] Non-cancellable future commitments Long-term Purchase Commitment, Amount Statement [Line Items] Statement [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Computer equipment Computer Equipment [Member] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Interest income Interest Income, Other Cash received for interest Proceeds from Interest Received Net loss per common share (expressed in $ per share) Earnings Per Share, Basic and Diluted Prepaid assets Prepaid Advertising Entity Small Business Entity Small Business Other expense, net Other Operating Income (Expense), Net Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Legal Fees Legal Fees [Member] Legal Fees Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Prepaid expenses and other current assets Prepaid Expense, Current Net proceeds from issuance of common shares Proceeds from Issuance of Common Stock Cost of sales Cost of Revenue Amendment Flag Amendment Flag Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Research and development costs Research and Development Expense, Policy [Policy Text Block] Number of shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other accrued liabilities Other Accrued Liabilities, Current Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable - End of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Cloud computing arrangements Computer Software, Intangible Asset [Member] Number of reporting units Number of Reporting Units Related Party Transaction [Line Items] Related Party Transaction [Line Items] Financial Instruments [Domain] Financial Instruments [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Management Management [Member] Geographical [Axis] Geographical [Axis] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Unrecognized share-based compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Lease extension term Lessee, Operating Lease, Renewal Term Marketable Securities [Line Items] Marketable Securities [Line Items] Statement of Cash Flows [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Milestone Payment Milestone Payment [Member] Milestone Payment Income Statement Location [Axis] Income Statement Location [Axis] Proceeds from tenant improvements Payments for (Proceeds from) Tenant Allowance Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Current Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee [Abstract] Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee Income Statement Location [Domain] Income Statement Location [Domain] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Amortization of intangible assets Amortization of Intangible Assets Potential regulatory milestone revenue Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount Lease, Cost Lease, Cost [Table Text Block] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Other non-current assets Other Assets, Noncurrent Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Related-Party Transactions Related Party Transactions Disclosure [Text Block] Outstanding - Beginning of Period (in shares) Outstanding - End of Period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Acquired intellectual property and other intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Fair value per common share option (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Antidilutive Securities [Axis] Antidilutive Securities [Axis] Investments, Debt and Equity Securities [Abstract] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Short-term investments Debt Securities, Current Specialty Pharmacy One Specialty Pharmacy One [Member] Specialty Pharmacy One Schedule of Performance Shares Activity Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block] Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities ILJIN ILJIN [Member] ILJIN Unrecognized share-based compensation expense weighted average recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Commitments and Contingencies Disclosure [Abstract] Upfront lease payment Payments to Acquire Lease Receivables Level 1 Fair Value, Inputs, Level 1 [Member] Inventories Increase (Decrease) in Inventories Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Additional paid in capital Additional Paid-in Capital [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Revenue from Contract with Customer [Abstract] Unrealized gain on available-for-sale securities, net of tax of $nil Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Common stock, outstanding (shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Variable lease costs Variable Lease, Cost License Agreement Terms License Agreement Terms [Member] Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense Exercise of warrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Otuska Otuska Pharmaceutical Co., Ltd. [Member] Otuska Pharmaceutical Co., Ltd. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Property, plant and equipment, gross Property, Plant and Equipment, Gross Proceeds from exercise of stock options Proceeds from Stock Options Exercised Prepaid deposits Prepaid Rent and Prepaid Continuing Studies Prepaid Rent and Prepaid Continuing Studies Income Statement [Abstract] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Operating lease liabilities Operating lease liabilities Operating Lease, Liability, Noncurrent Interest Receivable Interest Receivable Number of extension options Lessee, Operating Lease, Number of Extension Options Lessee, Operating Lease, Number of Extension Options Critical Accounting Estimates Use of Estimates, Policy [Policy Text Block] Current assets Assets, Current [Abstract] Cash flows used in investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Officer Officer [Member] Investments Investments, Fair Value Disclosure Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Patents Patents [Member] Licensing revenue License [Member] Counterparty Name [Domain] Counterparty Name [Domain] Internal use-software implementation costs Payments for Software City Area Code City Area Code Lease termination option term Lessee, Operating Lease, Lease Termination Term Lessee, Operating Lease, Lease Termination Term Document Period End Date Document Period End Date Property, Plant and Equipment [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Accounts receivable, net Accounts and Other Receivables, Net, Current Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Allocation of Share-Based Payments Share-based Payment Arrangement, Cost by Plan [Table Text Block] Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Marketable Securities [Table] Marketable Securities [Table] Cover [Abstract] Intangible Assets Intangible Assets Disclosure [Text Block] Capitalized under inventories Inventories [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Affiliated Shareholder Affiliated Entity [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Leases Lessee, Operating Leases [Text Block] Fair Value Disclosures [Abstract] Cashable Guaranteed Investment Certificate (GIC) Cashable Guaranteed Investment Certificates [Member] Cashable Guaranteed Investment Certificates Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Debt Securities, Available-for-sale Debt Securities, Available-for-sale Total cost and operating expenses Costs and Expenses Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement [Abstract] Minimum Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Operating lease liabilities Current maturities of operating lease liabilities Operating Lease, Liability, Current Options exercisable - End of Period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number Upfront payments received Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Forfeited, Weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Share-based Payment Award Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Corporate Bonds Corporate Bond Securities [Member] Net revenue: Revenues [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Customer [Domain] Customer [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Statement of Stockholders' Equity [Abstract] Assets: Assets, Fair Value Disclosure [Abstract] Incremental borrowing rate Weighted average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Research and development Research and Development Expense [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Finished goods Inventory, Finished Goods, Gross Minimum lease payments Total Lessee, Operating Lease, Liability, to be Paid Cost of sales Cost of Goods and Service [Policy Text Block] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Remaining lease term Lessee, Operating Lease, Remaining Lease Term Entity Address, Postal Zip Code Entity Address, Postal Zip Code Weighted-average common shares outstanding used in computation of basic and diluted loss per share Weighted-average common shares outstanding used in computation of basic and diluted loss per share Weighted Average Number of Shares Outstanding, Basic and Diluted Document Transition Report Document Transition Report Title of Individual [Axis] Title of Individual [Axis] Warrants Warrant [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Other current assets Other Assets, Current Document Quarterly Report Document Quarterly Report General and administrative General and Administrative Expense [Member] Total Assets, Fair Value Disclosure Basis of Presentation Basis of Accounting [Text Block] Accounts receivable Increase (Decrease) in Receivables Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Trade payables Accounts Payable, Trade, Current Other Liabilities Other Liabilities [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Expected life of options in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Number of operating segments Number of Operating Segments Unrealized gain on available-for-sale securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Entity File Number Entity File Number Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted average remaining lease term - operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Cash flows used in operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Common shares - no par value, unlimited shares authorized, 128,121 and 126,725 shares issued and outstanding as at March 31, 2021 and December 31, 2020, respectively Common Stock, Value, Outstanding Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Total investments Debt Securities, Current and Noncurrent Debt Securities, Current and Noncurrent Share-based compensation expense Share-based Payment Arrangement, Expense Balance Sheet Location [Axis] Balance Sheet Location [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Specialty Pharmacy Two Specialty Pharmacy Two [Member] Specialty Pharmacy Two Commercial Paper Commercial Paper [Member] Non-current assets: Assets, Noncurrent [Abstract] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Entity Current Reporting Status Entity Current Reporting Status Related Party Transaction [Axis] Related Party Transaction [Axis] Granted, Weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Inventory Disclosure [Abstract] Treasury Bill US Treasury Bill Securities [Member] Common stock, issued (shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total lease liabilities Total lease liabilities Operating Lease, Liability Total shareholder’s equity Balance Balance Shareholders' equity Stockholders' Equity Attributable to Parent Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and shareholders’ equity Liabilities and Equity Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Entity Address, City or Town Entity Address, City or Town Employee accruals Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Capitalized patent costs Payments to Acquire Intangible Assets Operating lease costs Operating Lease, Cost Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Selling, general and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Acquired intellectual property and reacquired rights Intellectual Property [Member] Type of Adoption [Domain] Accounting Standards Update [Domain] Right of use assets Increase (Decrease) in Operating Lease, Right-of-Use Assets Increase (Decrease) in Operating Lease, Right-of-Use Assets Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Investments Marketable Securities [Table Text Block] Other, net Other Noncash Income (Expense) Contract revenue Product [Member] Non-current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block] Short-term lease costs Short-term Lease, Cost Weighted Average Life (in years) Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Non-current assets Increase (Decrease) in Other Noncurrent Assets Long-term investments Debt Securities, Noncurrent Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Construction in progress Construction in Progress [Member] Entity Tax Identification Number Entity Tax Identification Number Prepaid insurance Prepaid Insurance Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Share-based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss and comprehensive loss for the period Net Income (Loss) Attributable to Parent Net changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively) Other Liabilities, Current Remainder of 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Inventories Inventory Disclosure [Text Block] Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Work in process Inventory, Work in Process, Gross Leases [Abstract] Yankee Bond Yankee Bond [Member] Yankee Bond Deposits held with banks Demand Deposits [Member] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Earnings Per Share [Abstract] Corporate Bond Short-Term Corporate Debt Securities [Member] Short-Term Corporate Debt Securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Debt Securities, Held-to-maturity Debt Securities, Held-to-maturity Document Fiscal Period Focus Document Fiscal Period Focus Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Rockville, Maryland Rockville, Maryland [Member] Rockville, Maryland Entity Filer Category Entity Filer Category Common Shares Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service [Domain] Product and Service [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Due to related parties Due to Related Parties Annualized volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Estimated forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Leasehold improvements Leasehold Improvements [Member] Gross Carrying Value Finite-Lived Intangible Assets, Gross Revenue Benchmark Revenue Benchmark [Member] Non-current Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee [Abstract] Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee Exercise of warrants (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Short-term highly liquid investments Money Market Funds [Member] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Shares issued on exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Related Party Transactions [Abstract] Net (decrease) increase in cash and cash equivalents during the year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock options Share-based Payment Arrangement, Option [Member] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate License and Collaboration Agreement Revenue from Contract with Customer [Text Block] Victoria, British Columbia Victoria, British Columbia [Member] Victoria, British Columbia Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Purchases of equipment Payments to Acquire Other Productive Assets Income tax expense (benefit) Income tax (benefit) expense Income Tax Expense (Benefit) Cash and cash equivalents, beginning of the year Cash and cash equivalents, end of the year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Purchase of short-term investments Payments to Acquire Marketable Securities Title of Individual [Domain] Title of Individual [Domain] Local Phone Number Local Phone Number Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Lease liabilities Increase (Decrease) In Operating Lease Liability Increase (Decrease) In Operating Lease Liability Depreciation of property and equipment Depreciation Entity Address, Address Line One Entity Address, Address Line One Accounting Standards Update 2018-15 [Member] Accounting Standards Update 2018-15 [Member] Related Party Transaction [Domain] Related Party Transaction [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Shares issued on exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Selling, general and administrative expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Award Type [Axis] Award Type [Axis] Weighted average exercise price $ Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Maximum Maximum [Member] Accumulated Deficit Retained Earnings [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Award Type [Domain] Award Type [Domain] Non-current liabilities Liabilities, Noncurrent [Abstract] Trading Symbol Trading Symbol Property, Plant and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Net Loss per Common Share Earnings Per Share [Text Block] Office equipment and furniture Office Equipment [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities Liabilities, Current [Abstract] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Recently adopted accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Vested and expected to vest - End of Period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number EX-101.PRE 10 auph-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 auph-20210331_htm.xml IDEA: XBRL DOCUMENT 0001600620 2021-01-01 2021-03-31 0001600620 2021-05-06 0001600620 2021-03-31 0001600620 2020-12-31 0001600620 us-gaap:LicenseMember 2021-01-01 2021-03-31 0001600620 us-gaap:LicenseMember 2020-01-01 2020-03-31 0001600620 us-gaap:ProductMember 2021-01-01 2021-03-31 0001600620 us-gaap:ProductMember 2020-01-01 2020-03-31 0001600620 2020-01-01 2020-03-31 0001600620 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001600620 us-gaap:CommonStockMember 2020-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001600620 us-gaap:RetainedEarningsMember 2020-12-31 0001600620 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001600620 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001600620 us-gaap:CommonStockMember 2021-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001600620 us-gaap:RetainedEarningsMember 2021-03-31 0001600620 us-gaap:CommonStockMember 2019-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001600620 us-gaap:RetainedEarningsMember 2019-12-31 0001600620 2019-12-31 0001600620 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001600620 us-gaap:CommonStockMember 2020-03-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001600620 us-gaap:RetainedEarningsMember 2020-03-31 0001600620 2020-03-31 0001600620 auph:SpecialtyPharmacyOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001600620 auph:SpecialtyPharmacyTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001600620 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201815Member 2020-12-31 0001600620 auph:CashableGuaranteedInvestmentCertificatesMember 2021-03-31 0001600620 auph:CashableGuaranteedInvestmentCertificatesMember 2020-12-31 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2021-03-31 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2020-12-31 0001600620 us-gaap:CommercialPaperMember 2021-03-31 0001600620 us-gaap:CommercialPaperMember 2020-12-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2021-03-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2020-12-31 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2021-03-31 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2020-12-31 0001600620 auph:YankeeBondMember 2021-03-31 0001600620 auph:YankeeBondMember 2020-12-31 0001600620 us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001600620 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001600620 us-gaap:PatentsMember 2021-01-01 2021-03-31 0001600620 us-gaap:PatentsMember 2021-03-31 0001600620 us-gaap:IntellectualPropertyMember 2021-01-01 2021-03-31 0001600620 us-gaap:IntellectualPropertyMember 2021-03-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-01-01 2021-03-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-03-31 0001600620 us-gaap:PatentsMember 2020-01-01 2020-12-31 0001600620 us-gaap:PatentsMember 2020-12-31 0001600620 us-gaap:IntellectualPropertyMember 2020-01-01 2020-12-31 0001600620 us-gaap:IntellectualPropertyMember 2020-12-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-01-01 2020-12-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-12-31 0001600620 2020-01-01 2020-12-31 0001600620 us-gaap:ConstructionInProgressMember 2021-03-31 0001600620 us-gaap:ConstructionInProgressMember 2020-12-31 0001600620 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001600620 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001600620 us-gaap:OfficeEquipmentMember 2021-03-31 0001600620 us-gaap:OfficeEquipmentMember 2020-12-31 0001600620 us-gaap:ComputerEquipmentMember 2021-03-31 0001600620 us-gaap:ComputerEquipmentMember 2020-12-31 0001600620 auph:VictoriaBritishColumbiaMember 2020-12-31 0001600620 auph:VictoriaBritishColumbiaMember 2021-03-31 0001600620 auph:VictoriaBritishColumbiaMember 2020-08-31 0001600620 auph:RockvilleMarylandMember 2021-03-31 0001600620 auph:RockvilleMarylandMember 2021-01-01 2021-03-31 0001600620 auph:RockvilleMarylandMember 2020-12-31 0001600620 auph:RockvilleMarylandMember 2020-01-01 2020-12-31 0001600620 auph:RockvilleMarylandMember 2020-03-12 0001600620 2021-02-01 2021-02-28 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001600620 us-gaap:DemandDepositsMember 2021-03-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001600620 us-gaap:MoneyMarketFundsMember 2021-03-31 0001600620 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001600620 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001600620 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001600620 us-gaap:DemandDepositsMember 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember 2020-12-31 0001600620 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001600620 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-17 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MinimumMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MaximumMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-01 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2021-01-01 2021-03-31 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-03-31 0001600620 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001600620 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001600620 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2020-10-23 2020-10-23 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-03-18 2021-03-18 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-03-31 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2020-01-01 2020-03-31 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2020-12-31 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001600620 us-gaap:InventoriesMember 2021-01-01 2021-03-31 0001600620 us-gaap:InventoriesMember 2020-01-01 2020-03-31 0001600620 auph:ILJINMember auph:MilestonePaymentMember srt:AffiliatedEntityMember 2021-01-01 2021-03-31 0001600620 auph:ILJINMember us-gaap:OtherLiabilitiesMember 2021-03-31 0001600620 auph:ILJINMember us-gaap:OtherLiabilitiesMember 2020-12-31 0001600620 auph:LegalFeesMember srt:ManagementMember 2020-01-01 2020-03-31 shares iso4217:USD iso4217:USD shares auph:segment auph:reportingUnit pure utr:sqft auph:extension_option false 2021 Q1 0001600620 --12-31 10-Q true 2021-03-31 false 001-36421 Aurinia Pharmaceuticals Inc. Z4 #1203-4464 Markham Street Victoria BC V8Z 7X8 46-4129078 (250) 708-4272 Yes Yes Large Accelerated Filer false false false 128156427 Common shares, no par value AUPH NASDAQ 156591000 272350000 191668000 125979000 1187000 0 15936000 13927000 6864000 7171000 372246000 419427000 12603000 24380000 11856000 247000 4758000 4786000 9854000 9332000 5761000 5489000 417078000 463661000 17694000 24797000 2000000 6000000 2382000 6412000 1075000 788000 21151000 31997000 17893000 16295000 7806000 7619000 46850000 55911000 128121000 128121000 126725000 126725000 952673000 944328000 43889000 39383000 -799000 -805000 -625535000 -575156000 370228000 407750000 417078000 463661000 884000 0 30000 30000 914000 30000 48000 0 39282000 11053000 9833000 13835000 523000 286000 -1771000 -1916000 51457000 27090000 -50543000 -27060000 172000 890000 -50371000 -26170000 8000 -238000 -50379000 -25932000 0 0 6000 0 -50373000 -25932000 -0.40 -0.23 127401000 112209000 126725000 944328000 39383000 -805000 -575156000 407750000 877000 7619000 -2620000 4999000 519000 726000 -695000 31000 7821000 7821000 6000 6000 -50379000 -50379000 128121000 952673000 43889000 -799000 -625535000 370228000 111798000 746487000 25394000 -805000 -472476000 298600000 688000 4450000 -1530000 2920000 1000 3000 -1000 2000 3496000 3496000 -25932000 -25932000 112487000 750940000 27359000 -805000 -498408000 279086000 -50379000 -25932000 165000 12000 523000 286000 7821000 3496000 2111000 -870000 1187000 0 2009000 0 -308000 2661000 -229000 0 272000 5764000 -7103000 1234000 474000 5851000 -53541000 -22608000 115168000 11913000 60940000 0 136000 79000 11838000 0 1039000 86000 6000 48000 -67247000 -12126000 4999000 2920000 30000 2000 0 0 5029000 2922000 -115759000 -31812000 272350000 306019000 156591000 274207000 425000 891000 Organization and Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company has developed LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an investigational drug, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle, Rockville, Maryland, United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are currently listed and traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH and on the Toronto Stock Exchange (TSX) under the symbol AUP.</span></div> Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2021 have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief operating decision maker (CODM), the chief executive officer, makes decisions based on the Company as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div>We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. Taking into consideration the Company's cash and cash equivalents of $156.6 million and short term investments of $191.7 million as of March 31, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued. 1 1 1 156600000 191700000 Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue recognition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inventory;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty obligation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent accruals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible assets; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two specialty pharmacies accounted for approximately 59% and 37% of the Company's total revenues. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments — Debt Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments classified as held to maturity are carried at fair value which is approximately equal to amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income (expense) is recorded separately on the consolidated statements of operations.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More specifically, these adjustments include the following: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt pay discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&amp;A) expense. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates: </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are accounted for in accordance with ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ASC 730) and are expensed as incurred. Research and development costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's selling, general and administrative (SG&amp;A) expense includes commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These selling, general and administrative costs include: corporate facility operating expenses and allocated depreciation; commercial, marketing and operations in support of LUPKYINIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense selling, general and administrative expenses as they are incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to specialty pharmacies, and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in selling, general and administrative expenses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. As of March 31, 2021, accounts receivable, net are $1.2 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of March 31, 2021 and March 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses if fair value increases. The adoption of the standard as of January 1, 2020 did not have a material impact on the Company’s consolidated financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Topic 820 requires to disclose transfers into and out of Level 3 of the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements, resulting in capitalized costs of $1.7 million in 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue recognition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inventory;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty obligation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent accruals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible assets; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income taxes.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two specialty pharmacies accounted for approximately 59% and 37% of the Company's total revenues. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the </span></div>status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses. 0.59 0.37 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments — Debt Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments classified as held to maturity are carried at fair value which is approximately equal to amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income (expense) is recorded separately on the consolidated statements of operations.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of securities sold is based on the specific-identification method.</span> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More specifically, these adjustments include the following: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt pay discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&amp;A) expense. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates: </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development costs are accounted for in accordance with ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span>, (ASC 730) and are expensed as incurred. Research and development costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's selling, general and administrative (SG&amp;A) expense includes commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These selling, general and administrative costs include: corporate facility operating expenses and allocated depreciation; commercial, marketing and operations in support of LUPKYINIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense selling, general and administrative expenses as they are incurred.</span>The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to specialty pharmacies, and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in selling, general and administrative expenses. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. As of March 31, 2021, accounts receivable, net are $1.2 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of March 31, 2021 and March 31, 2020.</span> 1200000 0 0 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses if fair value increases. The adoption of the standard as of January 1, 2020 did not have a material impact on the Company’s consolidated financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Topic 820 requires to disclose transfers into and out of Level 3 of the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements, resulting in capitalized costs of $1.7 million in 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.</span></div> 1700000 Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had $191.7 million and $12.6 million and $126.0 million and $24.4 million of short and long-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of March 31, 2021, the Company classifies its investments as debt securities of which $89.1 million are held to maturity and $115.2 million are available-for-sale. As of December 31, 2020, $150.4 million were classified as held to maturity and $nil were available-for-sale. </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashable Guaranteed Investment Certificate (GIC)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191,668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bonds - total long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,603</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Currently the Company does not intend to sell investments that are classified as held-to-maturity and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of March 31, 2021 and December 31, 2020, accrued interest receivable from the investments were $0.4 million and $0.5 million, respectively. As of March 31, 2021, the Company had $6 thousand unrealized gains on available-for-sale securities, net of tax, which are included as a component of comprehensive loss. The Company's investments as of March 31, 2021 mature at various dates through June 2022. 191700000 12600000 126000000.0 24400000 89100000 115200000 150400000 0 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashable Guaranteed Investment Certificate (GIC)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191,668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bonds - total long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,603</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2502000 2000000 41524000 40372000 133907000 67747000 5910000 7999000 5021000 5045000 2804000 2816000 191668000 125979000 12603000 24380000 204271000 150359000 400000 500000 6000 Inventories<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued under a standard costing technique on a first-in, first out (FIFO) basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For our product LUPKYNIS, the Company commenced capitalization of inventory once FDA approval was deemed to be probable, which occurred during the third quarter of 2020. Capitalized costs of inventories for LUPKYNIS mainly includes third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory as of March 31, 2021 and December 31, 2020 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,569</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory as of March 31, 2021 and December 31, 2020 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,569</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14367000 13927000 1569000 0 15936000 13927000 Prepaid Expenses and Other Current Assets<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes prepaid expenses and other current assets.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes prepaid expenses and other current assets.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4139000 3701000 939000 2054000 1180000 1018000 606000 398000 6864000 7171000 Intangible Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,713</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,496</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,642)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,452 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,120)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,332 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three-month periods ended March 31, 2021 and March 31, 2020 was $0.5 million and $0.3 million, respectively.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,713</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,496</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,642)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,452 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,120)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,332 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P11Y 1657000 1229000 428000 P11Y 15126000 8028000 7098000 P3Y 2713000 385000 2328000 P11Y 19496000 9642000 9854000 P11Y 1651000 1203000 448000 P11Y 15126000 7770000 7356000 P3Y 1675000 147000 1528000 P11Y 18452000 9120000 9332000 500000 300000 Property and Equipment, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment as of March 31, 2021 and December 31, 2020 are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three-month periods ended March 31, 2021 and March 31, 2020 was $0.2 million and $nil, respectively, which is included in selling, general and administrative expenses in the condensed consolidated statements of operations.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment as of March 31, 2021 and December 31, 2020 are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 279000 4467000 2951000 34000 1604000 83000 270000 381000 5104000 4965000 346000 179000 4758000 4786000 200000 0 Lease Obligations<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of March 31, 2021, the Company had $0.4 million right-of-use assets (ROU asset) and $0.4 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in selling, general and administrative expense in the condensed consolidated statement of operations. The incremental borrowing rate applied to the lease liabilities was 4.08% based on financial position, geographical region and terms of leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The lease term is expected to begin in 2022. The present value of the minimum lease payments for this lease are $3.3 million. As of March 31, 2021, there has been no accounting recognition associated with this lease, as the Company has not been granted access to the building.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland Lease</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its commercial office in Rockville, Maryland. The lease has a remaining term of approximately 11 years and has an option to extend for two five-year periods after the 11 years has elapsed and an option to terminate after seven years. As of March 31, 2021, the Company had a right-of-use asset of $5.4 million and lease liability of $8.5 million included in the condensed consolidated balance sheets. As of December 31, 2020, the Company had a right of use asset of $5.5 million and lease liability of $8.4 million included in the condensed consolidated balance sheets. During 2020, the Company received reimbursements for tenant leasehold improvements by the landlord in the amount of $2.3 million for the Maryland lease. The Company recorded these leasehold improvement incentives as additions to the lease liability and construction in progress. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta Canada</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into an agreement to lease premises in Edmonton, Alberta, commencing on October 1, 2020 and ending September 30, 2021. The lease agreement is considered a short-term lease as the term is twelve months. The Company recognizes short-term leases on a straight-line basis and did not record a related lease asset or liability for the Edmonton lease. The Company recognized short-term rent expense for this lease, which is included in selling, general and administrative expense in the condensed consolidated statement of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental balance sheet information related to the operating lease ROU asset and lease liabilities:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,075</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning January 1, 2021 the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs for the three-month periods ended March 31, 2021. The following provides a summary of the components of leasing costs and rent for the three-month periods ended March 31, 2021 and March 31, 2020. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office building</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of March 31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of lease liability maturities for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance Lease</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the monoplant, the Company will have the right to maintain unobstructed use of the monoplant by paying a quarterly fixed facility fee. The first capital expenditure payment was made in February 2021 of $11.8 million which was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be the beginning of 2023.</span></div>The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $91.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table. 13206 400000 400000 0.0408 3300000 P11Y 2 P5Y P11Y P7Y 5400000 8500000 5500000 8400000 -2300000 0.052 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental balance sheet information related to the operating lease ROU asset and lease liabilities:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,075</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,806</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5761000 5489000 1075000 788000 7806000 7619000 8881000 8407000 <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office building</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of March 31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18%</span></td></tr></table></div> 261000 65000 7000 76000 41000 1000 309000 142000 P10Y18D 0.0518 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of lease liability maturities for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 484000 1144000 1061000 1085000 1110000 6773000 11657000 2776000 8881000 11800000 91000000.0 Accounts Payable and Accrued Liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's accounts payable and accrued liabilities.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,694</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,797 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,694</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,797 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2182000 2635000 9727000 10855000 5785000 11307000 17694000 24797000 Non-current LiabilitiesThe Company recorded other non-current liabilities of $17.9 million and $16.3 million as of March 31, 2021 and December 31, 2020, respectively. The balance as of March 31, 2021 and December 31, 2020 primarily included royalty obligations that are the result of a resolution of the board of directors of the Company dated March 8, 2012 whereby certain executive officers at that time were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. 17900000 16300000 Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short and long-term investments that are valued through third-party pricing services that use verifiable observable market data. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,096 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,709 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,096 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,709 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 110050000 0 0 110050000 46511000 30000 0 46541000 133907000 70364000 204271000 290468000 70394000 0 360862000 130807000 0 0 130807000 141543000 0 0 141543000 69746000 80613000 0 150359000 342096000 80613000 0 422709000 License and Collaboration Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS for the treatment of adult patients with active LN in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Aurinia received an upfront cash payment of $50.0 million for the license agreement, and has the potential to receive up to $50.0 million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, a supply agreement will be negotiated in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional intellectual property (IP) that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0 million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 there has been no additional consideration earned or received since the upfront payment of $50.0 million in the quarter ended December 31, 2020.</span></div> 50000000.0 50000000.0 0.10 0.20 50000000.0 0 50000000.0 Net Loss per Common Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Common shares that could potentially dilute basic net loss per common share in the future that could be issued from the exercise of stock options and warrants were not included in the computation of the diluted loss per common share for the three-month periods ended March 31, 2021 and March 31, 2020 because to do so would be anti-dilutive. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,932)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,209 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding number and type of securities in the following table would potentially dilute basic loss per common share in the future and therefore, were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive).</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,932)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127,401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,209 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -50379000 -25932000 127401000 112209000 -0.40 -0.23 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding number and type of securities in the following table would potentially dilute basic loss per common share in the future and therefore, were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive).</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14771000 9685000 1014000 1690000 15785000 11375000 Share-based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Equity Incentive Plan (the Plan) was adopted and approved in 2012 and re-approved in May 2014. The Plan was amended as to Section 2.2 by the shareholders of the Company in June 2016 and amended and restated in June 2020. The purpose of the Plan is to advance the interest of the Company by encouraging equity participation in the Company through the acquisition of common shares. As of March 31, 2021 and December 31, 2020, 128.1 million and 126.7 million, common shares were issued and outstanding, resulting in a maximum of 16.0 million and 15.8 million, respectively, options available for issuance under the Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions were used to estimate the fair value of the options granted during the three-month periods ended March 31, 2021 and March 31, 2020:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each performance award which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The Company recorded approximately $0.2 million and $nil of share-based compensation expense related to executive performance awards during the three months ended March 31, 2021 and March 31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the equity award activity during the three months ended March 31, 2021: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest - End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three-month periods ended March 31, 2021 and March 31, 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,821</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March 31, 2021, there was $36.6 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.</span></div> 128100000 128100000 126700000 126700000 16000000.0 15800000 The following weighted average <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions were used to estimate the fair value of the options granted during the three-month periods ended March 31, 2021 and March 31, 2020:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.66 0.43 0.0028 0.0120 P4Y P3Y 0.089 0.130 0.000 0.000 6.72 5.44 439000 13.56 200000 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the equity award activity during the three months ended March 31, 2021: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,486</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest - End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14486000 11.35 1392000 13.62 877000 5.65 230000 12.33 14771000 12.94 897000 13.11 5014000 8.15 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three-month periods ended March 31, 2021 and March 31, 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,821</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1074000 1217000 6641000 2279000 106000 0 7821000 3496000 36600000 P1Y3M18D Income TaxesThe effective tax rates for the three months ended March 31, 2021 and March 31, 2020 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $8 thousand for the three months ended March 31, 2021 and an income tax benefit of $0.2 million for the three months ended March 31, 2020. The expense recognized for the three months ended March 31, 2021 was a result of income in a certain jurisdiction. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions. The tax benefit recognized for the three months ended March 31, 2020 was a result of a discrete tax benefit recorded in the U.S. pursuant to certain tax provisions provided under the CARES Act. The CARES Act permits the Company to carry back net operating losses to offset taxable income generated in the five preceding years, some of which were taxed at a federal income tax rate higher than the current enacted rate. 8000 -200000 Related Party Transactions<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ILJIN is considered to be a related party due to their equity ownership of over 5%. The outstanding related party amount payable to ILJIN is the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the period ended March 31, 2021, Aurinia paid $4.0 million upon achievement of specific milestones. The amount payable to ILJIN of $2.0 million and $6.0 million as of March 31, 2021 and December 31, 2020 was recorded in other current liabilities and non-current liabilities, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stephen P. Robertson was a partner at Borden Ladner Gervais (BLG) and acted as our corporate secretary through October 2020. We incurred legal fees in the normal course of business to BLG of $63 thousand for the quarter ended March 31, 2020 and did not incur similar fees in 2021. We had no ongoing contractual or other commitments as a result of engaging Mr. Robertson to act as our corporate secretary and Mr. Robertson received no additional compensation for acting as the corporate secretary. On November 2, 2020 we announced the appointment of Stephen Robertson as our Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.</span></div> 4000000.0 2000000.0 6000000.0 63000 Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's commitments and contingencies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various manufacturing agreements to support our commercial and clinical product supply requirements. </span></div>We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial and clinical drug substance requirements. We have firm orders with Lonza, with remaining total non-cancellable future commitments of approximately $25.4 million through 2023. If we terminate certain firm orders with Lonza without cause, we will be required to pay for drug substance scheduled for manufacture under our arrangement. 25400000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2021
May 06, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-36421  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Tax Identification Number 46-4129078  
Entity Address, Address Line One #1203-4464 Markham Street  
Entity Address, City or Town Victoria  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V8Z 7X8  
City Area Code (250)  
Local Phone Number 708-4272  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   128,156,427
Title of 12(b) Security Common shares, no par value  
Trading Symbol AUPH  
Security Exchange Name NASDAQ  
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001600620  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 156,591 $ 272,350
Short-term investments 191,668 125,979
Accounts receivable, net 1,187 0
Inventories, net 15,936 13,927
Prepaid expenses and other current assets 6,864 7,171
Total current assets 372,246 419,427
Non-current assets:    
Long-term investments 12,603 24,380
Other non-current assets 11,856 247
Property and equipment, net 4,758 4,786
Acquired intellectual property and other intangible assets, net 9,854 9,332
Right-of-use assets 5,761 5,489
Total assets 417,078 463,661
Current liabilities    
Accounts payable and accrued liabilities 17,694 24,797
Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively) 2,382 6,412
Operating lease liabilities 1,075 788
Total current liabilities 21,151 31,997
Non-current liabilities    
Other non-current liabilities 17,893 16,295
Operating lease liabilities 7,806 7,619
Total liabilities 46,850 55,911
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY    
Common shares - no par value, unlimited shares authorized, 128,121 and 126,725 shares issued and outstanding as at March 31, 2021 and December 31, 2020, respectively 952,673 944,328
Additional paid-in capital 43,889 39,383
Accumulated other comprehensive loss (799) (805)
Accumulated deficit (625,535) (575,156)
Total shareholder’s equity 370,228 407,750
Total liabilities and shareholders’ equity $ 417,078 $ 463,661
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Due to related party, current $ 2,000 $ 6,000
Common stock, issued (shares) 128,121,000 126,725,000
Common stock, outstanding (shares) 128,121,000 126,725,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Net revenue:    
Total revenues $ 914 $ 30
Operating expenses:    
Cost of sales 48 0
Selling, general and administrative 39,282 11,053
Research and development 9,833 13,835
Amortization of intangible assets 523 286
Other expense, net (1,771) (1,916)
Total cost and operating expenses 51,457 27,090
Loss from operations (50,543) (27,060)
Interest income 172 890
Net loss before income taxes (50,371) (26,170)
Income tax expense (benefit) 8 (238)
Net loss (50,379) (25,932)
Other comprehensive loss:    
Unrealized gain on available-for-sale securities, net of tax of $nil 6 0
Comprehensive loss $ (50,373) $ (25,932)
Net loss per common share (expressed in $ per share) $ (0.40) $ (0.23)
Weighted-average common shares outstanding used in computation of basic and diluted loss per share 127,401 112,209
Licensing revenue    
Net revenue:    
Total revenues $ 884 $ 0
Contract revenue    
Net revenue:    
Total revenues $ 30 $ 30
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Unrealized gain on available-for-sale securities, tax $ 0.0 $ 0.0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Shares
Additional paid in capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Balance (in shares) at Dec. 31, 2019   111,798,000      
Balance at Dec. 31, 2019 $ 298,600 $ 746,487 $ 25,394 $ (805) $ (472,476)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options (in shares)   688,000      
Shares issued on exercise of stock options 2,920 $ 4,450 (1,530)    
Exercise of warrants (in shares)   1,000      
Exercise of warrants 2 $ 3 (1)    
Share-based compensation 3,496   3,496    
Net loss and comprehensive loss for the period (25,932)       (25,932)
Balance (in shares) at Mar. 31, 2020   112,487,000      
Balance at Mar. 31, 2020 $ 279,086 $ 750,940 27,359 (805) (498,408)
Balance (in shares) at Dec. 31, 2020 126,725,000 126,725,000      
Balance at Dec. 31, 2020 $ 407,750 $ 944,328 39,383 (805) (575,156)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options (in shares)   877,000      
Shares issued on exercise of stock options 4,999 $ 7,619 (2,620)    
Exercise of warrants (in shares)   519,000      
Exercise of warrants 31 $ 726 (695)    
Share-based compensation 7,821   7,821    
Other comprehensive income 6     6  
Net loss and comprehensive loss for the period $ (50,379)       (50,379)
Balance (in shares) at Mar. 31, 2021 128,121,000 128,121,000      
Balance at Mar. 31, 2021 $ 370,228 $ 952,673 $ 43,889 $ (799) $ (625,535)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows used in operating activities:    
Net loss and comprehensive loss for the period $ (50,379) $ (25,932)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation of property and equipment 165 12
Amortization of intangible assets 523 286
Share-based compensation expense 7,821 3,496
Other, net (2,111) 870
Net changes in operating assets and liabilities    
Accounts receivable (1,187) 0
Inventories (2,009) 0
Prepaid expenses and other current assets 308 (2,661)
Non-current assets 229 0
Right of use assets (272) (5,764)
Accounts payable and accrued liabilities (7,103) 1,234
Lease liabilities 474 5,851
Net cash used in operating activities (53,541) (22,608)
Cash flows used in investing activities:    
Purchase of short-term investments (115,168) (11,913)
Proceeds from maturities of short-investments 60,940 0
Purchases of equipment (136) (79)
Upfront lease payment (11,838) 0
Internal use-software implementation costs (1,039) (86)
Capitalized patent costs (6) (48)
Net cash used in investing activities (67,247) (12,126)
Cash flows from financing activities    
Proceeds from exercise of stock options 4,999 2,920
Proceeds from exercise of warrants 30 2
Net proceeds from issuance of common shares 0 0
Net cash provided by financing activities 5,029 2,922
Net (decrease) increase in cash and cash equivalents during the year (115,759) (31,812)
Cash and cash equivalents, beginning of the year 272,350 306,019
Cash and cash equivalents, end of the year 156,591 274,207
Supplemental cash flow information:    
Cash received for interest $ 425 $ 891
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Organization and Description of Business
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company has developed LUPKYNISTM, an investigational drug, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program.
On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN.
Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle, Rockville, Maryland, United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are currently listed and traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH and on the Toronto Stock Exchange (TSX) under the symbol AUP.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2021 have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.
The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief operating decision maker (CODM), the chief executive officer, makes decisions based on the Company as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.
These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.
We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. Taking into consideration the Company's cash and cash equivalents of $156.6 million and short term investments of $191.7 million as of March 31, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Critical Accounting Estimates: The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial liabilities;
•Share-based compensation;
•Intangible assets; and
•Income taxes.
Concentration of Credit Risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.

The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two specialty pharmacies accounted for approximately 59% and 37% of the Company's total revenues. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the
status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
Investments: The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 320, Investments — Debt Securities. Investments classified as held to maturity are carried at fair value which is approximately equal to amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income (expense) is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method.
Revenue Recognition: Pursuant to Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.
More specifically, these adjustments include the following:
Prompt pay discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Customer fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&A) expense.
Government rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.
Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
Co-payment assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
License, Collaboration and Other Revenues
The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Manufacturing supply services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.
Milestone payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-
evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.
Research, Development and/or Manufacturing Services. The Company’s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.
Cost of sales: Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.
Research and development costs: Research and development costs are accounted for in accordance with ASC Topic 730, Research and Development, (ASC 730) and are expensed as incurred. Research and development costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers.
Selling, general and administrative expenses: The Company's selling, general and administrative (SG&A) expense includes commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These selling, general and administrative costs include: corporate facility operating expenses and allocated depreciation; commercial, marketing and operations in support of LUPKYINIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense selling, general and administrative expenses as they are incurred.
The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to specialty pharmacies, and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in selling, general and administrative expenses.
Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of March 31, 2021, accounts receivable, net are $1.2 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of March 31, 2021 and March 31, 2020.
Recently adopted accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The adoption of the standard as of January 1, 2020 did not have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement. Topic 820 requires to disclose transfers into and out of Level 3 of the
fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements, resulting in capitalized costs of $1.7 million in 2020.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Investments
 3 Months Ended
Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
As of March 31, 2021 and December 31, 2020, the Company had $191.7 million and $12.6 million and $126.0 million and $24.4 million of short and long-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of March 31, 2021, the Company classifies its investments as debt securities of which $89.1 million are held to maturity and $115.2 million are available-for-sale. As of December 31, 2020, $150.4 million were classified as held to maturity and $nil were available-for-sale.
(in thousands)March 31, 2021December 31, 2020
Cashable Guaranteed Investment Certificate (GIC)$2,502 $2,000 
Corporate Bond41,524 40,372 
Commercial Paper133,907 67,747 
Treasury Bill5,910 7,999 
Treasury Bond5,021 5,045 
Yankee Bond2,804 2,816 
Total short-term investments191,668 125,979 
Corporate Bonds - total long-term investments12,603 24,380 
Total investments$204,271 $150,359 
Currently the Company does not intend to sell investments that are classified as held-to-maturity and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of March 31, 2021 and December 31, 2020, accrued interest receivable from the investments were $0.4 million and $0.5 million, respectively. As of March 31, 2021, the Company had $6 thousand unrealized gains on available-for-sale securities, net of tax, which are included as a component of comprehensive loss. The Company's investments as of March 31, 2021 mature at various dates through June 2022.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories
 3 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories are valued under a standard costing technique on a first-in, first out (FIFO) basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For our product LUPKYNIS, the Company commenced capitalization of inventory once FDA approval was deemed to be probable, which occurred during the third quarter of 2020. Capitalized costs of inventories for LUPKYNIS mainly includes third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.

The components of inventory as of March 31, 2021 and December 31, 2020 are as follows:
(in thousands)March 31, 2021December 31, 2020
Work in process$14,367 $13,927 
Finished goods1,569 — 
Total inventories$15,936 $13,927 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets
 3 Months Ended
Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets
The following table summarizes prepaid expenses and other current assets.

(in thousands)March 31, 2021December 31, 2020
Prepaid assets$4,139 $3,701 
Prepaid insurance939 2,054 
Other current assets1,180 1,018 
Prepaid deposits606 398 
Total prepaid expenses and other current assets$6,864 $7,171 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets
 3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
March 31, 2021
(in thousands)Weighted Average
Life (in years)		Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents11$1,657 $(1,229)$428 
Acquired intellectual property and reacquired rights1115,126 (8,028)7,098 
Internal-use software implementation costs32,713 (385)2,328 
11$19,496 $(9,642)$9,854 
December 31, 2020
(in thousands)Weighted Average
Life (in years)		Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents11$1,651 $(1,203)$448 
Acquired intellectual property and reacquired rights1115,126 (7,770)7,356 
Internal-use software implementation costs31,675 (147)1,528 
11$18,452 $(9,120)$9,332 
Amortization expense for the three-month periods ended March 31, 2021 and March 31, 2020 was $0.5 million and $0.3 million, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment, net
 3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, net Property and Equipment, net
Property and equipment as of March 31, 2021 and December 31, 2020 are as follows:
(in thousands)March 31, 2021December 31, 2020
Construction in progress$279 $4,467 
Leasehold improvements2,951 34 
Office equipment and furniture1,604 83 
Computer equipment270 381 
5,1044,965
Less accumulated depreciation(346)(179)
Property and equipment, net$4,758 $4,786 

Depreciation expense for the three-month periods ended March 31, 2021 and March 31, 2020 was $0.2 million and $nil, respectively, which is included in selling, general and administrative expenses in the condensed consolidated statements of operations.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Obligations
 3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Leases Lease Obligations
Victoria, British Columbia
During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of March 31, 2021, the Company had $0.4 million right-of-use assets (ROU asset) and $0.4 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in selling, general and administrative expense in the condensed consolidated statement of operations. The incremental borrowing rate applied to the lease liabilities was 4.08% based on financial position, geographical region and terms of leases.
During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The lease term is expected to begin in 2022. The present value of the minimum lease payments for this lease are $3.3 million. As of March 31, 2021, there has been no accounting recognition associated with this lease, as the Company has not been granted access to the building.
Rockville, Maryland Lease
During March 2020, the Company entered into a lease for its commercial office in Rockville, Maryland. The lease has a remaining term of approximately 11 years and has an option to extend for two five-year periods after the 11 years has elapsed and an option to terminate after seven years. As of March 31, 2021, the Company had a right-of-use asset of $5.4 million and lease liability of $8.5 million included in the condensed consolidated balance sheets. As of December 31, 2020, the Company had a right of use asset of $5.5 million and lease liability of $8.4 million included in the condensed consolidated balance sheets. During 2020, the Company received reimbursements for tenant leasehold improvements by the landlord in the amount of $2.3 million for the Maryland lease. The Company recorded these leasehold improvement incentives as additions to the lease liability and construction in progress. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta Canada
During the fourth quarter of 2020, the Company entered into an agreement to lease premises in Edmonton, Alberta, commencing on October 1, 2020 and ending September 30, 2021. The lease agreement is considered a short-term lease as the term is twelve months. The Company recognizes short-term leases on a straight-line basis and did not record a related lease asset or liability for the Edmonton lease. The Company recognized short-term rent expense for this lease, which is included in selling, general and administrative expense in the condensed consolidated statement of operations.
The following table provides supplemental balance sheet information related to the operating lease ROU asset and lease liabilities:
(in thousands)Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Assets
Operating lease right of-use assetsRight-of-use assets$5,761 $5,489 
Liabilities
Current operating lease liabilitiesCurrent operating lease liabilities1,075 $788 
Non-current operating lease liabilitiesNon-current operating lease liabilities7,806 7,619 
Total lease liabilities$8,881 $8,407 
Beginning January 1, 2021 the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs for the three-month periods ended March 31, 2021. The following provides a summary of the components of leasing costs and rent for the three-month periods ended March 31, 2021 and March 31, 2020.
(in thousands)Consolidated Statement of OperationsMarch 31,
2021		March 31,
2020
Operating lease costs
Operating lease costsSelling, general and administrative$261 $65 
Short-term lease costs
Office BuildingSelling, general and administrative7 76 
Variable lease costs
Office buildingSelling, general and administrative41 1 
Total rent expense$309 $142 
The following table represents the weighted-average remaining lease term and discount rate as of March 31, 2021:
As of March 31, 2021
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases10.055.18%
The following table provides a summary of lease liability maturities for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2021$484 
20221,144 
20231,061 
20241,085 
20251,110 
Thereafter6,773 
Total future minimum lease payments 11,657 
Less: lease imputed interest(2,776)
Total future minimum lease payments$8,881 
Finance Lease
On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
Upon completion of the monoplant, the Company will have the right to maintain unobstructed use of the monoplant by paying a quarterly fixed facility fee. The first capital expenditure payment was made in February 2021 of $11.8 million which was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be the beginning of 2023.
The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $91.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Accrued Liabilities
 3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
The following table summarizes the Company's accounts payable and accrued liabilities.

(in thousands)March 31, 2021December 31, 2020
Trade payables$2,182 $2,635 
Other accrued liabilities9,727 10,855 
Employee accruals5,785 11,307 
Total accounts payable and accrued liabilities$17,694 $24,797 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Non-current Liabilities
 3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Non-current Liabilities Non-current LiabilitiesThe Company recorded other non-current liabilities of $17.9 million and $16.3 million as of March 31, 2021 and December 31, 2020, respectively. The balance as of March 31, 2021 and December 31, 2020 primarily included royalty obligations that are the result of a resolution of the board of directors of the Company dated March 8, 2012 whereby certain executive officers at that time were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short and long-term investments that are valued through third-party pricing services that use verifiable observable market data.
There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.
The following tables present the financial assets measured at fair value on a recurring basis:
March 31, 2021
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$110,050 $— $— $110,050 
Short-term highly liquid investments46,511 30 — 46,541 
Investments133,907 70,364 204,271 
$290,468 $70,394 $— $360,862 
December 31, 2020
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$130,807 $— $— $130,807 
Short-term highly liquid investments141,543 — — 141,543 
Investments69,746 80,613 — 150,359 
$342,096 $80,613 $— $422,709 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreement
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
License and Collaboration Agreement License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS for the treatment of adult patients with active LN in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.

As part of the agreement, Aurinia received an upfront cash payment of $50.0 million for the license agreement, and has the potential to receive up to $50.0 million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, a supply agreement will be negotiated in the future.

The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional intellectual property (IP) that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0 million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.

The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.

As of March 31, 2021 there has been no additional consideration earned or received since the upfront payment of $50.0 million in the quarter ended December 31, 2020.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Common Share
 3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Net Loss per Common Share Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Common shares that could potentially dilute basic net loss per common share in the future that could be issued from the exercise of stock options and warrants were not included in the computation of the diluted loss per common share for the three-month periods ended March 31, 2021 and March 31, 2020 because to do so would be anti-dilutive. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
March 31,
(in thousands, except per share data)20212020
Net loss$(50,379)$(25,932)
Weighted average common shares outstanding127,401 112,209 
Net loss per common share (expressed in $ per share)$(0.40)$(0.23)
The outstanding number and type of securities in the following table would potentially dilute basic loss per common share in the future and therefore, were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive).
Three months ended
March 31,
(in thousands)20212020
Stock options14,771 9,685 
Warrants1,014 1,690 
15,785 11,375 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Share-based Compensation Share-based Compensation
The Company's Equity Incentive Plan (the Plan) was adopted and approved in 2012 and re-approved in May 2014. The Plan was amended as to Section 2.2 by the shareholders of the Company in June 2016 and amended and restated in June 2020. The purpose of the Plan is to advance the interest of the Company by encouraging equity participation in the Company through the acquisition of common shares. As of March 31, 2021 and December 31, 2020, 128.1 million and 126.7 million, common shares were issued and outstanding, resulting in a maximum of 16.0 million and 15.8 million, respectively, options available for issuance under the Plan.

Stock Options

The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average
assumptions were used to estimate the fair value of the options granted during the three-month periods ended March 31, 2021 and March 31, 2020:
March 31, 2021March 31, 2020
Annualized volatility66 %43%
Risk-free interest rate0.28 %1.20%
Expected life of options in years4.0 years3.0 years
Estimated forfeiture rate8.9 %13.0%
Dividend rate0.0 %0.0%
Fair value per common share option$6.72 $5.44 

Performance Awards
On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each performance award which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The Company recorded approximately $0.2 million and $nil of share-based compensation expense related to executive performance awards during the three months ended March 31, 2021 and March 31, 2020, respectively.

The following table summarizes the equity award activity during the three months ended March 31, 2021:

March 31, 2021
Number of shares (in thousands)Weighted average exercise price $
Outstanding - Beginning of Period14,486 11.35 
Granted1,392 13.62 
Exercised(877)5.65 
Forfeited(230)12.33 
Outstanding - End of Period14,771 12.94 
Vested and expected to vest - End of Period897 13.11 
Options exercisable - End of Period5,014 8.15 
Compensation Expense
The Company recognized share-based compensation expense for the three-month periods ended March 31, 2021 and March 31, 2020 as follows:
(in thousands)March 31, 2021March 31, 2020
Research and development$1,074 $1,217 
Selling, general and administrative6,641 2,279 
Capitalized under inventories106 — 
Share-based compensation expense$7,821 $3,496 
At March 31, 2021, there was $36.6 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
 3 Months Ended
Mar. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesThe effective tax rates for the three months ended March 31, 2021 and March 31, 2020 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $8 thousand for the three months ended March 31, 2021 and an income tax benefit of $0.2 million for the three months ended March 31, 2020. The expense recognized for the three months ended March 31, 2021 was a result of income in a certain jurisdiction. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions. The tax benefit recognized for the three months ended March 31, 2020 was a result of a discrete tax benefit recorded in the U.S. pursuant to certain tax provisions provided under the CARES Act. The CARES Act permits the Company to carry back net operating losses to offset taxable income generated in the five preceding years, some of which were taxed at a federal income tax rate higher than the current enacted rate.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Related-Party Transactions
 3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related-Party Transactions Related Party Transactions
ILJIN is considered to be a related party due to their equity ownership of over 5%. The outstanding related party amount payable to ILJIN is the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the period ended March 31, 2021, Aurinia paid $4.0 million upon achievement of specific milestones. The amount payable to ILJIN of $2.0 million and $6.0 million as of March 31, 2021 and December 31, 2020 was recorded in other current liabilities and non-current liabilities, respectively.
Stephen P. Robertson was a partner at Borden Ladner Gervais (BLG) and acted as our corporate secretary through October 2020. We incurred legal fees in the normal course of business to BLG of $63 thousand for the quarter ended March 31, 2020 and did not incur similar fees in 2021. We had no ongoing contractual or other commitments as a result of engaging Mr. Robertson to act as our corporate secretary and Mr. Robertson received no additional compensation for acting as the corporate secretary. On November 2, 2020 we announced the appointment of Stephen Robertson as our Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Commitment and Contingencies
 3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's commitments and contingencies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Manufacturing Commitments
We have various manufacturing agreements to support our commercial and clinical product supply requirements.
We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial and clinical drug substance requirements. We have firm orders with Lonza, with remaining total non-cancellable future commitments of approximately $25.4 million through 2023. If we terminate certain firm orders with Lonza without cause, we will be required to pay for drug substance scheduled for manufacture under our arrangement.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Critical Accounting Estimates
Critical Accounting Estimates: The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial liabilities;
•Share-based compensation;
•Intangible assets; and
•Income taxes.
Concentration of Credit Risk
Concentration of Credit Risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.

The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two specialty pharmacies accounted for approximately 59% and 37% of the Company's total revenues. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the
status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
Investments Investments: The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 320, Investments — Debt Securities. Investments classified as held to maturity are carried at fair value which is approximately equal to amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income (expense) is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method.
Revenue Recognition
Revenue Recognition: Pursuant to Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.
More specifically, these adjustments include the following:
Prompt pay discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Customer fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&A) expense.
Government rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.
Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
Co-payment assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
License, Collaboration and Other Revenues
The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Manufacturing supply services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.
Milestone payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-
evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.
Research, Development and/or Manufacturing Services. The Company’s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.
Cost of sales Cost of sales: Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.
Research and development costs Research and development costs: Research and development costs are accounted for in accordance with ASC Topic 730, Research and Development, (ASC 730) and are expensed as incurred. Research and development costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers.
Selling, general and administrative expenses Selling, general and administrative expenses: The Company's selling, general and administrative (SG&A) expense includes commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These selling, general and administrative costs include: corporate facility operating expenses and allocated depreciation; commercial, marketing and operations in support of LUPKYINIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense selling, general and administrative expenses as they are incurred.The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to specialty pharmacies, and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in selling, general and administrative expenses.
Accounts receivable, net Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of March 31, 2021, accounts receivable, net are $1.2 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of March 31, 2021 and March 31, 2020.
Recently adopted accounting pronouncements
Recently adopted accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The adoption of the standard as of January 1, 2020 did not have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement. Topic 820 requires to disclose transfers into and out of Level 3 of the
fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements, resulting in capitalized costs of $1.7 million in 2020.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Investments (Tables)
 3 Months Ended
Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments
(in thousands)March 31, 2021December 31, 2020
Cashable Guaranteed Investment Certificate (GIC)$2,502 $2,000 
Corporate Bond41,524 40,372 
Commercial Paper133,907 67,747 
Treasury Bill5,910 7,999 
Treasury Bond5,021 5,045 
Yankee Bond2,804 2,816 
Total short-term investments191,668 125,979 
Corporate Bonds - total long-term investments12,603 24,380 
Total investments$204,271 $150,359 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventory
The components of inventory as of March 31, 2021 and December 31, 2020 are as follows:
(in thousands)March 31, 2021December 31, 2020
Work in process$14,367 $13,927 
Finished goods1,569 — 
Total inventories$15,936 $13,927 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets (Tables)
 3 Months Ended
Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure
The following table summarizes prepaid expenses and other current assets.

(in thousands)March 31, 2021December 31, 2020
Prepaid assets$4,139 $3,701 
Prepaid insurance939 2,054 
Other current assets1,180 1,018 
Prepaid deposits606 398 
Total prepaid expenses and other current assets$6,864 $7,171 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
March 31, 2021
(in thousands)Weighted Average
Life (in years)		Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents11$1,657 $(1,229)$428 
Acquired intellectual property and reacquired rights1115,126 (8,028)7,098 
Internal-use software implementation costs32,713 (385)2,328 
11$19,496 $(9,642)$9,854 
December 31, 2020
(in thousands)Weighted Average
Life (in years)		Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents11$1,651 $(1,203)$448 
Acquired intellectual property and reacquired rights1115,126 (7,770)7,356 
Internal-use software implementation costs31,675 (147)1,528 
11$18,452 $(9,120)$9,332 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment, net (Tables)
 3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Property and equipment as of March 31, 2021 and December 31, 2020 are as follows:
(in thousands)March 31, 2021December 31, 2020
Construction in progress$279 $4,467 
Leasehold improvements2,951 34 
Office equipment and furniture1,604 83 
Computer equipment270 381 
5,1044,965
Less accumulated depreciation(346)(179)
Property and equipment, net$4,758 $4,786 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Obligations (Tables)
 3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Supplemental Balance Sheet Information
The following table provides supplemental balance sheet information related to the operating lease ROU asset and lease liabilities:
(in thousands)Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Assets
Operating lease right of-use assetsRight-of-use assets$5,761 $5,489 
Liabilities
Current operating lease liabilitiesCurrent operating lease liabilities1,075 $788 
Non-current operating lease liabilitiesNon-current operating lease liabilities7,806 7,619 
Total lease liabilities$8,881 $8,407 
Lease, Cost
(in thousands)Consolidated Statement of OperationsMarch 31,
2021		March 31,
2020
Operating lease costs
Operating lease costsSelling, general and administrative$261 $65 
Short-term lease costs
Office BuildingSelling, general and administrative7 76 
Variable lease costs
Office buildingSelling, general and administrative41 1 
Total rent expense$309 $142 
The following table represents the weighted-average remaining lease term and discount rate as of March 31, 2021:
As of March 31, 2021
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases10.055.18%
Lessee, Operating Lease, Liability, Maturity
The following table provides a summary of lease liability maturities for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2021$484 
20221,144 
20231,061 
20241,085 
20251,110 
Thereafter6,773 
Total future minimum lease payments 11,657 
Less: lease imputed interest(2,776)
Total future minimum lease payments$8,881 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Accrued Liabilities (Tables)
 3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
(in thousands)March 31, 2021December 31, 2020
Trade payables$2,182 $2,635 
Other accrued liabilities9,727 10,855 
Employee accruals5,785 11,307 
Total accounts payable and accrued liabilities$17,694 $24,797 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the financial assets measured at fair value on a recurring basis:
March 31, 2021
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$110,050 $— $— $110,050 
Short-term highly liquid investments46,511 30 — 46,541 
Investments133,907 70,364 204,271 
$290,468 $70,394 $— $360,862 
December 31, 2020
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$130,807 $— $— $130,807 
Short-term highly liquid investments141,543 — — 141,543 
Investments69,746 80,613 — 150,359 
$342,096 $80,613 $— $422,709 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Common Share (Tables)
 3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
March 31,
(in thousands, except per share data)20212020
Net loss$(50,379)$(25,932)
Weighted average common shares outstanding127,401 112,209 
Net loss per common share (expressed in $ per share)$(0.40)$(0.23)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The outstanding number and type of securities in the following table would potentially dilute basic loss per common share in the future and therefore, were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive).
Three months ended
March 31,
(in thousands)20212020
Stock options14,771 9,685 
Warrants1,014 1,690 
15,785 11,375 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award Valuation Assumptions The following weighted average
assumptions were used to estimate the fair value of the options granted during the three-month periods ended March 31, 2021 and March 31, 2020:
March 31, 2021March 31, 2020
Annualized volatility66 %43%
Risk-free interest rate0.28 %1.20%
Expected life of options in years4.0 years3.0 years
Estimated forfeiture rate8.9 %13.0%
Dividend rate0.0 %0.0%
Fair value per common share option$6.72 $5.44 
Schedule of Performance Shares Activity
The following table summarizes the equity award activity during the three months ended March 31, 2021:

March 31, 2021
Number of shares (in thousands)Weighted average exercise price $
Outstanding - Beginning of Period14,486 11.35 
Granted1,392 13.62 
Exercised(877)5.65 
Forfeited(230)12.33 
Outstanding - End of Period14,771 12.94 
Vested and expected to vest - End of Period897 13.11 
Options exercisable - End of Period5,014 8.15 
Allocation of Share-Based Payments
The Company recognized share-based compensation expense for the three-month periods ended March 31, 2021 and March 31, 2020 as follows:
(in thousands)March 31, 2021March 31, 2020
Research and development$1,074 $1,217 
Selling, general and administrative6,641 2,279 
Capitalized under inventories106 — 
Share-based compensation expense$7,821 $3,496 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
USD ($)
reportingUnit
segment
Dec. 31, 2020
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Number of operating segments | segment 1  
Number of reporting units | reportingUnit 1  
Cash and cash equivalents $ 156,591 $ 272,350
Short-term investments $ 191,668 $ 125,979
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]        
Accounts receivable, net $ 1,187 $ 0    
Allowance for doubtful accounts 0 0    
Shareholders' equity $ 370,228 407,750 $ 279,086 $ 298,600
Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy One        
Property, Plant and Equipment [Line Items]        
Concentration risk 59.00%      
Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy Two        
Property, Plant and Equipment [Line Items]        
Concentration risk 37.00%      
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2018-15 [Member]        
Property, Plant and Equipment [Line Items]        
Shareholders' equity   $ 1,700    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Investments (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]    
Debt Securities, Held-to-maturity $ 89,100 $ 150,400
Debt Securities, Available-for-sale 115,200 0
Marketable Securities [Line Items]    
Short-term investments 191,668 125,979
Long-term investments 12,603 24,380
Total investments 204,271 150,359
Interest Receivable 400 500
Unrealized gains on available-for-sale securities 6  
Cashable Guaranteed Investment Certificate (GIC)    
Marketable Securities [Line Items]    
Short-term investments 2,502 2,000
Corporate Bond    
Marketable Securities [Line Items]    
Short-term investments 41,524 40,372
Commercial Paper    
Marketable Securities [Line Items]    
Short-term investments 133,907 67,747
Treasury Bill    
Marketable Securities [Line Items]    
Short-term investments 5,910 7,999
Treasury Bond    
Marketable Securities [Line Items]    
Short-term investments 5,021 5,045
Yankee Bond    
Marketable Securities [Line Items]    
Short-term investments 2,804 2,816
Corporate Bonds    
Marketable Securities [Line Items]    
Long-term investments $ 12,603 $ 24,380
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Work in process $ 14,367 $ 13,927
Finished goods 1,569 0
Total inventories $ 15,936 $ 13,927
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid assets $ 4,139 $ 3,701
Prepaid insurance 939 2,054
Other current assets 1,180 1,018
Prepaid deposits 606 398
Prepaid expenses and other current assets $ 6,864 $ 7,171
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (in years) 11 years 11 years
Gross Carrying Value $ 19,496 $ 18,452
Accumulated Amortization (9,642) (9,120)
Net Carrying Amount $ 9,854 $ 9,332
Patents    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (in years) 11 years 11 years
Gross Carrying Value $ 1,657 $ 1,651
Accumulated Amortization (1,229) (1,203)
Net Carrying Amount $ 428 $ 448
Acquired intellectual property and reacquired rights    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (in years) 11 years 11 years
Gross Carrying Value $ 15,126 $ 15,126
Accumulated Amortization (8,028) (7,770)
Net Carrying Amount $ 7,098 $ 7,356
Cloud computing arrangements    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (in years) 3 years 3 years
Gross Carrying Value $ 2,713 $ 1,675
Accumulated Amortization (385) (147)
Net Carrying Amount $ 2,328 $ 1,528
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible assets $ 523 $ 286
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment, net (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 5,104   $ 4,965
Less accumulated depreciation (346)   (179)
Property and equipment, net 4,758   4,786
Depreciation of property and equipment 165 $ 12  
Construction in progress      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 279   4,467
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 2,951   34
Office equipment and furniture      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 1,604   83
Computer equipment      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 270   $ 381
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Obligations - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2021
USD ($)
Mar. 31, 2021
USD ($)
extension_option
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
ft²
Aug. 31, 2020
USD ($)
Mar. 12, 2020
Lessee, Lease, Description [Line Items]            
Right-of-use assets   $ 5,761   $ 5,489    
Total lease liabilities   $ 8,881   $ 8,407    
Incremental borrowing rate   5.18%        
Total lease costs   $ 309 $ 142      
Minimum lease payments   11,657        
Capital expenditure payments $ 11,800          
Minimum finance lease liability payments due   91,000        
Victoria, British Columbia            
Lessee, Lease, Description [Line Items]            
Area of property (in sqft) | ft²       13,206    
Right-of-use assets   400        
Total lease liabilities   $ 400        
Incremental borrowing rate   4.08%        
Minimum lease payments         $ 3,300  
Rockville, Maryland            
Lessee, Lease, Description [Line Items]            
Right-of-use assets   $ 5,400   $ 5,500    
Total lease liabilities   $ 8,500   8,400    
Incremental borrowing rate           5.20%
Remaining lease term   11 years        
Number of extension options | extension_option   2        
Lease extension term   5 years        
Lease termination option term   7 years        
Proceeds from tenant improvements       $ 2,300    
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Obligations - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets    
Right-of-use assets $ 5,761 $ 5,489
Current    
Current maturities of operating lease liabilities 1,075 788
Non-current    
Operating lease liabilities 7,806 7,619
Total lease liabilities $ 8,881 $ 8,407
Weighted average remaining lease term - operating leases (in years) 10 years 18 days  
Weighted average discount rate - operating leases 5.18%  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Leases [Abstract]    
Operating lease costs $ 261 $ 65
Short-term lease costs 7 76
Variable lease costs 41 1
Total rent expense $ 309 $ 142
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
Remainder of 2021 $ 484  
2022 1,144  
2023 1,061  
2024 1,085  
2025 1,110  
Thereafter 6,773  
Total 11,657  
Imputed lease interest (2,776)  
Total lease liabilities $ 8,881 $ 8,407
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Trade payables $ 2,182 $ 2,635
Other accrued liabilities 9,727 10,855
Employee accruals 5,785 11,307
Accounts payable and accrued liabilities $ 17,694 $ 24,797
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Non-current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Other non-current liabilities $ 17,893 $ 16,295
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets:    
Investments $ 204,271 $ 150,359
Total 360,862 422,709
Deposits held with banks    
Assets:    
Cash and cash equivalents: 110,050 130,807
Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: 46,541 141,543
Level 1    
Assets:    
Investments 133,907 69,746
Total 290,468 342,096
Level 1 | Deposits held with banks    
Assets:    
Cash and cash equivalents: 110,050 130,807
Level 1 | Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: 46,511 141,543
Level 2    
Assets:    
Investments 70,364 80,613
Total 70,394 80,613
Level 2 | Deposits held with banks    
Assets:    
Cash and cash equivalents: 0 0
Level 2 | Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: 30 0
Level 3    
Assets:    
Investments 0
Total 0 0
Level 3 | Deposits held with banks    
Assets:    
Cash and cash equivalents: 0 0
Level 3 | Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: $ 0 $ 0
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Dec. 17, 2020
Dec. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Revenues     $ 914 $ 30
License Agreement Terms | Otuska        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Upfront payments received $ 50,000   $ 0  
Potential regulatory milestone revenue 50,000      
Revenues $ 50,000 $ 50,000    
License Agreement Terms | Otuska | Minimum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Tiered royalty percentages on future sales 10.00%      
License Agreement Terms | Otuska | Maximum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Tiered royalty percentages on future sales 20.00%      
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Earnings Per Share [Abstract]    
Net loss and comprehensive loss for the period $ (50,379) $ (25,932)
Weighted-average common shares outstanding used in computation of basic and diluted loss per share 127,401 112,209
Net loss per common share (expressed in $ per share) $ (0.40) $ (0.23)
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 15,785,000 11,375,000
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares)   9,685,000
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,014,000 1,690,000
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 18, 2021
Oct. 23, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock, issued (shares)     128,121,000   126,725,000
Common stock, outstanding (shares)     128,121,000   126,725,000
Number of shares available for grant     16,000,000.0   15,800,000
Share-based compensation expense     $ 7,821 $ 3,496  
Unrecognized share-based compensation expense     $ 36,600    
Unrecognized share-based compensation expense weighted average recognition period     1 year 3 months 18 days    
Performance Shares | Officer          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Granted   439,000 1,392,000    
Granted, Weighted average exercise price (in usd per share) $ 13.56   $ 13.62    
Share-based compensation expense     $ 200 $ 0  
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Share-based Compensation - Performance Shares Activity (Details) - Performance Shares - Officer - $ / shares
shares in Thousands
 3 Months Ended
Mar. 18, 2021
Oct. 23, 2020
Mar. 31, 2021
Number of shares      
Outstanding - Beginning of Period (in shares)     14,486
Granted (in shares)   439 1,392
Exercised (in shares)     (877)
Forfeited (in shares)     (230)
Outstanding - End of Period (in shares)     14,771
Vested and expected to vest - End of Period (in shares)     897
Options exercisable - End of Period (in shares)     5,014
Weighted average exercise price $      
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)     $ 11.35
Granted, Weighted average exercise price (in usd per share) $ 13.56   13.62
Vested, Weighted average exercise price (in usd per share)     5.65
Forfeited, Weighted average exercise price (in usd per share)     12.33
Outstanding, Weighted average exercise price - End of Period (in usd per share)     12.94
Vested and expected to vest - End of Period (in usd per share)     13.11
Options exercisable - End of Period (in usd per share)     $ 8.15
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Weighted Average Assumptions (Details) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]    
Annualized volatility 66.00% 43.00%
Risk-free interest rate 0.28% 1.20%
Expected life of options in years 4 years 3 years
Estimated forfeiture rate 8.90% 13.00%
Dividend rate $ 0.000 $ 0.000
Fair value per common share option (in usd per share) $ 6.72 $ 5.44
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 7,821 $ 3,496
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 1,074 1,217
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 6,641 2,279
Capitalized under inventories    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 106 $ 0
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Tax Disclosure [Abstract]    
Income tax (benefit) expense $ 8 $ (238)
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Related-Party Transactions (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Other Liabilities | ILJIN      
Related Party Transaction [Line Items]      
Due to related parties $ 2,000   $ 6,000
Milestone Payment | Affiliated Shareholder | ILJIN      
Related Party Transaction [Line Items]      
Payments to related party $ 4,000    
Legal Fees | Management      
Related Party Transaction [Line Items]      
Expenses from related party   $ 63  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Commitment and Contingencies (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Non-cancellable future commitments $ 25.4
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 128 295 1 false 50 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.auriniapharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity Condensed Consolidated Statements of Changes in Shareholders' Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Organization and Description of Business Sheet http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 2102102 - Disclosure - Basis of Presentation Sheet http://www.auriniapharma.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 2104103 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 2107104 - Disclosure - Investments Sheet http://www.auriniapharma.com/role/Investments Investments Notes 11 false false R12.htm 2110105 - Disclosure - Inventories Sheet http://www.auriniapharma.com/role/Inventories Inventories Notes 12 false false R13.htm 2113106 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 13 false false R14.htm 2116107 - Disclosure - Intangible Assets Sheet http://www.auriniapharma.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 2120108 - Disclosure - Property, Plant and Equipment, net Sheet http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet Property, Plant and Equipment, net Notes 15 false false R16.htm 2123109 - Disclosure - Lease Obligations Sheet http://www.auriniapharma.com/role/LeaseObligations Lease Obligations Notes 16 false false R17.htm 2129110 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 17 false false R18.htm 2132111 - Disclosure - Non-current Liabilities Sheet http://www.auriniapharma.com/role/NoncurrentLiabilities Non-current Liabilities Notes 18 false false R19.htm 2134112 - Disclosure - Fair Value Measurements Sheet http://www.auriniapharma.com/role/FairValueMeasurements Fair Value Measurements Notes 19 false false R20.htm 2137113 - Disclosure - License and Collaboration Agreement Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreement License and Collaboration Agreement Notes 20 false false R21.htm 2139114 - Disclosure - Net Loss per Common Share Sheet http://www.auriniapharma.com/role/NetLossperCommonShare Net Loss per Common Share Notes 21 false false R22.htm 2143115 - Disclosure - Share-Based Compensation Sheet http://www.auriniapharma.com/role/ShareBasedCompensation Share-Based Compensation Notes 22 false false R23.htm 2149116 - Disclosure - Income Taxes Sheet http://www.auriniapharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2151117 - Disclosure - Related-Party Transactions Sheet http://www.auriniapharma.com/role/RelatedPartyTransactions Related-Party Transactions Notes 24 false false R25.htm 2153118 - Disclosure - Commitment and Contingencies Sheet http://www.auriniapharma.com/role/CommitmentandContingencies Commitment and Contingencies Notes 25 false false R26.htm 2205201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 2308301 - Disclosure - Investments (Tables) Sheet http://www.auriniapharma.com/role/InvestmentsTables Investments (Tables) Tables http://www.auriniapharma.com/role/Investments 27 false false R28.htm 2311302 - Disclosure - Inventories (Tables) Sheet http://www.auriniapharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.auriniapharma.com/role/Inventories 28 false false R29.htm 2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets 29 false false R30.htm 2317304 - Disclosure - Intangible Assets (Tables) Sheet http://www.auriniapharma.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.auriniapharma.com/role/IntangibleAssets 30 false false R31.htm 2321305 - Disclosure - Property, Plant and Equipment, net (Tables) Sheet http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables Property, Plant and Equipment, net (Tables) Tables http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet 31 false false R32.htm 2324306 - Disclosure - Lease Obligations (Tables) Sheet http://www.auriniapharma.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.auriniapharma.com/role/LeaseObligations 32 false false R33.htm 2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities 33 false false R34.htm 2335308 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.auriniapharma.com/role/FairValueMeasurements 34 false false R35.htm 2340309 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareTables Net Loss per Common Share (Tables) Tables http://www.auriniapharma.com/role/NetLossperCommonShare 35 false false R36.htm 2344310 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.auriniapharma.com/role/ShareBasedCompensation 36 false false R37.htm 2403401 - Disclosure - Basis of Presentation (Details) Sheet http://www.auriniapharma.com/role/BasisofPresentationDetails Basis of Presentation (Details) Details http://www.auriniapharma.com/role/BasisofPresentation 37 false false R38.htm 2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 38 false false R39.htm 2409403 - Disclosure - Investments (Details) Sheet http://www.auriniapharma.com/role/InvestmentsDetails Investments (Details) Details http://www.auriniapharma.com/role/InvestmentsTables 39 false false R40.htm 2412404 - Disclosure - Inventories (Details) Sheet http://www.auriniapharma.com/role/InventoriesDetails Inventories (Details) Details http://www.auriniapharma.com/role/InventoriesTables 40 false false R41.htm 2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables 41 false false R42.htm 2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 42 false false R43.htm 2419407 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 43 false false R44.htm 2422408 - Disclosure - Property, Plant and Equipment, net (Details) Sheet http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails Property, Plant and Equipment, net (Details) Details http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables 44 false false R45.htm 2425409 - Disclosure - Lease Obligations - Narrative (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails Lease Obligations - Narrative (Details) Details 45 false false R46.htm 2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails Lease Obligations - Supplemental Balance Sheet Information (Details) Details 46 false false R47.htm 2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Details 47 false false R48.htm 2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Details 48 false false R49.htm 2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables 49 false false R50.htm 2433414 - Disclosure - Non-current Liabilities (Details) Sheet http://www.auriniapharma.com/role/NoncurrentLiabilitiesDetails Non-current Liabilities (Details) Details http://www.auriniapharma.com/role/NoncurrentLiabilities 50 false false R51.htm 2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 51 false false R52.htm 2438416 - Disclosure - License and Collaboration Agreement (Details) Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails License and Collaboration Agreement (Details) Details http://www.auriniapharma.com/role/LicenseandCollaborationAgreement 52 false false R53.htm 2441417 - Disclosure - Net Loss per Common Share (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareDetails Net Loss per Common Share (Details) Details http://www.auriniapharma.com/role/NetLossperCommonShareTables 53 false false R54.htm 2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails Net Loss per Common Share - Anti-Dilutive Securities (Details) Details 54 false false R55.htm 2445419 - Disclosure - Share-Based Compensation - Narrative (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation - Narrative (Details) Details 55 false false R56.htm 2446420 - Disclosure - Share-based Compensation - Performance Shares Activity (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails Share-based Compensation - Performance Shares Activity (Details) Details 56 false false R57.htm 2447421 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails Share-Based Compensation - Weighted Average Assumptions (Details) Details 57 false false R58.htm 2448422 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) Details 58 false false R59.htm 2450423 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 59 false false R60.htm 2452424 - Disclosure - Related-Party Transactions (Details) Sheet http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.auriniapharma.com/role/RelatedPartyTransactions 60 false false R61.htm 2454425 - Disclosure - Commitment and Contingencies (Details) Sheet http://www.auriniapharma.com/role/CommitmentandContingenciesDetails Commitment and Contingencies (Details) Details http://www.auriniapharma.com/role/CommitmentandContingencies 61 false false All Reports Book All Reports auph-20210331.htm auph-20210331.xsd auph-20210331_cal.xml auph-20210331_def.xml auph-20210331_lab.xml auph-20210331_pre.xml auph-20210331xexx311.htm auph-20210331xexx312.htm auph-20210331xexx321.htm auph-20210331xexx322.htm http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "auph-20210331.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 128, "dts": { "calculationLink": { "local": [ "auph-20210331_cal.xml" ] }, "definitionLink": { "local": [ "auph-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "auph-20210331.htm" ] }, "labelLink": { "local": [ "auph-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "auph-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "auph-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 388, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 15, "keyStandard": 280, "memberCustom": 11, "memberStandard": 39, "nsprefix": "auph", "nsuri": "http://www.auriniapharma.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.auriniapharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107104 - Disclosure - Investments", "role": "http://www.auriniapharma.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110105 - Disclosure - Inventories", "role": "http://www.auriniapharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113106 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116107 - Disclosure - Intangible Assets", "role": "http://www.auriniapharma.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120108 - Disclosure - Property, Plant and Equipment, net", "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet", "shortName": "Property, Plant and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123109 - Disclosure - Lease Obligations", "role": "http://www.auriniapharma.com/role/LeaseObligations", "shortName": "Lease Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129110 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132111 - Disclosure - Non-current Liabilities", "role": "http://www.auriniapharma.com/role/NoncurrentLiabilities", "shortName": "Non-current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134112 - Disclosure - Fair Value Measurements", "role": "http://www.auriniapharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137113 - Disclosure - License and Collaboration Agreement", "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement", "shortName": "License and Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139114 - Disclosure - Net Loss per Common Share", "role": "http://www.auriniapharma.com/role/NetLossperCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143115 - Disclosure - Share-Based Compensation", "role": "http://www.auriniapharma.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149116 - Disclosure - Income Taxes", "role": "http://www.auriniapharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151117 - Disclosure - Related-Party Transactions", "role": "http://www.auriniapharma.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153118 - Disclosure - Commitment and Contingencies", "role": "http://www.auriniapharma.com/role/CommitmentandContingencies", "shortName": "Commitment and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Investments (Tables)", "role": "http://www.auriniapharma.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Inventories (Tables)", "role": "http://www.auriniapharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - Intangible Assets (Tables)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321305 - Disclosure - Property, Plant and Equipment, net (Tables)", "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables", "shortName": "Property, Plant and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "auph:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324306 - Disclosure - Lease Obligations (Tables)", "role": "http://www.auriniapharma.com/role/LeaseObligationsTables", "shortName": "Lease Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "auph:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335308 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.auriniapharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340309 - Disclosure - Net Loss per Common Share (Tables)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344310 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Basis of Presentation (Details)", "role": "http://www.auriniapharma.com/role/BasisofPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Investments (Details)", "role": "http://www.auriniapharma.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Inventories (Details)", "role": "http://www.auriniapharma.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidAdvertising", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidAdvertising", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - Intangible Assets - Narrative (Details)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails", "shortName": "Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422408 - Disclosure - Property, Plant and Equipment, net (Details)", "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails", "shortName": "Property, Plant and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425409 - Disclosure - Lease Obligations - Narrative (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "shortName": "Lease Obligations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "ib56db10bcfbf4ff19e418f7bc72689e9_D20210201-20210228", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FinanceLeasePrincipalPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails", "shortName": "Lease Obligations - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails", "shortName": "Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails", "shortName": "Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433414 - Disclosure - Non-current Liabilities (Details)", "role": "http://www.auriniapharma.com/role/NoncurrentLiabilitiesDetails", "shortName": "Non-current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "role": "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438416 - Disclosure - License and Collaboration Agreement (Details)", "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "shortName": "License and Collaboration Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "if26c91fbf8254872891f77dea74f2721_D20201217-20201217", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441417 - Disclosure - Net Loss per Common Share (Details)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareDetails", "shortName": "Net Loss per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails", "shortName": "Net Loss per Common Share - Anti-Dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445419 - Disclosure - Share-Based Compensation - Narrative (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i7e466034229642349669ce4135c3606e_I20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "id80d7f721104420aa8007a9f5888a3e1_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446420 - Disclosure - Share-based Compensation - Performance Shares Activity (Details)", "role": "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails", "shortName": "Share-based Compensation - Performance Shares Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "id80d7f721104420aa8007a9f5888a3e1_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447421 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448422 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "shortName": "Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i679b44f6d3cf4efd8cef003e4f85614a_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450423 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i27fcef84584a48c2a43175c1e73c303a_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i27fcef84584a48c2a43175c1e73c303a_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i513eb36a15124ddcac29f0540ab1aeb0_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452424 - Disclosure - Related-Party Transactions (Details)", "role": "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i513eb36a15124ddcac29f0540ab1aeb0_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454425 - Disclosure - Commitment and Contingencies (Details)", "role": "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails", "shortName": "Commitment and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Description of Business", "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Basis of Presentation", "role": "http://www.auriniapharma.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210331.htm", "contextRef": "i15c5ea8f8d034fa98ed3c7f69aac01c1_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 50, "tag": { "auph_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "auph_CashableGuaranteedInvestmentCertificatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cashable Guaranteed Investment Certificates", "label": "Cashable Guaranteed Investment Certificates [Member]", "terseLabel": "Cashable Guaranteed Investment Certificate (GIC)" } } }, "localname": "CashableGuaranteedInvestmentCertificatesMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "auph_DebtSecuritiesCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/InvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Current and Noncurrent", "label": "Debt Securities, Current and Noncurrent", "totalLabel": "Total investments" } } }, "localname": "DebtSecuritiesCurrentAndNoncurrent", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "auph_ILJINMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ILJIN", "label": "ILJIN [Member]", "terseLabel": "ILJIN" } } }, "localname": "ILJINMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability", "label": "Increase (Decrease) In Operating Lease Liability", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "auph_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease, Right-of-Use Assets", "label": "Increase (Decrease) in Operating Lease, Right-of-Use Assets", "negatedTerseLabel": "Right of use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "auph_LegalFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Fees", "label": "Legal Fees [Member]", "terseLabel": "Legal Fees" } } }, "localname": "LegalFeesMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_LesseeOperatingLeaseLeaseTerminationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Termination Term", "label": "Lessee, Operating Lease, Lease Termination Term", "terseLabel": "Lease termination option term" } } }, "localname": "LesseeOperatingLeaseLeaseTerminationTerm", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "auph_LesseeOperatingLeaseNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number of Extension Options", "label": "Lessee, Operating Lease, Number of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LesseeOperatingLeaseNumberOfExtensionOptions", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "auph_MilestonePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment", "label": "Milestone Payment [Member]", "terseLabel": "Milestone Payment" } } }, "localname": "MilestonePaymentMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Assets, Lessee", "label": "Operating Lease, Assets And Liabilities, Assets, Lessee [Abstract]", "terseLabel": "Assets" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee", "label": "Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee [Abstract]", "terseLabel": "Current" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee", "label": "Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee [Abstract]", "terseLabel": "Non-current" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "auph_OtuskaPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Otuska Pharmaceutical Co., Ltd.", "label": "Otuska Pharmaceutical Co., Ltd. [Member]", "terseLabel": "Otuska" } } }, "localname": "OtuskaPharmaceuticalCoLtdMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "auph_PrepaidRentAndPrepaidContinuingStudies": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Rent and Prepaid Continuing Studies", "label": "Prepaid Rent and Prepaid Continuing Studies", "terseLabel": "Prepaid deposits" } } }, "localname": "PrepaidRentAndPrepaidContinuingStudies", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount", "label": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount", "terseLabel": "Potential regulatory milestone revenue" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "label": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "terseLabel": "Tiered royalty percentages on future sales" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "percentItemType" }, "auph_RockvilleMarylandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockville, Maryland", "label": "Rockville, Maryland [Member]", "terseLabel": "Rockville, Maryland" } } }, "localname": "RockvilleMarylandMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number", "terseLabel": "Options exercisable - End of Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable - End of Period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest - End of Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest - End of Period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "terseLabel": "Estimated forfeiture rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "auph_ShortTermCorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-Term Corporate Debt Securities", "label": "Short-Term Corporate Debt Securities [Member]", "terseLabel": "Corporate Bond" } } }, "localname": "ShortTermCorporateDebtSecuritiesMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "auph_SpecialtyPharmacyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty Pharmacy One", "label": "Specialty Pharmacy One [Member]", "terseLabel": "Specialty Pharmacy One" } } }, "localname": "SpecialtyPharmacyOneMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_SpecialtyPharmacyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty Pharmacy Two", "label": "Specialty Pharmacy Two [Member]", "terseLabel": "Specialty Pharmacy Two" } } }, "localname": "SpecialtyPharmacyTwoMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_VictoriaBritishColumbiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Victoria, British Columbia", "label": "Victoria, British Columbia [Member]", "terseLabel": "Victoria, British Columbia" } } }, "localname": "VictoriaBritishColumbiaMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_YankeeBondMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yankee Bond", "label": "Yankee Bond [Member]", "terseLabel": "Yankee Bond" } } }, "localname": "YankeeBondMember", "nsuri": "http://www.auriniapharma.com/20210331", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r245", "r355", "r356", "r359", "r472" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Shareholder" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r49", "r90" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r96", "r103", "r167", "r277", "r278", "r279", "r297", "r298" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r96", "r103", "r167", "r277", "r278", "r279", "r297", "r298" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r96", "r103", "r167", "r277", "r278", "r279", "r297", "r298" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r145", "r230", "r234", "r443" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ManagementMember": { "auth_ref": [ "r146", "r358" ], "lang": { "en-us": { "role": { "label": "Management [Member]", "terseLabel": "Management" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r247", "r248", "r368", "r369", "r370", "r371", "r372", "r373", "r392", "r440", "r444" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r247", "r248", "r368", "r369", "r370", "r371", "r372", "r373", "r392", "r440", "r444" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r145", "r230", "r234", "r443" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Officer" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r142", "r230", "r232", "r393", "r439", "r441" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r142", "r230", "r232", "r393", "r439", "r441" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r237", "r247", "r248", "r368", "r369", "r370", "r371", "r372", "r373", "r392", "r440", "r444" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r237", "r247", "r248", "r368", "r369", "r370", "r371", "r372", "r373", "r392", "r440", "r444" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r143", "r144", "r230", "r233", "r442", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r143", "r144", "r230", "r233", "r442", "r459", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r146", "r358" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201815Member": { "auth_ref": [ "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update 2018-15 [Member]", "terseLabel": "Accounting Standards Update 2018-15 [Member]" } } }, "localname": "AccountingStandardsUpdate201815Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]", "terseLabel": "Non-current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NoncurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r12", "r34" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r200" ], "calculation": { "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r53", "r55", "r56", "r427", "r452", "r456" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r52", "r56", "r57", "r93", "r94", "r95", "r314", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r93", "r94", "r95", "r277", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r97", "r98", "r99", "r100", "r164", "r165", "r166", "r167", "r168", "r169", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r295", "r296", "r297", "r298", "r395", "r396", "r397", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r249", "r251", "r283", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r251", "r269", "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r151", "r170", "r172", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r81", "r188", "r193" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of property (in sqft)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r87", "r131", "r134", "r140", "r163", "r311", "r315", "r328", "r413", "r426" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r48", "r87", "r163", "r311", "r315", "r328" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r321" ], "calculation": { "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r155", "r157", "r178", "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r252", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r30", "r83" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentationDetails", "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r78", "r83", "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of the year", "periodStartLabel": "Cash and cash equivalents, beginning of the year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r78", "r329" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents during the year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r207", "r417", "r431" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 18)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r204", "r205", "r206", "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity", "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r18" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common shares - no par value, unlimited shares authorized, 128,121 and 126,725 shares issued and outstanding as at March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r60", "r62", "r63", "r68", "r421", "r435" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r189", "r191", "r306" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Cloud computing arrangements" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r122", "r123", "r145", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r122", "r123", "r145", "r326", "r327", "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r122", "r123", "r145", "r326", "r327", "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r118", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r122", "r123", "r145", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r122", "r123", "r145", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r71", "r87", "r163", "r328" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r70" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total cost and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r121", "r145" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains on available-for-sale securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/InvestmentsDetails": { "order": 1.0, "parentTag": "auph_DebtSecuritiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as current.", "label": "Debt Securities, Current", "terseLabel": "Short-term investments" } } }, "localname": "DebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentationDetails", "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/InvestmentsDetails": { "order": 2.0, "parentTag": "auph_DebtSecuritiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Debt Securities, Noncurrent", "terseLabel": "Long-term investments" } } }, "localname": "DebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DemandDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.", "label": "Demand Deposits [Member]", "terseLabel": "Deposits held with banks" } } }, "localname": "DemandDepositsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r81", "r198" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation of property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r34", "r91", "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related party, current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r91", "r356", "r416", "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per common share (expressed in $ per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized share-based compensation expense weighted average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r93", "r94", "r95", "r98", "r105", "r107", "r115", "r167", "r210", "r212", "r277", "r278", "r279", "r297", "r298", "r330", "r331", "r332", "r333", "r334", "r336", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r321", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r322", "r365", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r238", "r239", "r244", "r246", "r322", "r365" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r238", "r239", "r244", "r246", "r322", "r366" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r322", "r367" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r365", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "terseLabel": "Minimum finance lease liability payments due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r339", "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Capital expenditure payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r159", "r160", "r171", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted Average Life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r192" ], "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r189", "r190", "r192", "r194", "r394", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r192", "r398" ], "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r189", "r191" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r192", "r394" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Acquired intellectual property and other intangible assets, net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r155", "r158", "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity", "terseLabel": "Debt Securities, Held-to-maturity" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r65", "r131", "r133", "r136", "r139", "r141", "r411", "r418", "r422", "r437" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r292", "r293", "r294", "r299", "r301", "r303", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r106", "r107", "r130", "r291", "r300", "r302", "r438" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r80" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Net changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r80" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r80" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Acquired intellectual property and reacquired rights" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Interest Receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Capitalized under inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r44" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r46" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r45" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r162", "r436" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r321" ], "calculation": { "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r161", "r412", "r424", "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r349", "r351" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total lease costs", "totalLabel": "Total rent expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r350" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Minimum lease payments", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r350" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r350" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r350" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r350" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r350" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r350" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed lease interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r87", "r135", "r163", "r312", "r315", "r316", "r328" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r87", "r163", "r328", "r414", "r429" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r87", "r163", "r312", "r315", "r316", "r328" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement Terms" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "Licensing revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Non-cancellable future commitments" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Short-term highly liquid investments" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows used in investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r78", "r79", "r82" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r58", "r61", "r66", "r82", "r87", "r97", "r101", "r102", "r103", "r104", "r106", "r107", "r108", "r131", "r133", "r136", "r139", "r141", "r163", "r328", "r419", "r433" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss and comprehensive loss for the period", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of reporting units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment and furniture" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r131", "r133", "r136", "r139", "r141" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r343", "r351" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r338" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r338" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current maturities of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r338" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r337" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r348", "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating leases", "verboseLabel": "Incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r347", "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r38" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r309", "r310", "r313" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain on available-for-sale securities, net of tax of $nil" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "auth_ref": [ "r50", "r51", "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "terseLabel": "Unrealized gain on available-for-sale securities, tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r59", "r62", "r64", "r67", "r210", "r330", "r335", "r336", "r420", "r434" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r38" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively)" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other Liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "verboseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/NoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other expense, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "auth_ref": [ "r73", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.", "label": "Payments for (Proceeds from) Tenant Allowance", "negatedTerseLabel": "Proceeds from tenant improvements" } } }, "localname": "PaymentsForProceedsFromTenantAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r74" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Internal use-software implementation costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Capitalized patent costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLeaseReceivables": { "auth_ref": [ "r75" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent.", "label": "Payments to Acquire Lease Receivables", "negatedTerseLabel": "Upfront lease payment" } } }, "localname": "PaymentsToAcquireLeaseReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r156" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchase of short-term investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidAdvertising": { "auth_ref": [ "r6", "r185", "r187" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Advertising", "terseLabel": "Prepaid assets" } } }, "localname": "PrepaidAdvertising", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r28", "r29" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r8", "r186", "r187" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r8", "r184", "r187" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds from Interest Received", "terseLabel": "Cash received for interest" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from issuance of common shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of short-investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r76", "r272" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r76" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Contract revenue" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r201" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r203", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r199" ], "calculation": { "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r201", "r430" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r199" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r245", "r355", "r356" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r355", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Payments to related party" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r245", "r355", "r356", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses from related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r245", "r355", "r359", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r353", "r354", "r356", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "auth_ref": [ "r288", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Upfront payments received" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r287", "r473" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r85", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r212", "r280", "r428", "r451", "r456" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r93", "r94", "r95", "r98", "r105", "r107", "r167", "r277", "r278", "r279", "r297", "r298", "r447", "r449" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r128", "r129", "r132", "r137", "r138", "r142", "r143", "r145", "r229", "r230", "r393" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r86", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r231", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Net revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r122", "r145" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Allocation of Share-Based Payments" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r189", "r191", "r394" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r189", "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r25", "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r32", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r89", "r357", "r359" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r252", "r271" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r85", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited, Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding - End of Period (in shares)", "periodStartLabel": "Outstanding - Beginning of Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, Weighted average exercise price - End of Period (in usd per share)", "periodStartLabel": "Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average exercise price $" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Annualized volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Fair value per common share option (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r250", "r253" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Schedule of Performance Shares Activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r263", "r281" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r344", "r351" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r43", "r93", "r94", "r95", "r98", "r105", "r107", "r115", "r167", "r210", "r212", "r277", "r278", "r279", "r297", "r298", "r330", "r331", "r332", "r333", "r334", "r336", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r93", "r94", "r95", "r115", "r393" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "terseLabel": "Exercise of warrants" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r210", "r212", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Shares issued on exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r210", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Shares issued on exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r87", "r153", "r163", "r328" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Shareholders' equity", "totalLabel": "Total shareholder\u2019s equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofChangesinShareholdersEquity", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "SHAREHOLDER\u2019S EQUITY" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r147", "r148", "r149", "r150", "r152", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable, net" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r159", "r160", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r97", "r98", "r99", "r100", "r164", "r165", "r166", "r167", "r168", "r169", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r295", "r296", "r297", "r298", "r395", "r396", "r397", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "Treasury Bill" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBondSecuritiesMember": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bond Securities [Member]", "terseLabel": "Treasury Bond" } } }, "localname": "USTreasuryBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r116", "r117", "r119", "r120", "r124", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Critical Accounting Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r345", "r351" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average common shares outstanding used in computation of basic and diluted loss per share", "verboseLabel": "Weighted-average common shares outstanding used in computation of basic and diluted loss per share" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5558-128473" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r474": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r475": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r476": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r477": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r478": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r479": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(6)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 79 0001628280-21-009306-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-009306-xbrl.zip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

@-ML",L(QUYBY; +=&F5T65USY[))2)&U?*[7YH8 M52 R?1"YXD>,44 .I+/@TAI>H72FB(A9L#H2!3Z6=6IIE>IEJNYZ5XNQ#&_. MZ9%SP_9P5/2_.]H,I=L^[86CT.GG7T.MU>U7Z_$>3Y1^>Q&FU(?WA$_W;/DT MD6FQN'C]ND2W.B#@L UB;83!3FR:LPK?'AM0OE:C0$;L: 3_#W&7,4-2H7_@ M3%99HAWQF#"[M"KU789T)^FPBMS,"T%YC/'^/$.IC'!,""Q'[C!*> M*NX[GED:<29HVJ<#&\H$&*]"=^=N9F*\OU#,YAHI\2'F+A]4P9IYYR /]KAV MP\! 8_VFZ76@2_O7I+TQ$G8%:H\"M1OE ;#03&I',\\5@!K2+M.>RDQ$YHSR M ;@(6UH5A"]S^A1@J\(FB\U**G.>H3E?J^AJ3.":Z,P;A,"<<..V_7PO_&>:#\UG'2[Z[ M3&?N%].68=:IB F/Y-[?+.1=X=NC\.WC=;I"'6%>F)!1F?;'==9GQB6D"U2$ MX(1"#O -#BZ3>R;02S3-]%C;+%&(I[QX4X8)J@IOGHXW5WQ*6Z>DDQK\(1\S M9@7P*>5I9@BP*NMEQ%PNK3(DE^4]94+FU.87:(GE \LA%8G/UQA8?TS!GL+ M?N!>/K!4PT@R*Q1$Z;M#VPJ7DGX:3-XGD)FRLO_]D[4LIM%!\S)^E(&O7BO^ MLM;QU6CRQ-%D_SI[=<))JQW/HE,X8\KC3!O*,VF4<@[Q2+R!T03+921+S5ZG M;L(SCA7^NF!^OSI48%X.9Z "\VF#^95K@'ST!#F5A9BJG" O,BN)S9B@#AD< MF,')-1!T68@IU_>:(: 6OL/K@8&'3M8(7BN6T3:]P[PS>ORM*6,70/5[\[#_ M$BE5HOV>D.DI_0@Y\[M1S:>M@KU@#T!K5NK V.0C\D\_6A MTP]%9;"B;XLYYYAW3,?E*<@[@!^*FD*O;JZCO-9'XV8P,JHI>]KM%PFE*[W0 M,FD)YA_?D54".BG5 2.^RL"C):]H7PIW]1+4,I;_7Z[RT8=L_JG[;U>O:^U\Z'EWW,D)$MY$!]WMQI;:[7W?ZWM MUM?6-S\VM];7MO=J6XWU5[6UQD9M[^.;O:V-K;7=K;N6G,+3BA><'VG_GYW\R^X M;.O39FU[9V^N7[,PC=_R#J!+=PCW\/WE6CAS :#Y-/1&\8H:0(SY_;MO<4L5 MTRZ'"9JO(*,8#N!=6N:T'U8F'_[P>?^T9^(W5U;R"HTL91PV M&M]_?/A5<>C6(#8Z)LDKHO%W#Z-7/WN,*O935_Y38S%^); N46,)>=!M?Q#P M>T3-KA^>JN^<>H\_,S*XN0K"-(]Z(=3:<-Y1OQ9@F/7B,9S'_W8IF;]V+HJ3#CAGZ5&GP M,5TZK:R>F<9Z=L/7T!F&69>#GNM[3'47%CKG"O&^U_5#-ZCU1HJQ7.N$9\E$ M?W*Z:OEG!^O4A,_YX&A]V(?^"+W-,]<:IGY>,R)OQW M>V>C<5R_V$IQ8;;?_(#A.>S@N(YWFB=\I_EWJ_'YH+6S<7!\%1->HXV+.MW_ MO,GJ&W_G]8L/WZ!-^?Y%*V\<[_/]XY.SQL6'B_WFI];MF'!]P]'ZA3_:3T7> MVEL7C8TU6O_\]_'.YRW2.&[E.\U-VMAH'#4^?XJ-/71>Q(/A[_KQX;>69(*1#EBO%56&:275I5B"S"]5Z()NGE&Q"E-LI#Q5*3C/.I(R,^,"84S8Z"72)6V)8C,(_ M@"M5"/+""'*3%2&4!@%/,REMRBFR-K,@ITPG6#&"*(G(O0A2^M*@<\V#1NL) MGL*"IK@6O:0;GSZ9'V'N># J*H\HBT:KX*F346AC',(.5_QHWM#M_!8_HB(X M[HW)J P.^!%QF;&,9)$Z$ZWV@$E^:57C18B-5?LMSP?L/)E4): )AD1EP2W# MV%@C36#2:G*0#57YGU'/MT4FSFJ(53G9-QLQH+'S$6[EQ-3U_4FXY_<4!=HHPNLP:( M-[.29\I[G6&.;,!"4"G1TBI;A,6G)>79F #^B9VSA)VI+0'#V0@M^/%RN'89.2$L74\D3X]MY M)^\/>L7*PFK^=LYISX/7=;\;R7BMX]=N2'ASY"]5B/>XU)2S,>)]^Z(#,0Q& MHPQ)&C-FM,RTL3$+1!%CO938^V(#$OA>9HY43>/^,ARI I*7 Y*+2R#!RG#/ M.,\ Z5-=;<$SJP%-E )\H80K;--FSW@9\2?O9#1_L[FE84V[H1^*=8N)+7GP M%UK=TU2_H8H0+0I5FD@8(&[C2KX5OOU4MLH549("VTB)RB+5.F.2\LQ89#)# M.?&612(#7UK5RXJ6>AOL*I94\:0*1::,(EJV-)+&>5:NPN-N3"%179C*H]E.H=Y*C1C^OTPJ+9\ MG'>Z=&O3N&ORW(E;E])<*X19P=GCLDVN2)&-!D=L7&8%,6DS)9KI*$WFI(U2 MS15L:$72T,K]K<>IZ ]6RV/A?'GYH'F/'X[ND+(EPF'HPUSQVY= M(\S-5G2E +B=]6M42"CCK0?/+F@3,Q84RA2B-J-!:43?TV]Q&JF\YD$GN%=(] NOH(Y2;;=AEBN"21 M9%ZXD(%INQ48FKT=WP^'C['CV42&*CM^ MNAU?;;]''<6>4I01947&A'"9YLYG@0(<.V>ET7K$6<1=SC(3._[5LH:VTE85 MH3^HY87"SVT8:+[1;AYB0#>!;"+7$8X5 >\*R!X%9%O7"0EVCF",(S 0 H2$ M6)0I9WD&] 1KKSC7/"ZM8KD(Z\WFHRI6!2KS$.>I0&7JH')MT2*& M=:Z\P$DEP+PSA$[>N0SFO2D4871>,ZG!YMF@9\#0\H[IG6\-0KO?Z';2F_2Z M1>V'"896P/DHX/QPG8UIB@+(G&:2*9\Q'&VF;4 9%3%2P@$VI2S"0_2>Q*4J M/#0'>%#2\%"%!W.$!U=$2GF&/'8V8SSMZ< ]RPS[?^Q]:U/%&_]WOXP=9MT*L][/<9@XY,2D,4I-JA$<7*$M8A0B85BD M11JFS-8>6>L:CUT2VD_"GSJP>!"PJ E.JD,9ARF%;:.I-3]'0' B@PR&S!$RW!Q8!!$WFLHHCHQZ&+M>AW-WPKF:J.(D25BL M&2(!EH@DE",1RP#%4G(3QY(1A8&HQGT6+8=*M _G?@8SG:^@ )M_G.M3T->R MK]H1VS:U\XE@_=1H9FM9M;6?SXV&^-B*DC_,-8SE4JO>"<^&/!O+L[R'_P&:'9W#OS[OA_MG[X.##^^CP^-W9P?'K[)\__H9Q;%W ?<[^ M^6/_XN#R]\'_7KZ-#W8DC'?O;!T(M0N$#K;G0"A48VD<)$I@ F1+242PBA'C6" =A3Q08 (< M6* _.*8".(]!L;+U:3%C2(1!BB(C51+BV,!:WH,WJ4N/NR=9_9U/,NF[M&6# MV50KGRPWUGEO<@H*0:MBI5H=0/#0@5+MC![X 2;X1N='=FO=+R/$5P:W[O)\ M"/,V*9_KMKQM..4W?(7X08?X-X@=D,T8J4A1HP,:H@@KB@B)0L2I3)%B@O P M(#16P<9F\)+<0PY/.SC?3PEM#QT;U4YH^P%R>P6TW9'D=M#V:-#6J(.%PTB$ M@&I)D(2(P.HA2F.&B%2""!4E.,86VE8TG6H9M/T,EKT/[A>M$(=1\1-M@Z/. M0#@=AYWT1K/I9 HDUY9/GTV Y&9#%SXUFU:]]\1#$.&'L1 LQ"VUWDIP2T>N M7[,GK+A>;J8MOY<.9F="YX?&(>QAO9.N MO.-K<6Z/6T8ZX;2MW2_[L2I1ZS M3'N'4H^"4@W[ID6I*&$JBCA%:22 #!*A@1:2%(4L3#55:2JDK2H8XCX.EM." MVHH4CB+^ZN( RI T^*<R*O\KU "CF M5_W;>::FIR6H-+[H%^)54'^%"Q@$R.J57WG$^?_N;..%(,;&OW:T#EX"K8@( M J)310E5F,F$IL#7I* Z-8)\PG2C_-)I7K[!& -B5SS+X@;>,%7?'#.+R8; MO\[O2]B4"_.^.&5^8C;_6^2_+H9PM]5[\^^M=_M; MV[OOC_>VM_XZZNT=;+_L;1WL]([>_WZTM[.W]6YO]^C*_=F"MW%[9OOP8&?W MX&AWIP<_'1W^M;>S=0R_'!W#?_9W#XZ/>H>O>T?PJKO_/OQK9_?=T;]ZNV_? M[QU_;/V;O0"=[L,U@L YV:SAP6 ^#'O#Q1+\J?_A-99/Q M@%^\RH;NT>Y+BZ .-ZTEX&7@I:#0_(O[%Q^_=!\M'$#^,QR_C)+PRH^#ES_Z M643)#WWS>X.E+QE-N['^U&,-\4O@U^LR6/@P^K';/LG,QL'-9O:NOO(?2NF[ MZ3W8G7SV_E1IE>ULVULWG:[WL%5LNWL\KWL\KYB6*Z(/9D,^4QDH<3]6M/ > MU^#&GIV6 \[=D>;ZF>CF&92],WBYZ5/OVC6;,QBL-9SP@5/SQSRS_CWWL^1C M:SOJYO-6\RGE[&PVL$8P-XDNXG MO3_Y<,;SBU[8[UFG>(M"&-8IR>$^PA=4%.LPE#IAQ!":,I$&1@34?RBZ=K#2]@:]Q^A]NEV^_+Y3_'N\$_?^P& M!\>[\?[.V^B?XX_DX^?=RX/+_6]PKV\'^.#+/MRG&##^^_'>[\_>7P M^%WV\?+=V3Z&L7[8#0_PWX-#6ZH!_YT=?MB-%]U^'S]_#.%YY.##V_C@CS\_ M'_SQ\?*?/_:^?3R&,7]X3_8_[U_^\P'>\WA@]IM-XVWV4D*E1%1S81LYAXAR MK5"B,*=!'),DXC8L(>FG.'Y>80GM3:UZ0*1I'9[?/,SV=B^_IO"ZG$+V8]AZ MJU@+!ZH%N?"TH@/4VP'J906HJ58LE1@05-L6:CQ*$9<&HR *>,0H_!\LU"8C MI!_AYU!+OP/4#E!;\-:W %20PR2*0L%UF!#*I(@"E2HI16!2S@SM +4%@!I6 M@!I2+4F@!5(JBA! 5XB$#C%2G.)4QYI$ F]L1JP?T>5 M-IG,M++]+/0WG=(WP%N.ZYI=V9Y3!Y;^ ]1LJON?OPT*_M;K'H[4E] M70OPS1H^<*J)3B,FD0QYBH@.N>V"AY'2*>@&TC!EBWO2-%UGV%T-<%UI]3:0 MM3O"Q^U9VS*P_,T',]WARCW@2L,5+$-#9"I1FG"%B,$""4X,"ABC4F"IPHAM M;*;])%Q.I>^0I4.6^S!P16%$.,.21%%*8LDHH1$P\"0*C0K3,'J00N0=QCPP MQM3>42$E#@(2(,IYA$A, U ;#4,D- F->$)4"-P%]Q-\#S4J.Q%_+!&O&FAT MIT"W1;HMTFV1-6@FU]&#MM"#IETYPC(D@28H58E!1 <,42-#E'(IA(X94YAL M;)(^8YT2\ARSJ%;7MMIMF(I[YSS/^7#ZY-VBGA/"ML%,O#T:PEQ-8%R'QO\\ MS42SQ&2\ DFVANI#<1AY-KH/-=J\?H.2VZ');696/ H# %' MD#0F1"01MO6[(BC14G&#:< B8&@I7NO.OAV6_"1&X@Y5GA)5:L-P@AD7/ RM MRRE!).4<46H4BM(X@L,B2 56&YL)NX>X[TZH.YM?MT6Z+=)MD?78(H]K%NX( MP9.:+!JFX#C$0 9XBJ*8I(A@K!&+P@314.B8Q'$2&;JQ&3V'[C-=#/'-[,#. M4 @4T;>'.!OKX<2U#.LBAG^"@[?SQW9;I-LB[=HBCVNUN;'+?DM]GDVFKDG0 M\:BN2/N&9VION.W+T+JSQ!TEVXV3Y)W^SRR;9%-]I/.OF=2>Y+W3@=0?;#3N/MMU:24I1Q$F,2!)01'%,4!AP$8F8"IHH&V1,\5KSN@Z( MNK.JVR+=%NFVR%IMD99&('9TIEUTIFFE8I0%860DH@)8#0E"CIC4'$E*=6PT M4X+@CM \0,"B1Y1@A<7*_9[9-J+35XB-6V/"N?!Z9:I6Z9NF9[;,MW=YD92A96VQ=@924,CTBBT%%5((:3"XM;^ M4'=ZS34>\LV&;..A ST]-,?\6\C2 ?O] _NWJFS3Y?MX_^13 M%"A" B40C1*.B A#Q"(1(DF)Y %.*!S3JZ"]BREY2*F#W=T;P"[O8D@ZBWIG M4>^V2+=%NBW2;9%NBW1;9*VVR&T2"'4*VI-0*8T,)XQA)F,A4IKR(# \C/&# M5)D#GEFK5)TJ=1M5JME*(>),F" F* X"C(B2 >)82P3KQV5"(FH24*+BH!^E MR]4,NA)RST)^[\'ZT=J+VMZG/KA)*YCV =WM:C"E@AB6Q'$41 &A241% M(*4T@0F%-C(,76.4U:67NE;U3V'SK8A*H),D5028B=1 5!+)D" 2?@T9#3BA M@=&);55/^^%ZAX;=5D[7M>_4C?"F3;A^SZVGEMY_37%VF4_^&,AVW:<>%5D; MC0J"E,=!*E# A4(D#"GB04R1P'&:1#**4AIL;+(8]Y/T6?=8[I"U0]9V(VL0 M$FH=W5I@!_E0_#"% A2HEAI@8AMUB MFK5NE-THNU'>RRB?>=Q-L!!W\R#8?JB 2LE3&Q[3]M M4@F:E[!I5BE%6BG&0&NVM2XW-DF*^R1=+JW585&;Y/4Y8]$MH$@8[JQ *M*: M:)FPE-+(: )*&1:&)IWZU0($:D8/A DC.C4)$D(D@$$R1"SA"6*2J8@QS1F3 MH( QVD^"H$4:V,]0WL][77J9:]S: \'3WW0NLXGNC0R,!<2@-QK;=>@* #ZT MOTUJA6.9$!*$A"A"J<*A$%B'C*4IDX$KVQ&493N"E4GM*V!LN2>O7W/WX:%? MV]UBT54'<[>!N:.&SRU.@0OC0".:Q*#P13Q&-#8:20KG4L)D3"-0^!)Z9W]; M5WJG+5*\3$WN*,*WYRA7--SN9/L>9+MV9"E)F-!AA.*0!8@8ID")(@;I*.2A MPL!MB%6B^B2^,WWII+O%1A!*PIA3%O&0"8)UPA+0JD&EI@EGQH3F!N+]@]:0 M3LX?3LX;^;UARG :"\2-3A&A)D4<4XT2IE0,VX;ZHY%GPA H,5$4$5%F[/$="2(:PX0&.0R,C%F]L M+M=![.2YW?+\5':[3K*?5+(/&B>U(40;D.S8$(F(H7!2"PTRKF"-31P&.I*K M3NIU#FIZYD+==6+MEJE;IO6TU'4'X]-27N_$@L,13L9$V6A(CA@&NDLD@9^8 M%$@:%E'-:$0)W]C$+>*\/TVHG4*"3[1]R;.Q'DZXG?U"E;^S2VU*?9Y/IF08Z<#S:@EFU@^.#-SQ3>\-M/LZF?.! U4'J=@-1W^G_ MS+))-M5'.O^:2>T9QSLM1R=#=Q='/CJ.<2N.L3NG? M-@C2,4!C)P,;T*T0E M92@2*0^ %D0J,1N;49^PY:RB#@[:#0<=:G?+U"W3>FKAW>&ZKH?KG (O1,", MB%"$8XE(H@2B+*5(@%XO4B(,#Z/VG:X_0WS-@9[V!J/)I,>'7HG/]2D(1O95 M^S^#_/6FI[HW=D+11=YTMN6VW*/;+FNQ7;IEZI9I/8(J#,:!D!&-&"N_@L.VXYBWHIBOIT>UO8;G"0)BS5#),"6 M85*.1"P#%$O)31Q+1A1V1?%8M.PGZB(HGH4$WX.ZV4GPXTIP4TD4FD72&(:2 MQ-:UQ#1%/$TQ(II2'#.>)%2U2X2?EY?WVH8%^SR7I[WH+OT*[M%T5C28\).S MJL?$W1IQM0\*;Y?# 3P&4R4 Y"00&4YH%*@@3C&+PM"VJ'(]J5:G;G3=#AX? M"M\W&QTMKV.\#W46C\WL7IBA'81V$'IEQ67# R-#;A35)""V=SV1&NM$!8"M M+.H@M T0V@B)8B0A4F&"L+0EW\.$(\:#P%+1!-,XH-I6#\)I/XJ7&]MW"-HA M:(>@]]TA(P:PE$DJA91$!PE56"JFA-!:\U#&5T-HUR'CP0"SYIP\%0%C(45! MG*2(!$PB)K%"7,=18NLL:)S7!-H0G"4HI@+ADB$ T0QM;4K26RDB@E/ M 3T)HWT2+!>=?D0$[>"S@\]U@L_;>-!Q$D0,AX('(9$LH6&J5E^QU4\,G<[K M_NN4PQ/AORK[NOG?\$\YZC.>GV1#_VP\#UA2PU;/'TX*W1U?V42#3'Y?+K&5 MR^-3W>/2QESSX05,2F\XFL+S> Y_'O8R&.M)S@>],<^GMOKA]%1/M!57I8<^ MXWKH)I9/X1>3#?E09G#Y9 I_<&D0+ZMU79RC8A@$OTQC&/QX-'%Y#J]R/>#3 M[*O^[3Q3T],2/AI?+)8\J+_"!0QB-KWZ*X\X_]^=[6A^-IK_VM$ZX FT(B(( MB$X5):!<,YG0-)2A%%2G1I!/@'OEET[S\@W&_$0CD6O^!;@*O. K/CCG%Y.- M7^?W)6S*A7E?G#(_,9O_+7+XZHK1MF.77Q4MDA)XC:WW[_8.]K9Z;_Z]]6Y_ M:WOW_?'>]M9?1[V]@^V7O:V#G=[1^]^/]G;VMM[M[1Y=N3];\#9NSVP?'NSL M'ASM[O3@IZ/#O_9VMH[AEZ-C^,_^[L'Q4>_P=6][Z^C?O==_'7YH__N\R(8 M(Z,9W$--?KGU<%?MS*OW)'S)872-'>Y0@'<=\/%$ORI_^$UED_& 7[S*AF[$ M[DN+)P#8_2_'+D,17?AR\#'_PLXB2'_KF M]P8;AB^3D#W 8./HZH?>9; 8W^BVU\3,W2)UY-I+V=*E*[08O\-;%7)W?)IK MW=N'ZTXGO5TX[^?SKKH9O'8&JTC%IYJXY4O78^) O0MO$-AYFP2O.67A6EMT M^^'IAO(UQO^43.AORFC.KSP$W&XUU#@H8 MJ()6/__J:I^_>M"OSCXX^#LX/@+V<<'IXL&WOVSUV"H[AO[2$G6]PA']Z1(K <_;)3 ZDU'O5R#X,ELH'O#LL@/_-7^+*WJ\3VE MH],Y'DGGB-*6[ZD=/89]E+E":=8+.<[M?IE>N'I1MG#:V.ZWI\X%;G4V[VH* M_[@,?OXX;"YJ=QK>XC2LLB/L:(R!7*>Q@EB:10C(T+;5@O32-G. M:LERN&\I+D]3N:@KK]D.7&A#>K:"E-;CVEV3H;P6 N*TK#)="8W)'AJ1X,M)S.;-A5D^B, MIJUI+ORAV:M6<\LM9@=XMP&\K$&$"#9)1$@$ MRV ,(G&JD!"I0,3$.(UP" <2WMB,\7)3RC4B0EWEMY^("'5(<9](45,C'N 4 M%"."%(E21$04(0'@@!@V<4+B2( *WG(_7L#UR+77VU295=[3UV=!6./MR#=KWCO;_W1N^JY:Y\T_<*L#Y>'^Z M7W@S#W9V+PY./FG"&(T2A;!*;>%;VX@&*"W2+,$XI4H+)C5R[HLY'C]:4EG03?08(;38E('. H M,L@806R@9("$"@5*PT2;@&O 8WIOE*2E;KZ;4)(GE<2U%R)AH2K0!N4Q(8!5^(! M8@K'B*0ZX#C&<6B8U7:2I"51!/=IMXF+"M&+/,G]GMD*X--7B(U;9,LY& W1 M/="CGT457"MZ5 5=^/7MDF!^ -O>UTXF>]_S3V&$*:9&(&T50L(3@[@2$C$B ME!2$A-R&76"\;,M9(Z;4&9,Z8U(')P\")Y6WJX"3. ZQ3A(4)+99*U,I$J%, MD&"!HDF0*)*RSK3TQ-+YSOYL2P[,)ET)@75Q?'DXX[/QZ2HL*X/Q_K*_N_4] M-.\G7:+P#P;BU)8D;)3B+$X0%6$ _"@EB NID [C%-.4&QE9_2^]2Z'!SI#S MDQMR.JE^%*FNK3H!39FB!B-0;*P'#!:/!Y(CD09$:X6)HF)C,^ZG"6F'7#]V M-,[35D8J8X;'_,*U;K*N+RYE/M./%V*^[HI9*TC+[4LD+Z-@N1O>^,VP-51; M?BO\5>^$#@MOA85OFPS'A+$PD2&(<@(J6QJFB)E0(QHG6F,:LL2$MF( +' 7 MS]-&26^;"::3[Q;(=\UUHCB):1I1Q!@3B$2$(H$50:EFF&M8IEBE-HT 1\M< MIS/(/(JL.GY_9V;SL^AT;7!:W4)O*V&L-0W&UP3$9",?:B_\Q!(FL0!>HI.( MV\)&!@D:,Z1%*GC,0AVD\<8F29=!;(T<59TEZ.=F21V@/"B@U*E9 "B$\0A+ M$B/-9(R(B($AA5@A+K6A<9C&/&'6!@0_/[^TK%;3H8.;](;I/;7UY\KNI^W& MP36U"\&>L)U*W^2CKYG2ZO>+][ W&LBX56V,#A5O&Q%4VX+"A*L8( M4&*K1P8<)2D+H@";2.H0,#'JQ^0NX8ZWDJ U,A.M*22TPDG604*;(*$1 !W) MP)@8(QG&"A%C>W\*QA%EFO.045A5VVP/]Y,5V10M@X2?M)]W-ORJ)VWKYWW] M2C]UU[U;CO"GZ@'^9I;+4VNT')G>Y'243]%4YV?%3G.M'Y^:GK?ZQ&T%";_Q M0?N&7[@E/1YM^1Y%^SS_HJ?66W.DY2SOSM@?LF[6M#N!=5-*$Z02Q1%1B424 M2H5PD@B<8)/B,-[8#,.X'R;W<,BN*;MNM42W@D-W$OVT$GW14*1Q&G"1H,0$ M,2C228R$TAQ)'F.@%XR&DEN)[K.P)5$5C]VB^NER!$%AA*&K2<_DH[,>"$RQ MWVLN#@GY#^E(<>Q'PVZP-C2GLYXTW;CS37ZG$MN!A!2,VOQ[3*&?D2A M.VF::"*1ACB,"(IQ*!'!. 86@RG2,0FQ28F2MHQO&"VWQ>K,,RV0V5:89SJ9 M?0R9K8TP *@Q$Q@V*F4VFH$GB)-$VRIP(N"A(B(&3I"VI$SMO3:QBUZN9![M M+=ST?FQRN*@W<*'P8R\;71C\@T+:D_J0?$YSUV?@!Q6@M[69Y?*+K;RB=9+H ME&&DN"WDE(0IHDD8(A9%J<8IX3)4SN),H[NXD%IAY?B9!+J%MHU.E.]9E"M; MAA=E88(T2*1"22(31*2+M@ILD>X@2M)$$*7DYE9^.!MM+A^E##+$RZ2)CV&U-NS6)>C_*C8LD[L+N5@O9EKDPWCC'% M081D)#4B"A0T1A5&H=*:QDJG*78=SH*H)3I:)[UK8U;I1/0.(MH(_]8JM8N" MI-+ 192.$16<(\PBH:5(A29T8Y.VQ.SYV$$L3QSI/_QW1\EVYD MLB$?RGGNU*7B=ZGX]Y7.IK_I7&9%8OYT)+_T1F,K^YT7\GEFL-DE/O0KO%LL MO>K.U]O:"QL5L 2#!90"F1@S&S,:(R9#@T(F*&=$1'%"-C9)G[&N(UZ')>L0 MQM5AR>-B2E=?7 MF#R=\SSG]U< X'FZ9]K FZX&M ]^"4LLZ^P.MPXQ;Y0HDB$5D32(!H(C$B<1 MHC25" NX%+A0,E@8S/J,O@[H&@K*>J XN& HB8]2F@>Q(:A6'( "FX21(T@ M*$B3 ,-< KO:2M#WEI&YOZD4"7U^66Z )= M?A 2/S:Y%9&Q-#A0**!! ) 8@AZ)(X4P-RFP+B)2PFU[K@"OM2/NMJ*[1@:I M9Q5^UU+_78=%#X=%!3T[?/L))P2G"25(I31%)#2V52!+$19Q(F(:!32*O"/O MONQ:+0N\6].L!55TT+1)"X["\:'R/]A*EU]!'%K0J&1-87)-$Q3/-,3K6R'VP-U?P?&E>^@4D9J>7^K'(PLPNU^TV>\N&)?L>G>M<8+:<= MZ-X*=.>:H@3*Q*DPMIBOL)'.6"%F,3C F HJ)0!PT10EC>^A/$27_= .7%G3 M[(<.5]J-*[6MC7,21S(*D"%)A C3$:(2$R020X*$! :+9&,S"OLT7&9S+8.5 MG\'^MGT5<>OWA#[)AD-KA1N9WM@)46MM<.U&W3L;X(R*N9**8LX888&B::1( MJI0*X7^,J4][%FM#? ==]TX0VR'FK1!SKO:Y@27$D="VCY5$A//0MH 5*&%, MD(1RH0T#]3?%_2A^#@%@[:""'2C=V1(G#)?:4*(BK8F6"4LIC8PF6*58&)I8 M4 I9!TKK TJ-#GLJIB'@#2(121'1@41"\@"%',>8APRSA-F U*0/2]Q9Y5HB MO-\AC<:=XWR_,-4_49 ^813O9J\_=>]J2I+[]^6 ^+.K#75)$F"B&! M"X(CPI*$24T 5V24!(EVK/5NWN+N@'B\ V*NN"QP546$%(B$L4($ W5EE$H4 MR9 F@B68JFAC,XR3?LS"=6:MMQ7?)[9A/EL87KV8/P$,W]UCC@&$&0X%#T(B M64+#U):=Q8I&R@28>N-!!\/K \,U3X\"+011$IE 0Q+21%+ X*4Y!2GJ:!A M8/-!4M+'P7(1JY9"84'5RX&4^YXXH'N"^BCW7&/%-GY5HYD8Z*596\-1/B^] M:C7G/9J-R\83 Z];V9I#O6SH 1)$Z4'#'-;]'C^-'R5W77JTL@PB?R9VS55LG8CL2U1)H!#'.D(D!-63$A8@3HA)X%3" JN-3;K"\/?$=0A^ MG=H6BO!?E7W=_&_XIWST&<]/LJ'7:?$\7DAM]\[#R8^[XRO7:T9^7Z*PE:CC M4]WC4H[.8#07-CAG.)K"\VQ[/#YTI/,D!RUES/.I=?A,3_5$6T%3>F@+S,-/ M3F'G4TM3?2(#7#Z9PA](LSE$Q#()?IK8.PW@TR>R:OLKU@-N6VK^= M9VIZ6@I^XXM^(5X%]5>X@$',IE=_Y1'G_[NS3>9GH_FO':V#CD K(H* Z%11 M0A5F,J$I<#4IJ$Z-()\BLE%^Z;2R:HSYB48BU_P+X@9>\!4?G/.+R<:O\_L2 M-N7"O%\U9]]==1;^]@^V5OZV"G=_3^]Z.]G;VM=WN[1U=.50O>QFW) M@\/CW:/>\6%O^Q# ^.!H=\?^='3XU][.UC'\\GKO8.M@>V_KK][1,?QA?_?@ MN/TO]6(VY#.5 2C]LCS6&TI9NM'XTM.\1OCR<;C]JJ>7IR2R!/<5IB]C!P+^ M #Z8G<$]Y3THF_,[Q^_C8%9#?2_WUW\\T&-!2;)/Q]>?X;O!8?''R\. M__AGQ;P'SXKAN%OY%;NVJ'<],3X/)M,,W/Q1.?^UBS/AAGOO3GE^1F7 M>N:(Y:2W-Y0O>QG0+5?,R18T [H)Y.E$]T0V&L]=W2M(6L^,I&ON W.D]%<] M&(U=:0,;IU/=)+NT?P.VEO.QK78P'?6F0 ZFO2E,D9[Z)H29[4(X'HUG S?C M<-4I7&&IWV1F#+PIW,)5G;)O/9I->BJ;V%R'2>\\FY["H$_A%4$'.]/3WIE6 M;I!#4)%>]BRKW"Z&>\HGY3CAL7^]?_,_'P_VCAX$V!(+4MY7#";7ZQ[@]D8UG*HQZ-1P&T7R_%GTM8?TTC">.R< M]'OU3_8+N3ZQ>V>47\#SOMHB,^[Q\.W);#P>@LN&^'&,^SU[G/7=N[Y_>?2R]WHT4AX'87UZ6PI8 M=S:9YA[67KS>V8+I'ML")0UY<%FOHS,!QYJ[K)"P6H?M96=GL^'(3BP\,[_ M)[2]J0E)2&^?YU].^5GO"&9#3_N]OS,)>S3C_=[O;L>? C8-9C#7\)=M/N2* MN]7*8*KL5$ZL;>>JI^ 5CI,:1JA,$AZ6[VMKQI$IM_;56?P'J-AO[^_'8YW#O,DOO>TLEP.XN_WE:S:P/\+; M70Q@O/W>^Z%EN#W'@+ZC:+=]6>T49T,YR@$BW"R,9[DM6>6 Q I5R1]@V?PU M[K#: G!Z4I?=H! MGRC^G]X?@Y& !;)["8ZW%_ZOO\!II[2'V\G%F1@->EOOW_S;W:7X^O$HM_N@ MY\IL]O_1"H9_METF=_Y))LW:-/SQ>#\^W#F%>\#_'[^-/AZ?Q/L[NY?[GU4&*@FQG_WS MQ\?S167DX/C/T_W++^3PC[\_'WP^.#W84:>'.U] <=F_.,!_GNU?GMC/OOSS M^?>F,D+V=T[B@_-/1(I$2)ZB.%6@C,A ()HR@22C!NM0):%2B\I(R#3P_$#+ MB NB= J_,I,2R=)$F"194D;$%6>>L-]%'KN M!(6;HYY[EN7VG'DRI6[=13F1 ^!\ P O.$3/7;P74D7?!,.D6P\ MT/8T\62L>3[V7KBS]X^MK3>_U $5V5EC_(T '$\(EH=@;YL-@],$!OW9>VK/HPT/ 'NPG?>89L[WB$_G<-S^@]/Y56QRRT>;@EZ*=VF3WE MO8?=DKGD>;C58 #/+0KL[ AL7 *>YTWOI:?ZERS&VH M); %2\[M.AN>Y79;56"P:EVKO>&)Q!6#!T+@OC(Y!5[9XPYF=N!A9T!"YG9T MT#MW6F_NPW>L#EW."Q\"S Q6SX.8V2 Y6+SA:#HW*:HR;5F*ZAI9N\J&\\.^ MG6<&WF(T&\!M--R2*Z^ ##_/AK)60-SZU@MZLV5TMQK-\MZ6?]5WVJF"<,]2 M4OZGPH<+S?,"%U9/Y,N>6Q!X<5!IW(2/@!P7%/"6*&,)H)W9O54]"B0;ID9_&VLY+6*P[,=F!NOAA@U_L/:-D57#X,]36)TB(6H=R;C? M/W>3WQ(.9D._5-.&&:C4L,Y/1Q;!1^=#N-MD)D!H,U@*#=(^;R5SF[OO360O M=O2 G]OU:RH*WFJQ\*V_LC,W_A?O_V?^8M#'!@./^J4EK9#G2:D%#">\@/7Z M0-(#N.'0O;N7D-HHO9ZK7*V(%R3[]I/>E8$5$WUBU_A^X\KV#E[/90/ VTB; M$7 .F PPO50W;V9QX= <>LD?GASY0=6A_L'/S*V/]R[VSS]%')L(,XW2U%9* M25F$@(LZ.A7@JB*!$5#M1BM:]B/I73I5=K-99>#16'A>O] M/H+_]%Z\WCKZ_9?55VR/5&86$&\961$LXRG-O_,F]4IR89TZR5UGR;W3JX0FP.FI\Q9EYW!RS@6WP\Y/,VF#T9VA MTYO1YI@MB),E"HZM3^W0W/W'^W@?P%?/\VT:;R W6,3.XPS_@7X MU(OMPYW]7[R&X2_5WX#W%T3-&DWSOKMT4GT3^#.?U':\BGA8NZME'?JE Z7< M6H(&%_VYB^JS$(:^>-OOG8]YB0[V+ZV0M0JOK/K;"5HI:(=O/S&8]E2%$@68 MVFY'+$$B"#4@=A)I%O)0Z:L$K5IFM_+K2?Q^F-Y;B2\4:(\L3NU4P.-Y/BG@ M(9LTY0GDVQ2*I'5<.Z.[O'#PHF%'>]>5\ZT,1XV/+0,OK"6U:M^;C4<+Q-M* MI$>W,\VM5EQZ/4]X!O(*BADHRY,"JW)M9;Z&Q"O>O'K?>1W3:PT<[C;UX##( MN,@&OH< W&?44 ZXE5:8]&']2G8 Y6NYBT"KG)L][GVDNO036!0J$6S>W&"' M^1+82 G#,!:KG [+]VP\IK@IZ#"Y#268O[F:Y45L0*&MONS9[-GIQ;P&M'!+ MZX(YZ9UF$^M)LX[^N9M.K-/3OWKU=[\6;LK*QS;-58:5@LF=SJH)G_% M-#8G&M1\/;7&'=C'9[U")ZSL#C=9X04SPHT<,#]QT&I\==!JF^-/@P>,/WU: M+%_ML+C> ?%!%^3MZVA:0L 9_PP"#<)O16*6UV)A1=R (!:P5Q\,7B6]9UF!KN%BO8&NZS?/<6L__YH.9K@A;\K,1MITO MP<'ER?G^Y_W+P^/]X'#K$T\"$RN:H@"V(B(QC1'56B"@;X:0F"4R,*XJS,MD MF;*!X W*?3@Y=<%(.C\K8JC.6KI%=K28'EG_AB,8VSY:H=L2?DO@ U"6I3"1 MUA2IT+8V!L1#/.(8)5Q(91@WL#=@2[#PY7)]BGI+N*5?X2*85PJ%'F1 MXJX MR&SJ8GAL:&0F7>AD$PDMW_4&[H9_ KXU ()J?1^%JT/HBY&U-<-3+"GQ=[:_ M_3@SMRU!M7JY@K?\8.0[B=H;11+];%$D1T WG,ET.*TMJF]@5\ 6G+0DSCW8 M+^/?OP\./MX>7)Y\,?NY0&VL>Y_9DNX M<+9/]C]_Q/OX]6#_P_[EP<[KTX]GK[/##_:>^P'@3?31QKJ?_=G0[4\N]G=. MR/[YIR"E&@SLS.K> !V-):E:>DN%^8'XDVN'\S\X(6@:)-#YST%&'2HK%SB@+#.;3T8G?<7R-ZD,>O-R(]BUKW7 MSGIXO0I:V">GIZ.),V!\M4'L@XO&4[)%.GDO+NNEU7Y ?'@_T8=F%U;PS*KA M/QL.7.X&!R[+^&-T<+Q[#OP@4M)$ :6(B9#:7.($"6"1*-&Q26A";.FR1;EN MF:"L/OFV+264\ZZW:MU?/;3O[%JGLH_;JAP)5K>[!9'I%U;$F\6!55$O_3(8 M9M*;.1)F+?<]7\M=OFOWZE4^CW[# N70(;RNKHW5\FW:W6,[OLMJ,6(3+W":KNO=!E_34 MJ_%6T;9A#0/]K?'6/I;%AL:=^7"7 A"UR]-9GK$>%Z-989%T\S+Q$5]34)T: MZ4'9T)IO71CU#%8EG_+,ZUDN=Z@!TO" 'WHSVP;,?K$>&&RKAO'1S7L.)%SJ M,O;Z*_MI>Y6S\S9?\7N[U:FQ\._)R#[$#;664V;ZM:Y4ES:7WLN;^BV(SU_?T:987:8C7F&4Q">;%5<>SMA;47 MV:A)/EA/%XB7DSD:87>"-0J,!E_MW-YH.5SZ7<$=[@9\OM""W5\#X#N35S>> MU3E=)$I6SK/_4V8',WV%0OH(6MOJF;<)&3CY[>G.J/GI"HE7W0I?BO,0P8ZP M2_C;E0O03?C=)WS;2A\(R80/]*2;ZH>=\"+ANS>UK*])9;MY?\AY/[(YJ\@'M%F]#OAD M!R^/<&I.^? DLU6JO?[VF^7^W90_Z)3#]M:]*?^VE,.^:$1_6$LJ'"TV1L2K MIIAF[O$ZC)^E_3L-GE*&^RK1G*& M3U"=,ZR.1U/X-7/)LY.9^%R:/$M7MRW9TK"*R.9;.G.6]*^9PVM6:9D-NZ*] MXNIN8SL4_"L]53SF FO)T.GC^I#*TV-NC* M^!^?P5L_6%R4]7-<7)$MKI*/N*\ 3M/YQ,;RV@C%^%ES*K)G!\CW D&GDU. M82 GLTRY,D'S8ROFS 6XEZ'ETR*VPV6B.2^2G7MN],G,9L\46M;,;4:#;&0C<,MOKK:U M9].%;PXR>5'N*J6->V=NC5=V%9LCZ_F0SZ]"E2[KPOM\O)C]>V/,C;!6[\3+N7)Q MJ+D;XU>P%9SQ53F\*G6G"=%*(N5U*J6TLD()'-8 M9:TL_0U40>?ZA8>?:Q>IW:MR/N'Q8MJ;5.%4OFC5>,"EDU/?/ZBTKSO_%K; M,,=!;\?/6V_/?NR$L5'ZQHVBJ%MT_87UB\!CK$@[Z!L46;)#ES2RC'C9=%:$ MOY<%(6:EM1J6,IN.BD'7Q0 \5+OB9#54S\\2@(V3;(]YC8A2N+*)FR[->C"S M[HWRE%V*")\//R_P2+J$=N=$Y)6GHO!D.=RTE2E\HG:=>%2Y?O*Z%TLCGKUZ MHAMED>;@?G9^)>MV*G?O<'%40D_/K3-SN1B%#__WD;7S#W+[M#Y8J]Q+M^ 9 M8(;_*D!P9K=[[;VLD;Y^MZ7(7?NF"^7Y1H,BA+<9"FQGZNJC=3$%A!"FV3L@_5*:Q22#QC;Y28"[4<+JU*7!N-('#FY@ MB*!*Y=Y;N5AIS-G<[616%>>\XU17WW-?JRYK5NTK7%V[LQRV%KS]>U<+Y,7N M^U_ZO3\YC*K?Q-_&;O\?V(1J=-;OO9M-)K;;LRY->CX4+4KR(!"> ?F2KX(;9*9A@+@;6)8QYQ%78J\F-F0ZM4 M]'MB! MC/V]-I9W,?;7J#"DA!%M I*$,34,@[@8S)E*C:)7 M+D0;\]:N-1-NVG"9F1/'VE[4,(_X],]".FRM+W[AU5FXP OG2$Q=,JK?O%]= MAJC)RE)O!8P N75VD[H.5/DL&VLU+(P<+N+,I;9.5YFQG(Y3&X9@<,:%VMD? M?0HM']8UI0ISA\V/!7Q2>O"R+#NZ J0\%2^Y6F%;D3W#I8,UJX(6T9"+ECV? MYEN@4:Y1%7_F$_<& QB-=^M5S+WQ\A6[KPBHT[*:%D58 1OV5+^-LZ).A*6 8<-!]G!+5RM6"1LD8C+D%H_:%JM2>=N0#64STH M[+K.+'7AJLU]Y=G RB0"G0993>WQ"S5%N'6%FAKKWG-F3?Q;S^91]NI$RJ>G>MBTSIT6BGEU!#KWP[0@IQ[[X2[6&F2O.VN.ZGMOL&)/?N<=[/Z<#8%F M#=Q(ETI$5!'X-B3>R8&-?<@UO,S$#]HZBW]U!V9ARW3%O>VP@2@71FUGJ[+# M?G?E@VPX^=++6-UE MXJ.'[5*.JNH5MZA9L6)'&_/ ._K)P566<:3UTDSLQLT62D"5) EE-OJB!K0S M/3T=J=I>N*A"/4+>5F'&LLTD;4R;56H_P(;>+OA=QT+F6,C;3RH@!)M (V4, M0X2Q%+'82*2CB"@EXQ@F>JDDMPXHAN51.&:$8TZ3&"N:V/62)B5\+0,0RJ#U M=W70^M.RG3>-;@W766:@\&8W4Q!=ARK]F(+)WB-U_F1BZ;V<]XRGUIKLW17C*9< MF.+4=*]J.4H^FIW8%CD&[@:+K'MI=]_<79 M#V2I=2]=5/H];_QHRU9>P&VK.9E?_1=67X"WY5?@%$5; MG3"=@O($2"E]]QX#A_@-@Y*FDOR8MV$'+ 8<8J M!;,,6BK>N,B G[>0Y%J5S6)LX-<*G\&+K/E0=Y+R"W^0%OGSQ4[^Q5D!JR2< MB^]_D[NN[66#"E=B9>YFBP&B!47[ M+]E@J,+FYCQY@*U $$<=%P!?-=HD5\+M#:1107:9A^2JD9 N9WMR\X&T])XN% N8-5>>-G;LYMV MKM( 3/Y"^6Q?K7>R6'.@OR(N;]B(Q[/2Y4*CRUQZ-VK?OK0L_[N&A0;V;87C MTO9DY:%?3$RS7U&S9XK/_H>9>/4LCBHX!\[&MO_H12UW[?'(U"A5L!I?_L'* M<8T2#GB:IYG52>9B,BP6CJL7=3MU,3V@0-,""II?=I+KPOK]QIB')Z/+6&6E M"SI6-AZ:PX>57_32;!]WDELS^6(=_JL2,,HCVE(K'\\]5_&_AIWG0:>VJZ!' M_=2TJ;EK8"M-JE![V1QCOPJR]ZMLPY6+ZQ2?4+%8!JFGWYO-AS8("F'VT7$15$HA]?*J=6I&RIU?=14[[847<"' M=76>6HR\"-2NI.*$7-;9"_N2<@>7"\9JAE#DCF@L&]#J,L9-.E'.R?R [918 MWQ5HXJ6JT>D9CKH71W_\/WXV_FWKES(0^@%$!U/X?_:HHO-',PI.7%M^ M[#Y&>&/YJ5'7(>#22)NA]?NN97WF,\#\+P[HA(_=KWDKK_/"Q@"I+CUX-)M: MKUZC*):G>8Z7%^-MF'7*<5GE^<+6DLJ^K=1(%IL53/A918N:"D>^RHC4+QA: ME> V)[@+!T$E>!7!K^OO%R'F#47#GV'S3-@58-"-+@2K')AS/0RNR>_M0A<7 M=G:Z!J&+UX4B+OCD,!:)-IS&6(?$))J1Q& 3*Q$'J0QI>&5U^VM]>0N^/TXT M,2$64<"(,K%((AG',9.$2<5DVCIOWQ6J1(E1)2QY %@XUAL*FYKS&EBSX;11 M_:VIS. )CY]1'RJ<*E?A\7,-1_UH2,+ M*)8M-Z&J ED[4 G^?HX]J7?U%$O4+T?PGQG/I[9A M5?$UKSMD\&_Q27&G1M?):CEKTQ8?5HJ*C>:QBK^[MF0\_?+CF@0UQUI1KRN? M7-UQ7)Z*O!Z)/_V*F,_2S%#<^BE/?U_=T4Z]JTZH=*F9N:,T<7FKNSH=G-:/]10#UQ&[-#;[:N^/4-GKG >F;I'5&%]:279 M^^YDOJZD(-<+%AZ;O=?4:74C=[1T"#1J(MH*R\[AYCI[@"05O8A.^+C8TO,V M)[^$HW-G(;)U0HH>)+6$>@2S7ZFXVAO8PKT=N]@G.3^;$^XJOWE>Q*<%Y5J6 M[^MEYX9R,\J_+[,7>DENYRRO#8Q8B2&N\5--)Z\0R9])+)["?#!"I=)K;?VV MH('4KYXT/&3ED.SL^\YMDT8B<.-S8 BN*H/S5I1RW"^N*.SH9SYF8I54EX^< M;TN>E=GH7B0+^73!JX6*K!M)[ZLR'[K!/!QC1"KXP/^*IN.;MOL<=&L>.!;"JQOX,"CM*(9W77YSK M?ZCMT7DVRBOC7L,M,AP-4:YMDJ6OV3T;(SB3A]5K%";21I/;?IFB. MVCY (,#VB24<]*N?BE+?PYE-K/*M$B>S\=C632I-C$OA394CH8Q*&^=J_E0=>!>%P:M" MS8+U-A#*O60^%[QQBR&56M<*7W=1#K5*P5T_Z=L;5D%=I1O995R,;9V/E3&0 M+C!@'L)!OLQL8#(;S>-Z0C5T\D(3+Q;5?EJ+\CSG+B*[)O/"T+.1>/-!CF5P M;2$W5\=VKHQ@K ,8J[N&3RYD@39]^$5O@.5H@?FXS,;\W38XW>ONM\0*NKU@6R M:?&R\'L4TV*?_IV!5]MSKC6K6]MY1]3,GD-?],7\Z&X\CA*/;'1#>=#82C&2 M3QJVJ/GCP?DY7<6V_H(E+*^,//!6DY%C6#;AQ'Z_\+;VZE[AM=4_*Z*'M#SU M%7-]2Y#J#)K,I(U.;B8 HWF" M7??%9JATSQJJ?!"$Q>MIKPH[M4OI/W EBC)37]I?H@D^FLW5KG*GE\4JKP?; M=W/@4I0;+,H:N$W@RY$U\E"^NPD6XDV*I/ZBEI<_,PN[NG_J2F6P>IFAMNCD M(KL:T5QS-VK,7K/=43GBQN'W+$!N_WM*P-/:>K;FM"SGFRW./5Z*FMMDA4FB M&+N-@[1F&QL'[@TD-I38_J74]MR![A/095GXO7EH.DM+75+,W[90ADH$J?#5 MGI:Y7A4=6K PSY5'XT:EP:7$C*S4>XK+JL"61H$_I[FN1#;X]F34KYGG0E6P M295^>V6ZQK/8R$OJ[A/O7K]AJIRYO0J:FK-/KI2G1L'@S5 MM[PJT]B75*BR&"B_K$KX,C'N\36,>9%]L*&YQ MDS(*>L_<,'C8 V\11'SNXFRKB.#B6)I,1C)S2%W/D@^B6A':O#3>*R*RBTJ8 MPWDF\CUEP ?2%-$:WU$J7'>S?L.'\GVZY" DKWG/59RL=A_5"5P6&NLG?76<8Q6L;0TOBI#:1E3^7*#+R"=15SD8 '/R%,W& M)41Y>/*@6Q3BO;$EUI\C-\E_< -=3'.I:B6[XZ_H$U.;<%V:8?.C>G)_J9Q2 MJY+SYA.:W"GR+"B0S9[CN3SM]W8:6PYFZ5<;\3!'](^JS/.6!(57A+KA\FF: MNO+BW8J,@3FBM.#(J#P8CJL41V7MB:TSP$M':*5Z6]:Z+XM**L)UZ*M9&[@-8^H%?_*9VQ#4>:4^F6E>B7O6)C.JD5R[Z&GZ274:(?ZM#E(!)6'5B\-PUK9EET]\ ^?<1ZO-UT_Q%KC9E M642JJ66YUW7ZOK21!9[F5F5[;_ V"TT/FB]WY;=M NS,E=JH1["DXE4WA&7T M]H&F:?@[]RXGI;F]FF96:UX8Y:YU4C45"\X>ETA8)-:X^Y7;L[S7G++B[?&% M'\AWH?*]'4J[>ETOWBL4UDW@8V]=B8]2NUH1\5^FSMLB'GEC<>L"2"OJFM\Q MJ?=A^<61MZW_X9UOP#*VYI*4"Z+1*1'SE./\4Y@:H8-$HB1*&2)1$B/&HP"4 MB$1&,4YT*J(ERI&*D&EBHE"FA"68TQ"S)(@5QCJF!'^7<@@NOYSD<)PJ5-7Q MM?_WVV-QD:,;I+272+Y:67G$5[C6:/:OR0_FZ->*2\/).*]_+-RC"A/K-UH/ MPK'A+=\>&@LX\>A6I4I8^^UL;%4?[P]T[1'+OFU+#;O*A/&;O%<%H_957JT: M5]TDKN[2-O>6397JM\9D]!?&61>EM@=%^3[EN/=@X+^5B27-W(PR*<2-]+?> MZ>S,%7Z8C&:YM%D6/EL%M,"!/K$/S8;.B.,C?6R,'>RI$S^]Y3/K>+WRE7YK M<(QZ#OSDE.4TIGJ@ZP8\OAU0I7GV>WQFFUHL=/_AQI:B@"/_0R43-UJ6>JHG M=5!"Q<7N5V]M$5V]#A?G4AY<,"CW9@/DS0:PTM86*:OHC[QH:V*WA"MZ97,' M\^+OKEUA<7 O%0X[=]7BRU8LL'=.L_'8_J) (N7TZE*+1>"^HPJ^>ZRKA^@H MPQ45&'U#O?(!KKK^9&S5$]OVU!=C\QS,1?C:_=BWK6ZE+DRTM:)EC;+6ZG&2 M^V+_PG*=JLI9PR#CRKY92EY$._L\2I@%5T+4D;'"P#NUMNAZ=/;E3N&?08/I M3OS4VC#V)@N]>-D[^L[7&LXIOR1SMUA()+^-T*P;]3K.N=+ N%P^4E$9>_*N M*KC4&7>LN7;K$\PN25FL4&PB@D@22L2"A"(E52!IPD@4Q:TPUFPM%\URK1Z> M.)AJ52FOW"M!5>'-+'M^J=O_O_X1)\%L4]GMV0_=7 MU0ASK^ON_E]7=E><3=1":\54DR0!*<( ^@1'< (D3&H21K&,DB#1G_96=51$ ML.C^Q(=;?)N^&L[.U&A:?+XH:N4DE-)62]GD0$^W?0IUU78Q^=F$;N=+<'!Y MVWP^/W^.#M)RYDG*:"(0I+@(A4(1*1T4@:3((X3E1LR,9F^!(OM5VT MH00#EY6RNU@TM:;>=:\T5ZUV-!-3. 7F^T@W?(YU'=9O1=9Q:3QPH?EESJ#- M-.SW3C/K('#VF:K3&Y]:@CTI2PC/=VW,X!0$TF!O517QDEDN9V>>BI9-KJ\9 M\SF*$2^?--W&__SV_&#G_05L M_" F))0,(Y7$W#H'*6)I$*$XU7&@0A-HHBMF<)-E-BKF<%11S!DC+% TC11) ME5(A_(\QY98Y"'&WS(^YS%HS$0IE@$_$0"H8I4BD,D:I#E@B \:I +5CF V6 M\&T9\/A59Z0O'+?T]^ :16YU;('7E+0B(@B(3A4E5&$F$YH"VY3"=@,5Y!-A M&]\-6+PV ''!9)62B!,9F# *4T(-$SAE0F,EJ>0TI>S!23+0H+IIS)M\-(0? MI0]R\@2Y79;)PZ-R:[_+W/8[WK_8__S^V_[.6^"T7\CAA_?Q_N6?GS_"-OWG M\]O+_<_OOBQM[3_LYZ]/]R_W+AP'WMD+#X]/XG^.OUSNGX&HG!V<'>SL7QS\ M\:[1,%G"?=^>'P)?!LU92MC5.,:!;9AL$"T?VLLG$%H#<.GKO/D%AU#8?;]T(<\^&$,]\]"3J M;?M>M7_Y;H ORMZ6R2^O>OOSZ>;S5P+.KKSETS:8=/QU4C3<*LW+#SVF6Z[$ MDX8W^>+(S?[$/@"ZZ#:YW)FYN,CW.\KYM.J@4"0N>>_DW%5EB=2B8-? 63)5 M5:^KJ+O8K4K]\$:9-YLK"+,)ZJ &"W4M7#ZP;+[2B2;@+)DYQ M $Q\IR(%O=U>M(6< M(-S4M[Z4L#6IA[G\(<]KJT]>< IDNV/[)T[ULRPX_XKTA6&93I&S[FIL#!<5 ME?ZM)MXL?['QS6)QEQ0I_RZXLQI@-J4I#UJQE\.J97K/R1!^M>,$I0+:^M,; MHJBE*S^9K0T$=?U%_F[-'1NT" M2U[&&.*8$JU3%/VU[4E_U'.N-6UKQY)C^B*7*8;IT8W[TY6O4]3-E &QF6^= M#,%/]>U1IZ!C6-H+NR13@ ,,'X2,\8*&H:QG7!AE;B15CT5J9]'VLMQF1O7E1G3MQ9N.C>[&R'P4RR:TV\>P0W_D3DQ] M]+';#06GP83\&6V/*@315T#*O[MID-/^:O_\>^@&9:178,3QO]!8OB?@O#E+ MK;F=ZZ?S$I<;^5V1X+8]#O\5/4S>M;O#4$CDL+ALBIH+9!50P+(A:;^DNO:V2,B$ MV1NG=Y8QC5I9<5_: OF3N>LF#=TN7"RQJ'I PY9]4V>I@T:YI,6+M#KC/UZP M=V>SHE!7Z[_75^6M[3GXA?9)">-LZWQ<[FON."*6<%$M[!WB<@:RX(CXB4,8 _%841.9E- M+>1VE$;!**,M"\-L^L8J:?-&]V>)##?1YWK9]/E4%P< AVD=.HX(8?VO-Z!L M+3SP;'SRL%VFQ!<;U,7!:>ZE,?EZ 2D3J_7YV7QFO!1?O,B%!SKR2Z?(3_J3 M-_(SZ!&E:I^D4"Z2M]L" M):>ZW(,//NQE553*XZPW&4*_^#[J)C3Z?NU'=IY';6DN%K)0-;#)+JR(R?=: MQ_.O,^.QES2BW)/^Y MX=2/3:OLK$PJ5>9IP!8Z=*S71LU_\@S,+WY!+AG');[I=G*0QW$A"ROEAH]0 ML'+%*U=\:93W1/Y+D_Z*\T/G<;'7(W0[LP[ MH+N'/R@XIJV]K:^_X'?2V/K0V?OXH;5WN'W:./S6KG_?A?'LTIWO>],IV;1Q M_D,T-O29<3#/_V:;.C2UHXS (#<1/<)V6IHX8EC06\)F%A M1LN/'IM^.D^*=^!L\[;WS> MYYAJSUA$CG.'N(H!.6$8PI@Y(XT16()^(.:RB-"XO+$0D*5>^$;WV%=K/[/V M.Y_WB=!@*2>''*8>H%C!;QHGE#@101)K +Y@[>F&?+BEOV,)8+7G'VC=>1ZXB2 MAF6'A2#(YK(XL,FB#=I2+7JXSI)BE[QU MB#H' D.#0I9&APC'BM" ;:8]O90WHQ23RU#E=R90P-F= [<%1?]YV?,Y\RV/9*"0??DHKAB Y<%%H,>_!?&]Q]] MO%%\].]!6/Q,Z W-R94?XXV[?L8TO].5UPV6Z W&[W;;9QJLNM%M_UVL6KER M( (9$@K$G93>A'S(\(:>_*J1621HQS28EXL2,Y[^!*<0P'^669I#N$?H3\[@ MQS-PS6:\HO%[K_F9_# MAWO_Z?N?#X=[']ZR^]YWZ&;S;V>[WQM%NTY_6/WY) M]18^^[/Y?E#_&[/&^?9^L-KE)!$DF<>(Y[YPFGOX9\!&X-S5UY.UMW1=X,6 MR3,E-!5R.4H)>:Q=F3^]Y>ZLT/7.B_D*T/7R%[\%ND;.@C.&LN3!6U-$6Y., MTLISV+T,WXQ(M4+71T=7/(VNEA/)L-9(".815P"Q3FB,:$A.:TLMERRC*TC9 M%<4W2X=PMS:P?^]D+!T>O9OT0OFC>QP>U3VCMYNY2_%\I:U&2Y/2$FL +\J% MH;F!5%*)<^.=ME)55N,RX-K9K-4HC)>!8HUP- *!D9B/835'#/".,%@X+-7: M6T[6!5T\.5DAL_%R['I4R_"U ,>]#2+GB&*@2*7A18<42W' E($PYD2 >%5= M<04<3PP<,P81)&;]5?.S7J,J.&-T.N2N5LZ]+JWV!D$1Q5#YX[BJS M9PG0J_%NUNR17 @:2>Z.0L#LT=*A[,4A1:W2X-(%5F31,K9N\&+N_ K9/9?# MUW-&Q%X,"@0A*@Q-.(3HB 3$B9I7=LQS(@6<=IIPC&CC" M.#G$L;#(@(^+@G::,)D(UW;MK53KBE]%P_():0&?,"XJHV<9H.OO6:/'.H"KQ S22N>6<#P@ M8YU%$A;*:B:]D&+MK5@W9#&&O4(F3Q7J65Z3QTCN><0D9IW)=-">JF HYBE0 M)36O3)[EP(T9DR<[MUA$@411]2^P1? GCQ@3C''E%4G@+*EU8TP5Z7DFB^>N MIUNOQ5F[M\5#/"7&62ELI-P&:QU1SG&O +NBE:2R>)8!N>9RHHQ*7&OI4?)< M($Y]0EHZC:A6S!"M@Z,Z6SQ%ZN[J6CQ5D&=Y+9ZHN60?>KJ4%;G!1Q7B>=.?M MVN.C6&7S/$&$AT1&:"1.$L>MIL;R@#6-7G'AE*R.M98"M^:R>:BRX%]+BR0- M%G%/LJ=&07 I#L)C86'Q M[B"SR6;&I@6BIN<.^%R9H;[<$'=OT^B.C$$5Q#TEQ.W,9?PHIA+XVPX9*SGB ML4A5# HY%ZW 5D@1;<&5N2ZE7F7CZ%:;[/]CUG#@>9$,,F($ZE1P8G@83U.'"<$T%,QL1UL*U7 MV0"[U?Y>1"=OZ$9LZ!-^@XSW39ZTS?NVC_23;]ZPEX/7*4ZX:F M](BPD\%RA>XP\W052WD/('PQ=%CWFYIET0W+' JTPY.#RSWSS>-0J8@[JHCW MLS:I$DGE_M6(,RD1E\H@HRU&'O[,F3$BV00J O-UJEY"BMA#[-[58-1Z4=C] ML&1;+P.[ESFP6F'WXV#WC'D?K*4XX8BL#Q[,>R>1\\$AJFPR1/(H4BHX_]>9 M>. 8Z[/@9V']_[M@#W^[V!GQBN:B4RST5S8K?/M_7>_?<\T5IZX;[2].-Y2 M/7C2[;?RO=\47;E;/^,%;_D_9KLECF8)7UQB'F8 M_GG0NZ"[_A&1ZT5[A(INM&]L^]2>]=?^/\O;1'!^PY--.CX\#V MRUZ_KM4>_ZVX]2#?^J";VWH4!N<]R^Z/71.JX5&SI? ;.:6PF778KA M@MJ)/2LOZO[,WX!'M5LICILF3]WUFMY7US;GM-[W9T)JG$/@A&.'N-<":4(R96_R M$3X!YX2OO;VV9\T2=O*KUORJ-1>-TWV=N!68,.24LXA;JY&+UB)IB(Y",RIR M21+>6"PL&*_Y;'^^&[?6NVV#WSNUG'F0^/=\/Z.OQZ!BV[F;X$?;.OZSVZ\Z M&14"U?QZ"B#"F;< V P9Z17BB3OD$M9(ZZ"%48H+0M?>7M(%=MS9 X1@/+^U M'S#!_=S:?K&_T53CQ?7:<1P4JL[^6A^U8,QZN77LV\-0:F6;6T2>=(^SQBW[ M19[TXD$\[H/4UMJPAANUYH5T_I^%7H]7:,Q".8-:']1^VEX+7J 6["!F70_F M^H^#VJ?A<I\5(KV!G>Z:B2X_LD M[XFIRYX\G%D8:F*CG,/%GX_<<2IWLC@>='MG6ZV^AR6'A5N2AE._ZN?U7W_2 M/7 PO00'\WSO$#[OP'[[V#B"/29VFK#'.I]/&^#(U@_?G^<]O=L\^AD^?N/A M?S^U]VC[ISL\.6B<-SIY+/!;:WM4D:S:.S>K,.>_K@8.>; M9O7F9QC+-OP=]OOY^]-]JAC'GEJDHLHM,(/)[5P9PC:)7".H8$,O]*NGA)J( MJ00[C7L#RV))3$Y0[*UW(LRWJ!JO >S:19]Q3JJO%OG+3?W?#64Y_9:I&2E MZZ=M9S,;?/WSE663:['41_<-SZ[S 6L%A+K5Y_@%J@A8O?:MWA MH/;/#]L?=OY5<[;?ZA<66;XOW&B0H7!0.@==,,]+(,P7]0H$+6&WL.B+4N]^&,(H\_WL2=P-;SZ.MR[-!;R<^$+ M-H_\1ZUO4QRV_YQH2YWL>>WBSR51,)N=B/KKPC=J'KZ>+^Z*8G<,^\SL?#O"+E(XM[P>OV8#>= M='OEE.:5ZO;LCYC7!"#;PJNMPZN ]H:9'8Q]#ML&%"]$L/!/CW.6G'7=WL;# MZ-C'54Q_^X,8ANVXDR8J:A25:.8EJI341$G]VF<))YI$0$'FGN-8*V2+SJK& M1:FBETK'A;Z(3V#K7 [N&=0F=F=_=I->;51>'88I.PCG'0;R?MI_<_,6GU5W MR*H[9-4=LNH.676'K+I#WO$L^WNW=Y1->3 =/9CL5?/'JOGC:J>T+02&LH1O M'_]5RO>R!'7O87=_:+F/7^5NY\OA7O/@H''X/F,[V.8P]@:MCZ[Y!L\2QWO-D];>QT9[Y^-[6F_"Y]_K\'Y'8K?S_FRW^>5H M[^-[LMOY=E3?^LQVB?[U9W,[%YSEC C:./?[U"=)O79(:1H1CY@CZPA&1MI@ MHE!$";+VEO!U)E\"IWW5 G(IM=8KP-AE3CVK,/:!,?;S#,:*J)UCBB/,E4&< M.HX,,QA)HSQ63'(FC_JT:0#[ Y/[2.6_V#?,+9[89GK]U=ZH*Y ME;(@Q^OZ,2]KA6ZW0[>S>0M2)9>H\0YYAR7B(M.E2"L1)EC01(B@N4, 61=R M,:%VA0S(BC_NI9M&Y['7#;9_4.'&(^'&K%64F"-<.(JBU2)[GA*Y$!2RDK+@ M&?=*B+Q+-27T/Q6#W#,5U$[R0*J"VN4+,;Z,HJR5LAT;<6DJL%8%^<_G+49. M7!0T*N2BH8AS:I"F.")A"&-4)2U9)G41ZX8MIJ"ND,FX!/5?%50O2:3R94#U MDECJ%50_'E3/&NE6>,^89\AI5G 2.F2C=@AS;>$#X<#3?YS0Y1*4RT[*8V<2 MH"\KE[TV\?]AJ@*PGJX*>,8,Z-Q]T M)Z/>P>[ACU/ @$ZN$6I\_'!0IY_:.\T/K=W# MKZ1Q?D3JS3]:>\T?LOK4K&N?PIN?;8C]9K%DF,[4J>L0%!0BQUN:.Z2D*8HT- M;+%. ;!?*J$X]UQH83 A)O+$!?.183R?,OI7+YY8V/[O?YW$X_XH=[M8E]IH M86KERORVBN&N^<:7%3C\YAT>6RZW8HHY1_Q=3M2>R@(?3=;F<2AFJ)R892RR M>6[AK9_N1Q]P /L$')3_A .*L7D?BBGJ MPQPN4>SKKB9]&?O::WYKUS]^Z.PT=^%9F[\:6T>G.UM'Y[MT6\"8:6/+DWKG M*Z\W%V)?[<;WKZ>[W\&T/PQ']:WW>*>YR7>:#1C?T2F8_+AQ_O4,GO6K/I,: M7:>-PZ_[W-@D$Q'(!\_ "X@<&8P- M^ Y$9UPFNR]I:O$[;2B2U59O1RP&N5 M&;W$APH5O#X O'Z>@5?&#/:))12C]HA309"VQB,GDW>PAHD1O?:6K2N\2**\ MI!#W&I*BQP;TA.BARHM>3M/Q4@#;'J]:!5^W@Z^S>>N02!%A*33RPDO$>1#( M).F1=U%AK03!@J^]-:MM&U9)SY754X'&?4!CUN:QW*5(HT62YLPW LAADW,H M";!\ -*YX2+WS ;LJ#*>GW3C[5QRZO7+S5PK(+A M4P'' P#'K.G#4Y!&4(648N O!2F1T4(A TL0" N)9G^)K&.B'RC<4T5T;A?1 M";'HN5(5NB^IV3/5)FJT9%_*YE"C?[TKDQ%AZOX>#$,K+E.)ZDI@%IXW=I(, M4; 0@H+,"\"7)1WL9 +X*LXY +A:)^J!<]=>3E7\S=OAF_OR6[S$T"&/VM\WSUO;#4Z.]\_=/:: M7W\UZ.ZO70H0<'YPN%O PVP#I-WFMX-ZYU.[<;Y-]@[KN$YW\3XWQDJL(](L ML_PS)T%?!8*,I2H9D$D>S8(\,BTI2TICZCB6S!IGE5[VS_*GM@!X>E/W )ENM#!)-FMG"5AAVAF5?1?@^*-&RU=_& MU7UC;S0W2U;FSL6&8#T9Q^['7[_=J[D>51S.BWW-RYFL?;S>/FA3E63.+F ME$E6S>7MYK(!%NZ,1&X6]O#K8PP!:3I^Y&* &]SC3F*UM(>=E\8'8E*,,ZR3 MDYQ'BRW\+A(W+GECO(Z7Q@>FXN(P)O\F#'M9!\T'#JX.%WSMQS1L9P6VLI&" M,AA>I]NXL95Y7NMBM[/7:6P=M'8/C^#Y[:,\WD9S\W3OX_8YC'DN&-X]WSW\ MC.O-71A#N[77V85Q?FKM-+^T=KY_@?%])O5,I7?8.*JWIRLAMT_KAYO[*D6# M,0U(!(D1CXPAC:5#)"@:':<6@1UBJ8_B'IMY9SD/V^Z=+5$< M(62A),YS8YPEEHI,/.])$( J#Y M<4T4LK#IENBD;57 Y?,,N! ;:"R]T+AN0XD6W)UW!9(@*8U<68_^Y,B [Y?!-^WH5[-X: M=G=G8)<)1UF*$F6[&W$N&3*&,V0#\X#'(N4#3(!=2A?Y+1:B/Q7J5:BW JCW M)*!W8V1;LNXE*X)B/V90S#L90G "14D"XM(#@%EB$$V>>Q*%912,1TX72S(J MT_'UU<%N^O\.6[V8JZ)S#(LZ)@I!?M^$O%I#UNK>S]YG=I M ?;2V)\V6 J*C676<"&$3LXI*;'7 */6ZRKVMPP(>SX?^TLI4"^)1]@ZA7B4 M"FD9!:*!@R[DUAOI'RSV]UK*1N]MGCA%E9,R2689][G4Q%CE:3#<8RR,J0)? MR[BSY@)?WBA*@T5.Y,"7XQ$Y9@)B7*4 #IE2A!5-,@FMRL\K''F&?.YTIA<3N!#4VI1H2"I0 M;AG1D03BJ&%>1 &06@4NE@$_\7S@@H4DPA8:(%V$#.($N=(+"8R;C, MUO,4.4LW,DM6@=GSWF:)$8IKSA6)2G',C"8R6MA4B7JB;96PLYP;:S9N8:1F M0B6&H@J9YS,0I$%V48J6>NHL+%[*%.>*L%4V3"J"X"4.6]P=1ZK8Q)/#QVQL M@C#MI/,>.963B8W,1>Q#,E(3G#N"J7%_=-.JKU;F0!59.(!=O!L9((+ M);SU8$IKPA LID164H>()N 1<2&=9MD 8"\B[6(9DBL>(H'@/O=X(&ZBE<"P MAR,VJ6( 3XQ49#X&0!5V07&.K,J]3!+F2&.?4*#P:V*!D$">*GGA*?;82TL^ M?UGYXSJ/E"KXK^'Z8V-7SXG<5UGHH1)\-:R4MC&&$(X\91ERE?-*4 M%#))&!92T%+E;L'KL.3W3[FI\+3"TQ>-IRL#IU4\\2[0.1M/=$8*+))#L/8$ M\2 \,M989%DD/%DA@],9.O4E/9,K6_@I>+['+S5Z?4XWE( I*KH)PG?>]"(8 M%+ ]+GA(_S%+%SMZ6WQQB77P;L/!U9!"+"=LZN=![X(F\$=$ MKA?M$;()!OO&MD_M67_MW[/,L*UC-#>'\Z]_-:7Z-2S/-V!M7N2G':V)A$'< MB+'V+X4$LR*[ MK*[+;BNRV(KM=CCC5M8WA+LT9D9P&[C71RAA.F33,1P\^4I!,:DUH MD3."QSDCHY9P5<[(.!K5:(:#W?/VP=[WQM'>X9=.X^.7=IUNGS8./QS5.W6\ MT]QKU\_]K\;Y?.>W+FG0#X=P__8NS=?MXKV/7\]AW+3^_?/9[OEGT>A\/6^< MOV=UDBF%WL_FIRH=B/()I: 5XC;Y7#?B4?*&4B54IH.JR&Z7I^_DJ@2Z[]]9 MTB>.:<)2>\H-)5;Y#"0F8*,MT>D!.DN^FKR/IP.7^BRX$..Y]@8EK3CBW'%D MJ=6(RA032\(FF4JRVP=N*UE1+R[+CG^=.'>;!(GG!;J7GB#Q=-#W=?:4CPBK M/2,("^P0I\D!] 6!G [68^&I(;X@G,6+98,5X6R%>JN(>D\">J\R5^'I4,S/ MIGDYG8CS%!EF-.)$Y"HHR9%T @<&KJ-69.TMYXN53\MHOE6DKQ7IZZ/&P'#D MT>OD"!.!ZVB-#TEJD7"BD@KOJAC8,J#<^7P,+(97>Z]?)L@Q_-NYBK(\5#;>S;(8:WS MFFJ)%&8.@0;ER";E$V7V=>7BWV4/S[KX2C!0 MT%DQ8X<1EYAE%8V1U-AB[(R7E.<]S,0R:>C7D+M2D9\^N0-/L \\L) <4]PR M\-VCC5QI:;1WGOC*@5\&#,/S#KRE@7-C#=(R\PLP'9&5PJ)@01MA[YP3I"(_ M?6+3@$8P#4@ &U$S+@4U$4N>$M-82+ 4<.6_+^/&FO7?11":BZ"1DR8@;IQ' MUG./A @A4A4$%D7;3*D6^0LK M+EWLJW<=_OOI$5 NK1[=V74<.6AWV4'SWKH@H*+KDC* M+CGL8.%U<0D"ZM"2@#UF:N5"^\U*8.^]P BVHE#0Z MFWM?&6,LM])KV.M8*\%3=0*]%%M\FKF3U ]W]Y726$;JD P&(RY@G[MD Z** M6<)"@-6\*W/G[]+Q7B#QT"US\EX2O]#]$_."L,$'3:TQW."@%0M &"<%H(E>YV*1G>UZBV'I MF-@J>*O@[5;5%L^*;U60XZ$0;W<6\0*FUC&'@HL"<2T5LL1:Q'" 559!,J,R MIQJAMTA$J+"NPKJEP[J5@;HJ\G,76/LQ VM!2\\X*;I%$<2I- !K1"'#;<1$ M"\=6J#@PC_ M]6)$';C)0>T$[M\-_5H\#C'4ZK;G#\K5&3%RD:(L8_'ON'9J^[7_N<66OU/C MEJF]+VZQ]Z=??R?-;__)WI_\?"_G]I[M/W3'9X<[#:_'=0[G]J-\VVR M=UC'=;HK=K_OM1O-]VSO\,/A7O./PYV/C8,:@6@ MX)V.*CF^+\G:[_'WZ0FM"K#5&R4T+OY\\$96L[+]UZAT[J^V/1YL'H?W_QVV M3G+^W5:K[]O=_K 7F_"\/]I=?_2\\DWK?YN.[WPXWCG\!.;*D=C9"JW&^1$K MV*JW/AS4S[^*!OUTL//],\CVYJ_Z]V]'?[(O[?B_7\[VOH<31[FL=\!<:1[Q M!MUF.TVX?NOS:?W[^_-&$^[3>2_VMOXXK&^]_[7W_4NJ-]\3^!S&OGVZT_P* MWS_:9U)*#28GDMJ >+L0D<-<(6I5HL)+0[0MD0HD%+S@#"_>>$6DMEXYQ15S MEB3KG+!2>F55C&NU" AR HLRZ WCVMN_IJL9)^NQ7CN.@RL#Y%>S"?_VZ0_? M*NV&$E;)52%7'-YK'Q S!4\"BC*;PLJKW-O,(Z693LY&QP*;EY.5L")GA#F. ME[X&AE\W76DKCCE=Y\S%G!\,%Z9NN]T][;^IS4K_M9B^9+350F]H?E=.XB][@]P+QZEI.3.[!_+'J6^;Z>C6[__LL2H[]W.*!F+C5%. M"L.X<6 U*YX"QLEHD1CA5[UI ]V.[_:.X?^=&?KCZ.]P\WS M'&VHGW_FN^=_%#V'ZLWZ>6/KZVGC/!S6#S?Q^!IXUG"/?I6-\TU>__BE4]]J M'.SE@//6P6']X[;8^_@U1T5PH[G)&K1^5M\"Z[L(0!<%-J?[05#GN"6(!9\) M@)1'&APDY)T@2CHK(_5K;ZDRJ]RJZ+;;;U6)U)8=1A^;2VUI8?3>1WV$4N85 MP*@BDD?BG0MH2% MXIIAB:/0:V_Y.I>+%1I+BG./P+.VC*;SG]'VXT&W'7)-=J_[LZC*?EPRM57G MF[BWO1@(29KSY)37W :9#\B9E9((9[R0X0':7U9 ]W! UYHR)2,@6I(\(2=8 M1-QBG\^\)/*!V(@U9TQ9,"77S25DX"MD3%9L-9Q6.R+ M^Z*(:);1UME)J>7C]/G4<:BE80_VVK!WHTYGK[:"]]XVC[6T>SY4E0CDP<<#&EL9QD?O/4R6LIEY6-L^S0,2%S6,EETI3CI@3 M,O-S4*0)\8@([#,^:*7PVEN]F ZXM*7]+R6^\Z[;.1D.8N_"ZJEB.X]Z%AA< M#$KI:&S@E%-'F G6!"(YCT2RZBSPR9&J\6[*F"'2\$2C0Y' #XY]0H9X<-$( M]RQZ,$RCS&>!BR5V*V3*5.&;Y35EC-4!;!CLA"&;;:'W&QX9K,E0L$N$A)A M(0/B$C2R84NU MT 0Y31FH>9R/;BE2-@99@.S\GT5:UG9=A.\\:$C$" M IN($:$*# GXB<#'-PC,=Y>TQ(KF[4PNJ0-XENW\2K(R+J\='A7"/UO]UHLB M('O8TJZ7P4RVTB&<)>(E6PU5<#9GV1GLA0B"(*](1#Q1DNG)-$H,5+SFW$3* MLD^IQ"(=_0H=!#W@QEV->K$7!=L/6TKV,F![I8.!%6S?&K9G+7@<'8M)*D2E M!PO>$8F<@!]2,/#)'=7,I0*V];W[?"X!=,Z23$Z8T::9H8H_EF_D>O^>8XI: M!>:@:7?X%?)/3K_^LE ,/CE55F/K"#?.?YS6#^MGC4/8_IO[%&"9!.F1Q>"O M%RR#EFBPU (/BEHO=/"98'"1,G9)N":+'C2P]*> $/UX7*W[[]>=[WS>3R9$ M'8Q&TM.40S086:XT8L(QV)1)@]NV]O:XU5Y8]UE"R?7:Z4'+']1:_5KKV+>' M&3-: &X19./XQWKM1SR./=LNA,2&3NNXU1_T;+YV#$+YP@*$0$A"_D.V8X\+ MA"\.5?H#^)^B6#9SG&6%7RQF_R&I+/GR4EF:YZ*RS*=;,>Z4\WW\HZA?[B\+ MR6#CW6@'=1J=G:T/1XWF'CSK2.PUOQS5::.5B5GW/GYH[WV'S[8^'>XU-_G\ M#MJEN[S^_3-I=#)Q8+O=^/CY?)=^:C>:'XYVOW]K[\)XZIU&N[YUD!J'L"// M-^E.TXM&VW%@/Y1"?P?&RM\_: S+PY18W/%-:P"/\S>P@+ZU_*#;:]GUVA^]UJ#5/ZB]Z[:''=>R M*VC-#7NP)PO83-UA#\RV_PYM+Z>? T9FK;E>?):3TNWQ6:V@4RN0>="M)>M; M[=8H#CRIRJNUBPU>F(0MP-J#: /XSX-M33O6AWTI=H MV^\+M3)V(">6 7Z]N,;KAV!!@$4H;!1"9;9IE<]BP2+4,.DH2:$-5R3 2JR] M)6R=XD7?K];/<@A"&>.@4->E )7B,/8V)@)8B-Q&K7DPDKX:2&FG#T+1 7WO M0>! 8#Y90+/>66WL?"SRV)2X,1K*<("J)O0L)]I<#/U?.V? M7W:^EK__Z_9>S5.+QY\MZXH=4 E&%HSF[BFX-9@$YQBX-5I*ASB/("*4:41) M(LE@*IVTOQ&,$HG:H]EM@4KLQ3*]"W3GX. "8II38 (^9O?',2CP,/900#N7 M=_+=/HC6X, ."L;E.WI)-W62YGRD8I#PR%[Q(3S!=7N][FD>'7P%!/_DI-V: M>[69=\\QG2MW 4BKB[T'V0C\>F'_7A@_8*'^A+_^B)E-OSL\'GS).CSV_'3& M!J*O;1O,^";U7^";:!ZU%BX@3&)6Y)H!4C*!HN'")$U88)DF; ,O'KK]H^9L MOU2]J75LCWT+I.:DVV\-BF82/V+W1\^>'.18*DC]CW$ J-3<('RCW7$3YWQD M,X\,6TXWE #C=_RL-\6V@RUPP0_^CUG?8Q0KQA>76 =;8CBX^I(%CN%GLM\) MG9N@J9\'O0N&Y!\1.;!9CT"]P6#?V/:I/>NO_7O620$/96X.YU__ZM#U-8[C M;QW!.<JQL'F*DB680BT_/))+_8SQO^T M[6'A7>5Q96W1&79&=SJQ9V6LK+23X9[EW[/JN8TYX[5RB820I,UQ00HKJ+2A MUI-(F1J?WF%]#W/FL@#3Q*CY:_0>6\/X>NV;&>>LSNH_]ET*#DP;@8Q@">P; M89!A .PI"BFB-$GF%'UV23^@,F8X,G)F_*/9TYU"V$%8#D#QNQB/:\?=G..> MM6UA-92&3B$^8"EWN/_H)0B MMMMWX<).C1CL\.;A40!J% M>[23WH\'MU.,K5]%&TN!.:^?[BLCA8V2(.:I1]P'CW3N=1@T>(XX>1U57'L[ M..TN.NR/" %7'"9?C@+'\=2VJ^V/=S[O2^65<-Z@$"5L>B,-TA&<3Q&YAZ45 MROFP]C:!4X?RAE] @7'N2>'M%&JFPOFE6V@*V]8R:0D-"GDC%>(T8>2D]XAZ MS;._)YV(U^!\QOA8- D+9W'GV#\%P(P+Q:_\T=F#FWL);'[?/%MW-N[&0358<[]I:?Y&:3G M*]G9>@_C^7R^ S:CQT0;FI CCH&E"( "@A,0LSXIYI(AA*Z]%=?%[#.&S,:N MSY9>(JKSFSE9(( D7',A(N4(3 ]IO7U] '+ M-2 6 M7T5056'0P\K=U^RW*FN\LL(A3ZPN6ZX;@W7ABWBE,Q#)C$&_:;E^3PQZV\@D6 M?TK1>0J6-E?@Z0EF88?H7,%AHE5SF=N7"6H^/8'?;E/D,SH)^-#M_=7KPJ-" M_T.OVVD6K[V9>Q?G.7R] GR1!$'JY[MG(, 2S!>K D7)"P[FN"-(8X&1ER)B M6"IM.%Y[2R\Y))@(\#C+:A*\GDK5FLYYZ&4AAR_VX^4"F'<"_ _(;C\?">1: MG2($=GG"09G,Y:]H,KIP8#:3)U;&IPDM-?9&[?L!.!L=^/)%IN3Z0BD&CP\8*V#,J\\H3 #10)\I3 M$CTQ<=3H#3.PKZ>VZ0*I1I6*<<<3.]KXL1^D\,Y)C+!6%'&2&#*$"[!MF:1@ MZ6*37+8L%@MLIC(QBH3'A6R,\0GP2(2O3\Z8Y&:\B/.U]R$7J^6$E,TVR/W MUM[98QM>628WC-8"-)9("_\> 1<@3FM45[,P3^MCU,P/!?'8\8-N[FH]KN$K MN$&.\SEL[>]X,ABUO,9E+&8:@2\>W.H7D-T*Q< L6#/=W@ 5,C?Z:GD6/$YR M&)S&]L]8*ZH-KTJCZR_(JN4G&CM+ZI\?3R6\^64%X1S^O,@2+".ES5P_6Q4(E05".YO[1D70L4JC2/-AB! ,:2TI(DSQ MH"Q1FICY@I^5@*QF@579\BZ0*R][-M)^ @+ OAV"73,Q>:8=')#LTN@OTJ]G MW06VAE-)+A[ W9^2[[!67A5EO%0A1;Y8X\-S4>G<,\I34>IV]H_IY MG=:_?SZM-^'>AY]/&UOM5N/P$US7/JQWMG_M-3\=U+<^G\]3Z^UU/I_7SW=_ M[6UM_H+W:#7@_7:^;]-ZYU,;QGJV>_BA7>^\A_LU'M.0: M<4,8TH(X%+5SP47,CM*+G:]6B$VU.6CVE]E++PO.^DR8^$JL(Q66/B M6$@G6.B58PD0#R4>/.(<2Z0]\RC%A"U/V!CB,Q9RO=@FX-D[ ,[5KA->AII7 MLRM@=8\;W.,%>7B7&Z!3YWG+XLE5][CF'@\44BN-';I!Q9(;/.^&O>+@??ZH ML'U/N7T$X%@%^_&YI_.ZGE>73.?->UYU6B&T8^7%7YWL/5KZRG2]A>DZQ9 / MIJMA4>+;,.G M;$YR)S?^B0#C@9J,W,Z-?]9W>X;^?Q7B/23B73CKCF)O@W(HJIB[;^>2 A$I MTAJ\>.MRKV"U]E;I13ZYY\.;ST=K" M5B;R[Q0&++^O=,:M=<;.WU-6X8;;@BVJ*6O6R?E$6 M;:6&;I.HT-P<--[A7X4JVMRGQA%"&$'):8NXYPG9%"02EC/'L ZF8 19UWJE MT[:6H!-KA=?/'5]^47B]P@Y$A=>WQ>O6!*^U=U))GQ"-1B%8+XZ.3X=;0F/B*D!3\D=NG% T$YCL(3M.IN/C#%J3# MK1RNJ?VTO59!%S#=N@MV^XB,.OYJ]8MS@'%7EX*=8-+/8+HSV.3J$0W(!5=' M<4UFE"Z(V_SX>W=JQ5ZRE5QP,4Q8&&RM/^QT\EN/.((\O'#W>-Q%.0\T?[]\ M=!Y0<=#QH.W@-VI/P4ER0=P-4_\.7J=B(9EF(?F\[S7V@L%R*D'!=Y%1(N=R MFV*K+#,)*X-OPT*RA(0:8H-SLR*T#XQM<$Q79+"$;G C5V>P M]L0!6AQA(= M^R\AE<&[:<*MOZ<)MW8FA%M/-*.K-7$3_HS"-KTAA\;KF8V73(EQ,]: PMY\ M[H.BU6;(6.U!/D-.W@O9 ,^7A/>L$_CW[YDS*^Z,BCOCYA3V=PDUW#SC/$<@ M7D;D_A#&B_O']6>/C>P%C/=_K?&LW#O-S&^WZ86C7OW^8I<>(GB0F M,$621I;;EA>=%S@*P3!&?>()Z[6WM"+'J,"N(L>X =AE>(N6)NU,XH189Y6- M7'G#!*">,'/].BJP>WRPN\ANI-%BDZA H(3V.^;<%2^6K5/2HJC(NH0DHM'VM_#%OM//[G#JBMU"Y_ MI'C"L]->O%H'O,#MW(>YLDGO8I,VIDOVL,?<.,]19"(!\6135H@@IWQ-#KJ(U][RZOCX@H;5L-?K;#AGMAP<;P: MM%"<*8:\$ 9Q01DXJXDC6*G$G-0D*<"&16AX]M/5%^*R7,<=,]U ^R4[+#?, MG[V\:OC:PN'I!-ME3,MY"O*8VTW0LBB=Y3-(*V5S)V4S?6[B?6("_A])Y1SB M*5FD97(H).&5(B:"-;KVEN%%GK(5LD0??$^N,DG,2J/S4U#%K"8Z+Y]+4*'S M'=%Y*M/2.9*BD$@X@&C.!$%.)X&"5D8YSHR+&%P!3I^"#.9)$/(22IA5X.R8 M);,H>09Z\:07^P5Q1::F**^/ 5F8 /LC?YZY-"XJK(H$OAPD#:V^A\49U'IV MD-OLYOK=2^@KWLRR5*P2\X'0&YK?M0;_R>OS]0;C=[OM,PU6/0F9P*.>GIJ7 M5IJ_>;&-:^,=?+^JZB4[S+Z-:ECRM?H^@NK:Y@BJOTR@NC!J:CDQI_;/LVA[ M]V.H>+Q:Z5>P*%MC-?D%U.1K)RAX]O2)E92T:YVF2PF_;D.#/$6D"4/Q;\*P MER'C^M*TL9B/I'R"/,6'&7?(2CM17P[V/NZ*1N?386/K"-?/OQSN'7YI-;?W0:Y^_)O!/5^/CA:._PB.YVZGBG^?F\\;'1:7S<9@WZE>Y] MK^/&UMY!_2/,1/-;+E?[-7&BN&8V"AJ19RXB'C%'5OJ E"?8D(2UD;GG'1BS M8I%^LMI4CQV).!YV7.P]"-LXO]76&NN/K#[^BCT_W?$"T6J7W627G4]V&9,Q M6%@SA%U,B',OD)%:H!!8<$Y''Z59>RLVR&*CM7\L*N_K26$?FY"QWX_Q"G+C MNAT,>_"_%5GCA*RQ?EK_O*]#BI%BBRPA.<-:2V2I$,AFFD:E,*6*WXZL<5G" M.)+!EY;QJ]N3S(M60! M':4WM+KZXR6,D=R,'?)EE0]7A(L//7<77E@9&/C+GF7&Q?ZK]%K@&"RX#O,/Y[G=XT_/W MIS#^7XVMKWRW^0,LR3UXIT]'N^='>*_SJ;.378:_IQQS@94P+)!\NFD19YHB MK2B8D HK1[7W,N>><,U?3N[)(Q^XLPZ\=$60H1A UG%-O5M[ M2]8)7VFDK1+:;PNF[%'CVZM."O&2P#0;JLW3;H6AM\'0LRD,#3QX$2-%DG ' M&.H=,LP:1(2*$1/'DK890_%J4[P^/('%2S=(>660OB8,S?W%*A2]!8I.FA$7 MEBC&1-@ 1JAF^2A>!V09=HA*&0*.V!/*"Q35B^2Q*X2BE25Z6Q05E27ZBE#T M0W=8A4UO!:+385,KF:4:/'E#M$&<1@ZFJ$^(!.>X8U)[68 H(7B50;0R16\U MN\U)9D%ED*XHE-KAR<'U.-KL_A'_LJVPF=>Y0M*[(.ET8%2"]VX2QB@8JA%G M/"!GI00DI4$E;+CG;.VM7%>*K3*25N;H[9"T8/I(P\&P%VN9KJPS'!/KGXSL MF-ISFZOWRW2H /AA;-D*>6^#O&O;G;RORH O@4 [TP'$:@.1'@CD$@X(1ZY158&B81W@B0=K,V,Z!1, MWT52](4#.<6TK^I@KDVM$%&PM>+VHZGO7[UCLL+_]__1U.B_M.OQ5^M?E%KU "5YH=']X8#%'PY.3]EFM#U.4ZW7S:#HQ#L;6E>]V M8'_Y%MA;(7;R/*V>D'X]@6F$%SEIQV)&8+#JL3L:,DC,YM(JY']FRM5,0N(X%\8"G?XBN-\RUM=DJR(_^GUO8&D[( MX AV/KG$4R(&[ R=E/.*2FVB&15]TW'1-Z5ZQN@0MS Z1L!6X-I?()F^=6+; MXYC@Q/20JVEZ/$1%.*\?UG$=/$SAI=$&; <2!>*)6:3!O$"".\:4C$2HD$-\ M&XN$ *4VAQW3S@L/.]\?%,(RZ,4"PVPNIJX-3U(/IɚI0H!=]5MP@QF5% M8JZZKL$#$&!!P>!M^_TXZ->ZQX6$@RR%3.B=O:GC0L<73W&V7:BP_@'@1K\4 M:H"3;H:9T<-:?;@M6 W#"(\:M-K%[2ZVPK"=X!U*^K]>!L8,M-W2:NT>PZZ M7=1NI8S,\._^Z$WAIA%@I5,,(BN-Z""A4<%"5%99L#K'R).9=T3H>VM(> MF\*P$6YPNJ%RRYV3;K^5O_.F%]N%QKJH /_';%W^R#;"%Y=8!U,T'%Q]R4+% M[C/!(^%S$S3U\V#26.W$_HC(@6 =H;(NW[9/[5E_[=^S.@ 4P-P!8WR?^=DJ 2Q9 A3V*O<*H\[*IU@-AB?#+>&QL1+WH2)801( M[S/G)1@4OB3H&NMWV^O9XQ^E893W,.B(TDHLMW"Y6S?_?E?3,,G%?ALQ:-9^ MVO;P0B-=?B8W**(G]@1L@%_%[@'E=!LM/]:[*X]H#I5>N/\YV-OE2!B9)1'71[>Q@*$[^47M?-QE/VU38N0=L%\[%80!P#=QCS MJ(+.[K3Q4BOBB7/ _RE-XQAO%M;L9]YH\ O 4MV2?A_R,YXMQ[6SW?/ MOY[6#[_B^E:[E9^Y>_Y#- Y__*IOO<_\U!1V)=W[OLWF=VO]O''8:&Z>-9J? M3W>^?SIJ?/QTN+-U!,][?UHO^*GW\O^W=P_#]&YE]>;VK\;I/C-4J:0QBF#I M(6X41M91A0BSTEH3K!.DQ%O8,3%L9K3D*EKJ#-724DZ5=\9(38B48!_BZ.(\ M7]!X<6JCU2EVZVA]:E,+="6+6['++E5QOQW*:NCOR_B+2M(BN$E_VAW\/_VQ M=NYG#3J93CN:SO;%="YZQE>;.N,9?L0M^K<_B&'8CCMI<6LN$RO7L^]*T*$Z M2BN>2 (G7@&-2O#%4XV)#$K-%A*'X(' M:SD/61^([NH6K%:K15YU#1GY*YN)2:Q_-!GXU?%W-7LY$#NR!)XSR^"U)Q%4 M.0(/FB,PY] 58OZNC (O2Y[ 70W%$==OXZAQN'D.]^?U0S 4SS^?PG@.=@__ MZ-0[WP[JYQ_ 2/SC8 ?&O="6B'ZF]:TZO,N/L_K6-FML;?[:I1]:]8^[8("^ M/Z]__WI6__A>-.B76>*NR'T*1B9D/,OQ&9^0]2R'9JSBQH7D(LW)8T0O-B9: MV2R!E](5;O4 ]F&;OJT0P-Z[IUL*P@8?-+7&<(.#5BQP%4(@\)\QH0!83&@% ML,L L!=DZDYP010%@)4$_':8>N2B!C=>,(R9B2HEE@%6LD6>A"4%N==0H;!3 M'#1?$D*KRA-6W(PL5G8QWE@!W1V ;KH"5QM,F,,$.4IRK_L0,I=!1"$Z@X5D MQLFT]M:L*[K296 /6 =1HCPD>ER821*,(AFH1T9'B[@7'&E+)8H^ M*(&U>NF%]J$%L%$VB\HE]R MRF"%8_?%L>EJ>,,9-LH1Y&D0B$=FD L>(ZTX#\0E3WQ<>RO6U6K3XCT@HU,% M(*MG!54 \L 4[A_S-_!O,4<1X)TE)3E(@G3)& $]4%G0;#BWY4QHQ T>^NJ\J[GVZ"ED5?K(+!>9-@ O5' _4+ M=R!@9WSB!#&: _+Y$ M=J;5+4GSRJ]'\[EWM9[NO?QV\%>\P-@5N.P\?';8>/P /#GZWGC M8RXP^=1J''XE]<[NS_#Q&P__^ZF]1]L_W>')4;VY=[3W'3#J^Z>C.JWCO?R\ MC#_-.MZE=;AFFS::7\_VVIK5FY]A+-L$GGW6V/)\7YCD094$)# &XU(3AG04 M'$5LN8DR2,;%?%&8B49K:5P4AG+,HK6 6LIA%;&(@KKY>GY'7NS#9:FD M?HZ-B'>:G]G.UN99_7R;U@]W3_<9"919%9 ,AB >A4#&,HDP%<'YB#-Q2O;R M-LR".5 ;TW#DB-5MEO^.QF2U_ ^\_%[L.QR5C4PC861 W'"%-+;@Y#O8EE8I M1K/10>3&(LW]Q?(7 %"4#)46XKANJ!",<0'-S$=X':"EG]D@6C]C^ZQD=!BS MJMSE?K637BO7LK;/+HKS>]TSVQZ?_S)&!U+,IBR5DKG<1!:.\W--MQ9S8-!FKF3 MXJ_HAP7S5S>S6D6X"XR@&,8 T+YV&C/M44F&-:+1&O%0G70'(*Z9ABJ.3\Q= M/(ZI-9AYH\R@T2NZC^?"WN(&4V-<+SZWD^&<@"[I%F^5GU[,>^9SFKI?,:"" M *Q4'C\RV(_H<+J^W$2^(-P8'H_O.AIQ_)G)*BYA0*C5[FST,D.7F 6!OC9C M^(-M];YEQI4+"[>_+(9M_?SH; RH\!T.("? &6;UK:\4'&11@.16N],XK'.X M_JQ!ZV"8;LX!:A?&\^.\?MAN[S;]::.YFQWZ]N[WKZ<[WP%.SW_ 6+?9[KG_ M5<]L*,TCN/^N:)SOBOJ6/]UW,CFF %"Y=P;TJ6.@3\'!!KO6*>Z925$ML!T( M:X@DP;.(N=?1))FB3%X2SUDD:=ZPS8M0*U:A5H\VK\&( /CVY :_??+L2 F M+S?$8$4LMX0:FUP@F@:F67*2K1 9P@7;04DUE(&V=9QI[DK.H$SXU>H/IA0+ M0)ZW_8-""Q6_9-ZNGV!+P-?7X=J?L3_HE/^8'.J!YHCP'? ;UV_.JE![/R'Y M2GFI"XJC0OLMS/-?Y@_+Q@38^]G_N8*,B%N9Q[$X^-8 M&J6%>NP4>Z:@P2@XV<8SG">X!P>NZPT'MH'M:&XWLQ.8 6@LN@,M/ MN\-V**7CBMGXUT9M,]-T@2BU2ANDV"\A]DJ&3;"(IAX'L@\C[L6(X-K>])0? MP+^S_716.P"SS\5XG!GNX%5:_8,8UD>\=S"2;I;D,5/)Z"V'_9*"Z6)!I^YL M^R.^D_Z;&TOMC$9E\E(Y_L]T6 #E+SV39.=UI?(_SW32MF" ,%H:('^"%=BN MD1JJ[2R(Y4@N:O\==C.XC>#GG\-C&_+LQO"OO)RV\ I&@ED*5RO/=H[O3O@9 M>]?ST%RRPJQ:X =<8 H+O%VN:AD; I?F>&YA)\[6%$!-"/_R.DXO([@JL57< MJ?2WLL+M950<_6OLJXSYB%PB6!G2%N]R(6HWN>7X7I-7 M_?_9>]?FMG%E7?BOL/*N=B%&V_)J51YXB3;L\?R)'$FY7Q)@0!HT]9M MD5(<^]>_W2"INVS+EFW*YEY[9F2)!$&@\?33C48WIHA_+I$ M'=K9R4S2 4DJ+?]!/[,YHG&RAQ,=V;_H32NN+20\L]RV0N-I9ENM(. ;F+DU M+UBEI4:Q[)T7"R,_A0%RAR;K3C/;B9Q;)8O9H'$0RU5440F[F':<"BB6/7LV MWYA]6$$Q^C"S-SX5N$1_=(*.CC33+E*7RP6N6MR$'.DG#F1JY6%*-*88V805,)>I=B,[Q &E7.?&L\#3B\U3(I\U86WJ"\RJ5JYE.= M-XF#YQT^WMP /6WBX*4V_2UL],=*PS?V%NU:_;G;F]XV+5T7^K#W&0U5Y.]_ MH#51ITQ]=? I_?KA8=YZ3Q&71IA4)=(!YDM/7*&%#OV0P+=T(5??EF#8?%+* M,1@5QOG8-5,RL&XI-.A$G[;<>]:%7XI1897>WNQ;ABXU2W4HHIT@"+8E>R#9 M\2*OZ6S369]L-(GD&MD%5Y_GHEN:B?":G(Q-#LY;R<;*0,/KC@W54!)*:G^; M$T$WOO&+&S;6#-M=AHTWP[;>L-G3?2\N66QAZ+V^C;#<^43V+=JX54CY?1[0 M=');>_@23A:_6Q6F<+>%>=N$44T;SZN-#2FLXI0@K_F:V5NQ&_(4"<_K?,AR M0SG-:WE,\MYGWSW-/)$$ ?%]+2*?QBID6HHP261(11)MX.P[8OMN3^-_WD^ M?4E<9ET.2=[#A_XAC3]^]8^/.F>'1[O>P=DY._[V9Z>]=^)]/SJ_@'NA#[K[ M_6C_ZOCH_*I]];6\YQ]XEM?[?C0XA>=Y!WOGEX='WT^/NU_)X5ZG VV1 WA? MZ%_GX*Q]>GATP-O_A%=_'>V7!<_W^<&9^D'"Q*="4U?(,':%9M0- P6? JT3 MG7@Z#&WJ%-(BWF*EN2TZ 5^_[$L-0#Y3@.0T]HB*N"($ -(3TB@3:Q9+%C"E M@_!V 'EELKX& &RP\?&P\=,,-FI. R6]Q#6A34/NQ6X4*>%J'1KJ49C16!3! M0I2]:;"QP<8&&V_$1B6\))1!$A@3"A&'$5&Q1SV=,,\H'7D--M85&X]GL%%Z M"M#/!&Y,?=\5L2]=F80:L)$J+L$T($8UV-A@8X.-M\?&R#.,,2^6AG,A.(U, M[ 7<4!D*:HB)&\.ZU@!Y,@.0W-,>QQHVV@CF"L9]-_83Y7(?V&1(O-!326-8 M/TA"U.WPQ7Z9!)^?PM>=2Z>3PI+4TT'A3>&90(*1,6 M)<23E 6RP=OZXBV9<63NJ1]1) F1,G"]A.#!=)JXH:>YZX,^)93&U$3\U5OA MMSQ*MQENFUHZ-084'AON*<8#300S-#;$5U'@AYZ)I?3X:D!I4..Q4./3#&IH M0F@8D-BE*E:ND"+"5)&A&Q#N^X$00>S35V_Y5A.T!C'JBQA1((V($B^*@7PP M&H1Q''C2 MQXD(21+Q6(4RX2( @A:R33B'IN:R0=![(RB;>(2^7K;WWO_@7I+PF!@7R!D0 M,\^7+J;^HMY;P5+2D+MD406K\MR@9&)L&RQ MBZFE?<.$G M1'*BN 9.1I0@)A0-C-0/1C[-P B+8B_Q#7%CIC#9J0($(01,NT0I2D48Q29Z M]38@+>YO=8FH&J/('=I8(T]_0$3H43]@4MMB 1$)I0Q@5EED?#:3I_]7GK[N MI9TR_TBS#A]V'58N%G5QN'?^(TI8P*D7N)Q1Z6)*?5<2(4"=&TV484#2,"7, MX@IL]-IV%D!LUM.&U]/)C%XS)$PX]SR7 \R!7C/4C0/X%_=\ZGFQ\E4D7[UE M1+18L-4>AAH%J%@\ 32@T<8/0MYTW[45RFYQOO@Y1A-N#;(_@N.C2*#0 M@/HF?1Z%UUCQ("1!XKF&R<05DBLW#DWL$LJ%\H5FH*@!U"/2$GZXS:"^P:6[ MS:5L&^!N@/L174T-<&_>RU0 -]&^X89%KD\2#M9M+-PXAG\9K373,94!"0HO MT_,O1-[@=H/;+PBWUW% KA\#UD#VYAV2Q0D?X<.L: (8S3!U1LR%*P,A7>E' M+/2IXKXTSRGFJ\'L!K,;S'XT]W<#W)OW?!=VF6LK+J>G1=+:IEE+_]/M[1IEN;+*J8 II"J:L M+Q[/I19#4S"E*9C2%$RI^; U!5.:@BG/N9/;VL.F8$I3,*5IHRF8TA1,V>3H M/8^\KLO?;8W-0F9BCQO!31@I(>)("H79P;P@DB0B95HP0EF3EV.-SUA M_+TX^/85OO_CK/WQ6!RP/\\//NY[AQ_;9]_/#BZ_'^WR]MG^_.;A^>&1NC@X M.OGU_4C].OAX0+Z?G5P==S]=')^=BV/6[AY<_0G/5NR@,U\PY?T/$RL2,$E= M'4KFPJ1R-^0F<:. 2Q)X)@DQTP_EI!4N.56^]6 MA74T\IH"&DT!C4?$O,@SDC#C^W$8BUAR*3U?FY#$D9>HF"<-YM47\Q8*:! 2 M,\&2V/4BX[D"2Q?% ==N!'9C%!E.I"U8)&C+$_R^F+?!K*_-JM[PJE:"A0D1 M*F;:" W_%90:S4T82!D+TEA:M5W0)#05 ML7!#(7S0T'[H2DJ,RWPO\#RI8A/39D&_@ 5-$JQV)HRFGA ATT"^%0>=G?A, M!K[7\.YZK^K9TZ@Q6$LD-KXK5:@QOW#LAC[H:DS^0&,>>)29.O+NEQ"XVE1; M>"1$BV-/! D-P 25@GEQQ$.I3,@CRGSC$[,!1'LAZ60?"<;HO/L ])&O=1"[ M<2@ Q@A66S!,NHH)X"8ZD$9%K][Z42L0?HT\ILU*WO!*#C@/?!4DP$4Y&!MQ M%(6A8CJ)3.)+6,K-2J[?2I[U&TCJZ3#@OAN:@&!-3(TE4[CK1\I7S @O"MBK MMR%I^?3>?*19R?5=R6'(?*E#7REMI[QF$6S2H>QW5J8%]*ATQ&$1;- M &37N(.M*?P31;K1Q_5;RK,.@C @01R&W$T"S[B@?ID;QAR6,A.1B(5DBI!7 M;ZE'6MR+:K24FV()6^#A>-EY +?!;_'\\P ^$K N%$O@FB@_L"6D:.P*R@A\ M4I&;$!5R(+@FU/ZKMV#%MDAT;Y]%#7+Q->#9@&>=P/,17$4->&X./&?/&2D3 M"Q8)[@K?,%?$?N2&.C)N[-,D]GS@D0'9E)>HP-/ MOI)">$2ZQ@]L9)YR0QHRE_K /ZDR*B3QIF-X&MQL<+/!S4=SAS;@N3GPG/6$ M219T4>UD!MG'VG[=CX!WGWKLHS,DQ"3;A(9!0:S560^)&4BL"H_]BS M=8O@?^ZD@-$LO?EL?IK>R'S(^MUWT#1JUV_I\/3=* ?-9;(C>-8?G;XZ?W*. M\\F;<)S]*RPT='CT_J*]I],V\(OO1^>7\/S3]MF'\X/NA]/OWSYWCH\^ 5_Y M1^C_^;/SG75^QF=][_C,%AKR@/^0-MLG[:OOG<.C/\_;']^S@V^?H/T/G>\? M_SF%9P(7^@1]V:?MLUUXWL'%CY@KK1F)744"2"E0'&(:7:"WG,8E\0WW_E&*"1 YB183:"%?I7JDPO M-S:SYSNL0@&>9C':%E^G0Z!+ZGK+ MP"[/PV$^.I=.):@+&'0]0)7=GR)M9R#E:7+Y^'9.\38]9YSRGP9%RO^6,SPU M\()=Z,^E8S->&SP"/^P[$N%]2AY00CJ5M%2R422U+,?I[U,)1HXR(\M)H=6= MEO/74.\XOQ47_(Y6D'V@QOS?_8%MP>:4[7=!M%0*PW15/*V?./#@CO/7U[__ M][B]_V5\ZS STD:+X"52CSI#9P"WH)P6G4&^_M,X?[4=F_;?..]'67]@8+R_ M]K#EW]Y__;WE_"GAC5N.A)M,IX/_Q4OABB&\__\"*NI^M^5\'N5Y*EO.%VCY MRF0=Z&O+:?>S"WG929B(G?6E M8UND:C>'\<_L;. (CB6CY>R.LK272B<#H8,9T3 @SFB09-!DD41X("^KB?S7 M.D8X\U5$DS@)F2?"@(7P1Q!H(P.1L( 56@B,D:/+7C_I6NW MO4_TAPD8B[7R71^TG"MTE+B1IHDK)?,3XX7&#^FKMQ[9(2ML<1#F#HI*A0P+ MX-2R2_"T7-N#/JS,(4", ^!6RB3((_ZUCO31@/J1%QC*@TB(V(1>&)O(8PDA M ?/4V'5^!Z&3H\'I?22N_%OVE#F, 1JLZ/U=O7;)O':[_5%OV(CB6!2/+WYX ML4Q([$L012R?[E.*@:^^2YFB(O%C+6'QWD84 ?4S)S$K]ZR)9(R*,;3^4T;H"/:\BW@INHTA5FJZ!>B#2C) MS.2G_8[.?\=+>F98HM!H '\N4'30KIT^8%-!NK5.\4O0KF/4J_A=[L0R!YCK M%W1<#H= B:LG*Y/AGZ"IP7[LE ^,+TN38L?9[XW;A@ZI.G\MO_W[\4SD(3E,&1I J8A="@? C5#^9EN)1U>[CA'>'F:MQ:- M/;#HD,_U$3,F9Y)TB/TLQP(:+4A@6C16O5S!$5-\ MI-/KPV#\&L!;V'$L;P%K%GM6&3C[?Q0HSDYDNR#?K,V:%A0@J;@"CL5DAJ=''WM5 M&E*),>O:3]KG2<*I+WP>"<]P&8$.TMQ7<1C&TL25_51X\19W,]>SGZYU][W_ MI3HC]$'BKB?\OSZ2OQIJ.J:F"JRDB&D5Q9[K^\QWA0$5("-T! K!J0:60$QP M*VJ**SA)?QETMO1R6#&E6V?B5RD61"7GG2G'(-X+G+4/"^P*&K#Z8-7UZ927 M"<7GF0/P9'GCFK#+=W9\)9#YGQ)6/.[ZQD;)$4+KJ;FTORQ1RMC6Q') E, + MQRI4G@"J@VE7*;@I/5U-)?P.3P:CHXWX6L[/4KL$/+0^+PU&S\0WA%5P)HJFZM3XZN&L M([(:0NA.#YW._1&\'72FGX%B*'J*PX2W="5(Y1!Z;@%WRLK/ 'HR&!C\/BM@ MJ 6P6!(. '09]T> ^^AH="Y.3?':DY?+3,.-4PE/QY:H!&&;]3G5E]?YYBD];+B4F@>[ :!8ZV&KV MH3R'[H]9D^W(U'S+ 2I)& FX D71CF8_ U'N.2=]&*6"C6ZV_XS.F?IMED1=*F,&0\X%7+A0CWE1IESQ@R=BU"'*"A M5)7=I3@,,,E(D>Q*7$.52RIP,XZ$R@N$\63DF9@G3 =)Y-,@-DLWY%:JK\HI_IW/0>QQ=*7KJ6/SJ@/RBF3PT"Y0;4:!?L\L2-N (MKT.889*8@(:O MWO;ZB^;=E.$UNV*-'6;$MK'_?8PJ8_:X%1[XAD'>G4&>7_PP@00*;WR7>#$% MV9+$C7VI71TSDOA1Y,'/MW5NHNS\=P0J'<@=:B0]X7I5$?$Y\%X:V%&A;@F- M@NT$'L"G+98'U[RV.@%$]DU5]]V&:4[=6,;3D-HQ$N+HT$M"L_$/9\OI\ 1:Q(X(]I?HJ[J?N@=GOV9'K/WE]^/ M]OGQU=>K@[//I]_/CKWC;_"\C^U.^^,_9]_W3KO'9Y_3O_CGCOF?SY??O^E! MS(1_T/WS[/CHS\[!F3YK'QU)$24AE!(A612$0T\JA'B0;-/!\VTP:CZZ]^GJ-U@*R]"_AHY^$.L3(W/ONZ M!?>F-M3V#YF#G*,9H%-$8FTMTTXU2*H8I!P'"9UM\/? 7@5&";Q>:@VZ\1WP M)>J:XH%H6H&5 NCF%'L;A94]:2^W-A6Z%*&1G6H^RI^L1:;ZHXZ>&(>=R[*3 M:%=#KZ_IZ;0S>;JM&-\B!_DI-N?P(O,+'>2YM42!G:ASIS\H;,7"B8),N;*6 MT=^'IWA1VM=YJ9ZMI5&H\;&Y@9U9_)Y, MG!-]1X.9UW<=Y8&C[HDZ-'G7,83(/>!+./,];J((+0U?)1(8 MO:=DH*@)E!#!_H,^ MBDZG?X$%QJ_#U'6Q<2D&WS@,;_^?C5^>$%![;1VY:8W"T;2$QW46Z#9I/"W@YISK)HK]9NU M4,;>M)G#61LJ9E63TYS+!^0W"[7]$;2A\Q;P#V4&0PNG!8YJ.92_/V@1JUNT M<>M#;C67/J0K]QG+F\>A&64[RN1^Z_CF1/$E%ZC5(>1V288>(E'\3?>ME)VZ MGW%?+D)KEQ2]_?O7Y2#["G6P3ACS7>RTV2/M&' #G];PY8.0[_> Z1MTG=3E M//M=+;?3X^ZOSN'9I\OO>\=7!]W/G>_?WI/VWF>TUDZ/K_;)\;?]7X=[[^GQ MV9_GWX].1'4//&OTG7WUVWM_GK?QK/O'?]#K3\#: ^L.W@>>>WSV7AP<_9-B MNX=[I\E!BN?8W^-Y]HL??I!X-)&!FRC?N,+XS V#6+DR\'U/QL9XL8\>_18/ M%L^Q+_"!C:V.FM=&WEJ4VU#AY.U#N>4OO@[*A0EC!*L;\4@*%LB("<)E8D+% M/9[HJ-BHK%".-"CWY"AW-48YYOM^Y)G(%80I5_BA=&-/$==32B:>IR*A&?!% MKQ5QM@4H]P#V:!UY[+=YC_U*/_U3%U>>FO&YO"RW4@CUHW\K<;$8^\T3P%LC M8B44NX5,M.TFSF%B??J'$XF8<^\WT+D&=+:_3!%$Z4?,TWA&A$2>*\(8H),H MY7)FC*_\*/ 3/%?$@I8@= $['VP!4WFVH6X-/M<*G";7C?J0YEZ$;\#C"TVS,1 MN#2BF#8] &,6B\53UF*;SL3V@!CQPCR5B]NVOYE?@\P&8>(>\+\F&Q%WVX/8 MC+W_K))Z;M;A^3R2>M[!%UK%DVR6$K,I9\'UP7JK%,D3Q\)OA2(Y?#=%=+D. M$T-""LQ6AQCQ0ET9JL#542PD)2+T-'GUENR(Q=CFNWH(:IT'N8',!_:>/@_( MO(-C=05DWI.E-Y#Y2) YQ;T9Y3$%M/2)3UT!C"*91Q//:C!++NPJ.K^-DO1HTR>]:_.+MD='&V:1S[NQCWVL2X MEC&N)S]\H'M<1;X;!YX"\8T\-V*)]X%>EN MSQ1?#HJ8\K'DC,/2;82L/0IMHU,OK@]SOTV(>W&(V60&3PBW;AVLOA"H;MMN MK0HJM^?.,U@=JLQGL<*BG(D\_WWUP>!;36O](GBI\+8H*/9!(G@]OOJA301O M$\'[@B)X'RU4]_G$BM8@(O?Y#.:#!][6S@WP9?J4WD,XJ6^UX7=3"$J]-_LV M$8P@:0+_BZ3P=2#\R(MCW[!$:I\KE<0>L]DI[Q>#4'D1C)Y.1C*5O>2/R\DE M?Q=Y,78O9*;?_W>4#B_W,5'1R*8SM"E-CDYE[["0FW;?5K WNETFWGP6VX)? M^?&1/H-[6/M*07\^D?;>]_1P;Y<>'OUQ_OWH_:^#HX,K=$\LN":.]&F;M<'" M.^;MJQ/>WH-[N_OB "VXCY\[!WCO51O=$\G!=-@"U<0C( .N!T:#*V(>N5*% M'#Y1/^&"*\X"/.O?"H*MCEI8:[T_L+NYTN:R__=@-2M0&KB/Z4DY+$7<)>:*')%J*@K*:5N M)&,9>^@_YY)5V.>.A$'D1LGH7%9 MZ'M44.T+GP!7:Q$JMIFJ+0>[;0DAK37>;()V41X13VO*:60$ [M1^Y$A28@0 M9%C8T*XMQYL)[8I-+*CG!V[B$; (.?%<$.[0-40IWR C"S"DO>5'J](8/L6: MOZ\/[4Z["YNWZ)9OX%^[AU][JZ\&9V@:^*DU_%Q.T1UC5"R9IUR?:05T!S[% MD<==Y>M8R"#D881TQVL%2\R^+>([&U_WV^>^>HY@5X,#.0W8U1SL)EQ+"I($ MTO/=R*, =HGPW3#PI,N%\9@6! B7C\=S6CS8L(_K"0'G*8N4!_S5VSO&-#U) MMF7OI65;WDMSU>GGH\P<)M/;AY^+XA7O^ODP7]@]S&L2MLD/+BL ^G#:[D*K M5_^M;M?Q>'1_L7QT3]389LG%^VK?7;XZ4<0QUJ&OG9U MP@-7$-^X44 35Q&N2.@3&NJ%G,RAC&D8BL1('@K%31CSD <\H49ZH6!\/LS3 M3D!9?61ZDNZ0DOGF1\]E46619HQK+?U8:$TC2DSB<3\DFFN/LRV*02U+T/S? MW"DVOIW]'D:K8+G2OSO0I=\P6A,__6[+0DG='PS+VC=%G9DB1!2K/I1U:-SI M[P_D)?XFBN)FMD7;3+?(5RQM71O0^78NV ZK,D%;2H+E9$R6SU?+@6;_'/4, MMNL7':E:L\_/AU59P/(J1HJG#T;9H)^/*R39SJ2V U+_E%6MC-061<^'\T^- ML5ZZZH\R:4NTFF*TL-Y1JM)!*4R]F5N&IZ#[3DZ+,H@*;BB*%RRDL[:5DZHZ M,4NR-U=%%V83.+=65XY92N@"(WP?()&QR >9%I'O1\H(RCW%?5BA*X(NUBG> M463BME$V=G7F^S9E=ET*=#P^,NZ=$Z!B%P?V&8JW/_W@,.8Z2CR7Q#&0+1'% M;BB,[W*5)'$ L\$-6Y>J/\7,3IV3;Z9W,KT!"30H#M]E?NRY(HB8&QJ?N(RA MT:1Y$$8QIN((=Y:%M,Q7^ZE*L2 (K+DSISVIE0Z9C"(1$1T&7(M @ZZ"?Z)( M5_5_&Y%X4)$0!Q<_B-34#S285R Q*Z06%4IB@53?.V-UR>8W@;+ MYV=6!Y+P!! \B-!+:!+MAL3W74V\*"&"2FD-9^;O!+=?[*VY%%KV1$Y9>L+6 MPYVLLE99>Q;Y"-94=KKR5]H==9%+U$Z#W#D@ MAQ4>!M3%-XF*E0G)RZA4^M.(EP.'<281M?_$8/ M@[6S,[27B_),4X63;*%AU%9&JM-26NSITZ+8;0*UT\]ML629G9OA MY-XIB_O__'\AH\&;?#X+9=& EI=.VNT:G12O@:< ;*'W+!W"\!1U>*MZ3%C5?IACW7J5&7ROHLUJ M190*?;("!CA*MA".4KB=@86FL.).7GH:8 :&PPY6]9QR>Y7U//,=YWXG99_8 M^534$<)1^*,CU;G[19WV;77@P;@ M+^3"WGV/34*2X,$-H>2-]%.CQU4*!07G\5@X5R!..$ET^JF$/'NBBK MMJP83&_5CZEE,-O/M.I7416^JFD-BF $ XG-M9RA/"\H*;K6"G&>M&*Z@T[_ MTDRA "Z;\<^#?CYTJY557&O?$%O&JE,H$+$YE3]A[3YB:;+E[,*B> GB_U3% MSG=A:7>+[^I4L>RIMP7XP>X/F3 _5D'L,B5\5R0)&,4)DZXT 1!%X_.8+&P+ M! E06AJI1,>14"*,HM@W012*,*"AB>)E%1(6*@I>OSO0E*^=W_L+5I>O M?8)*M,N+N=V\&[/TOALE:SL4J9S@3>$L*+3INFK2T:/,:H1-%9A\?1=.,A;V MFB7O\-F.+VZ78J(&R3O\'2'X-G4VV/[D'?<[0U7## 'C+!W.?1,OO/"Q>Y$% MSG9[H&L[<(.>,HR:E N/$;O>*_,2;#C9[88\LA^ B*"M9*;LI+F$[/^,!>8S MT)>QC]9EVVE!E9&=GT\/]SZDQU?[OPX^?KW\#GUK[V&_#OCWC^_)P=F'[O'1 M,6U??24+D9T?WXN#;W^>'9R]O_A^].=Y&_K9/COA!U?Z_/@(GOGM^RE86[Q] M9 \O7Y:1G?0 VO_AQ306+ I<$GC"%:%'72D9K Q)@!\S%K($F*[O/Y\P]LV? MG'Z*Y?WO!P7+6[1QITQ'6Q3UOA0F[Y_@MH')+8%),@N3/N,Q$=15H0&83 C# M/+F!&P0\9MKWF) DV(Q2^Z_[\?NMK/LU^?EONTFX4*]69QX4'A"H?@ ,K%? MBD2#2FNC4CI'WG2L)9 W[1*)J.0+Z<:(2DR'L12!AXFR;/;NQ3WY+:)OFSF! MO3TD[7'<(B^6])Q+([.'37!ZO_&L'Y)O/))@*K81^J1>ZU&& ML[(4E>*;42F^#2I5(G%DLBYM,.AF#+J)2X(C#2 M#7G 7 .S*GBBF&&PXOBM5MP+<;Z\+^,Z;(1H8E(;B=BX7[;(_2)'@]/-VB,? MQI+06"+K8E+[W1P+@'GSDR"6+LQQ[ KM$3>B"1Z, %LD2+R$2?GJ;;BS6*NX M<;HT3I=ZTJQ'=KHT"%5+#@J^2%_+7OHSU0;3B]R59FTPBNDYT:Q1KC?+L?;;'QYS#[ZR_RH!:7!I M+5R:#U8*/9H(S:@;A2$PK]B$;LSCP-54A[[6L2^HQOVN15C:(N:U' *?+_-Z MX0ZNVX#>/6E7 WK;!7JS9,SWXL@3ON=J$8#-:3SMQH)[KD=\++F0\( &RT'O M1<8>?9B<9%HH(%QL@3V$?7AOWU?M:I'^ZSZN@IHKJNN@MTH;7%_>69XHMAE* M\OW>W_8$WAP&VQ_WP!H9X_48A4D#PC>#\'RDE6"A5DR%;ICXP#P-9VX,L.P& M7,O$#P"@E7CUUM\)V#93S_K5M]EF7%T^)<\#5]>GM"MPM4;4ML'5Q\#567*K M(L*U,=SE0G!7A+YP8]SD333W5!(1RJC_ZJVW(Q;KACUQ'9_%Y/ K,T/<-4_3 M4^846#-A%2P6&U^!>;OL8EJ=M:JVF1(.>\ZA&O9CL!H8KY(HSV26+K(RK5D5 M*/$5X21BVGA"JCC2Z$^G,A0ZT#+0!M94-QVS+M[TIHC^/WJ M*X6V67OOTU5[]X?TB Z$CEPA:>@*1J4;14'H&M^/1!#2R 0"3P9%+9#>Q=1X M@ZF%(^W"<7[[>S?_W6;H^&64K7KBP.^RF,'YO.,7IYBSO,J(E.9E>IP3O-3F M8.H:8W_"Q'MIDJJ9)W;-,$O57"ZI(FMH/LY$A9$T97Z/I:G&Z8[S'A.T+;P* M="Z%[[%SF"!DF X[96ZT<5[TGDWFED&S^)I+\[)!W])QDO=EG<_-<,(6;?&V:^*E'#8 MSGS^E-[\17C?O^[ C91201 SGP@2"^T3*9B?Z" 1@FKMT\KFY"!WU8>'XD9K M L2S9TT;JX9Q9R"3^%K!EJ>S^*XC%50E8: 2'<4B$"'H.$,#PD*/,B_R32"G\T!^^B$X8S#&GDM\@#K!O< -0V)1WKEM^8>O^>3S99YJP;=<$"AD;*9,=%H:""+\M2(-9?2:^=Q1R_ MZ_@8RAR4OG6^-LGUFN1Z6Y5<+WK6">+H1K?QGSK+X9WR!M5PBHK2$6/^E#N_ MV?)N_1$TJO/?[Q-DY\\>*YH[QW\^K[WE1YW_^FT MKT[8,6NG"[N>[.M%^TCQPZ/OZ<$9?-[KP#N>D(.K#^?MHW_2[]^^PO._GQVS M/Z?S]ERV]_;I#R(2WQ!CW""*,>FBB=Q0A=2-E/$4@?\%!#U^HB7")O'BIB)- M&A#;6##*N).&==X"K"_G M6&?BQ8S&)'"UXCZ =2Q=R8%UQK!0 Q'*, KP5&^+1TT0-EM^=FC=>L MX68;!X 1H%A#S#:,#;/$+ H27Y"0N"&CGBN\Q',E3R)7D81S);V 2W29L1V^ M6)MNBYA9XS*[7R3@^Y[>@AC YQ9!LY3'29K _R(I?!V (05ZW34=$7,(U>JD,,G+-PGN.(LL&& 04"W M&;S77?:-4[!FQ/-ND-7$^ST#Q)IEFZ$713*0Q%4B#%QA@'*&AG,7K) HH;'O M"5:PS6@Q7]/V 5;C![SU !?.>'N>VU2%!X=]F_IE(^QS@[Z"*37$85)U?X2G M71OZ>2/]W$3ICEONZNSV]+AT6A^_FK)F&N:Y/H[/AP(:(I2?,.4&$HNI:D)= MZ1//E5H%OC @%B9\]3:,%G=[MPC%UU[OC?'.)X>JA<3X1133WW@^M2&B MZP'8+!$E %E!XBO7& JFLU21&U$B72\0) E#&GMSHJ%3J-3PS'JPV0Y'&$K^1^7?W=DK\E).9V3 M\N1'%-. ASQVJ4&/F><1-^11Z+*(RP0S-:LPN2XG96VK'LSGCS[IPZI_KE0V2 M@?KBT19U]I9Y-F_P?%SCX*A=4;ZUUJZ?V MV>3&C@"J%FU^FDY_@'3G(;Q\#Y@7K'90<_LZ=>N]_/9Z!^:\ CXF[Q.)#PP^ M$2;1H3()(=R()/1\*N0F$^RL61)AJ]V1\,SCHT]P[3\IM(GJ M\$C/)64\OOPAE!>'83HV;L0)=ZG/PH@& 2/*(-XRNAB%5$?,>X!(S]J!U!?3 M@2]/6LZ)Z9E,=BSIEKJ;]M)\F$FLU_/4X9W/;$MJ'@3]P/,"+S%2"B$"$HLX MBGBD)0EUR)1H2&>]0?!RCG2" I.*T<15$58/#:EV0T(#-_1$A$6Q$T7XJ[=^ MRQ=-'%,#*0_"JX@P@IN0D5AQ80(9<\5#$QHL-$JXH VOJCNDS/(JRJ4( #U< M;:0M!LA=Z7$#O,HW//02GWC>J[>LQ8*H;C75G[FK\IT4Z#9!M' MLMF4:X 0,S46B.62Y"YI(P"*120C(NP$(DSZ%&2HV\;L\&->Y- MC?R8:IT 2OA"BU DD1^%D:=5'"4LU#>7/9ZC1E@9!?J?F%=O@U;(GH-';A-K^8D]>2\1R>^[A?P;!^Q MVTCTND>)H%3&,I!&!"KB'D"Z%S6.T+HC^2SEY[$B.O("UR1 ]$7B*>"8/G-C M^)MP+R 1!23G+1$M.A"V#TVWY\#-JO5*/5BON\-EYP9:>-0@,\Z%S)U_K>/V M,\+W@9'QP;Z71W!^#+LJ_/RC-\8"/SM!()-G<3QVB<_PD11 MSR/"!736KM B 4N>*)=)(B.F$\,$A67M[ZQ:U2"U'92;?@*BL\Z1E\QT9)G8 M:E3.IR/MA#HG155+Y^(T5:=.FL]DP8K-],F:/BQC1SH7Y5E-MRI?7QR>P5[) MP2#K_P)A&YK.I;/Q\V13H@VK5+W6H^S2R.S1!+O(PO"AGY5?X77TI]%T1^L:-(D/<*/220(2!)V/,!KK#YW'=P=G+=V;/3>$U*"II;R0+ MV^0NZ/_V_\79?]XNGLBR7O C?H[CV.7+7M\I=I=-!9>,[[C6=OE88^([O< OLR1_+67YJK3ST=9 M74YR_CJX.KG\BWV_//ZF8+W &KDZ_W5\]*%[P&"][7T&,G@"SX5U5*RYB_;1 M!^C+\4_]\1^A_^?/SG?6^1F?]7]]WSOGATX< M''T_+];<+CWXMG_1[H2L#7]#&_ L!>T=_/I!HX#'4GMN@"3Y1D8B+H@$K!Z -L1*7PCC2T8B3HT(E194I]!X!GI;%D[%/9$X MTG!.\TW]^S2;G.D[ 6Z7&7GNR@0Z^UIV+N1E_NH_LXH1M.+<&,Z__NJUNFTK M]N85.,5:H=,3:1\S8A#I= M%:6XF)=U1>F^SCHP\7-8F/!I@S+UQ-;YT\O4V3'YH:@)5228*YB$?P6ARS-<2*E)HRXF1/L:L-67S8DYOET*:@F9VE,F& M$CZ=C;(TUZGM+SX7+/UI/(0_>WV\.>V M.,8RG'0Z0:HY@%^&K)2RD!J[>%89Y\-(,\\^% _%O MF0TOCS+H>P%\>1WM]*^BTB3'1Z MCKY>'%^=B\.C]FE[3P'B=\Y L\ _ZNK[ MV>GI]^XGJM]*:.^\>%U6YC+S87]O_[< M;Z,N@S?, 9JSL1M;CGW@ SM>>F3P%T"W-'.,S53H]"\ 4_/3=("(:9W=WK\+ M'.]/E22;;4=V^R- QH&\M.@,38[[@,@YK7L Q8<=F]#,.ND[!EN!"?AB!D.# M25E!::'BHAPZ/+PPIE>VA=1S2F_L.'N@,*$G^%WI>Y_2@CB-?!;X2$NA0$'!%%)&2QRR@-P:=K[,-M0):=NW YH?)U'9YF"7-]%2:NB$7D2JZU&T0D)#ZE'JC95V_%SF)QU=G=I-$ "9HZ M3Y5K9Y6\KVD$>92;F/N2>I0)K954+$J()XB, MJ30QV<#VYM[('/6GA"LU^;N"Q^SV=+O?*TE-(U-CF0*S6I#8",UCERL,-D8[ M2)K =Z6@T@LB%2B3O'K+;I0IA*QUY(%%'@-A\!,_(,)/="R) JN8@E%,/*9C M*P^$LD8>'E$>]J]^$&4(@17JADFB 6-BWXUBD >>>($F6D91 E3$OUD>0>&![USN MK/0[UY;*?!F:P2E0@+]WH#48GV$.PU@8M,@\>K@5/W3^P%'J.7])C5]\--E/ M"/2ZRL"7H=8 M^P&3B3 RB+4!Y0#8$R8T IMED^%K*]A&Z1;+/V3][C25_I8.3Z=OJ9$3]HG1 MX>R<_O!4X(5,&C<2"3 0%G,W]$GH4N:'E)F8AAXP$'^Q?G,!#@NNV/^.8(Q! M")>P65)DR4NU=5-9X73R%-:=S,:RB9AB9?=4XF7 K4_ZR)-1V/#)(Q!:>%*) M)_UN-QW:],+SVUZF=R)/\,:#;'KQ@7!#(]QP4>6+K9EK2]XQSVG#88)86A4$$E$+)>#QB9,H6)( <#>.5A1>,J M$)ETJ.S]^U]&C>SNY#^I,L[?\/)@+O6&+<"0(C_*.V@U-YT6?*@Z\V7F1=\! M84RL30*PBYZ]PP0(H\EN%!NWT%/Y@,*7Y@-Z-UDQP)C>V3D],3T% MVK9V;B!Q^*X*B_K>.3CZ!W"P?=9F7W\='GU.C\^.O8.]$\!+S+E_( X8](.] M9_-A4>WNUU]MQ$)VP+\CQG[\,VV?G5\<[OUQUO[VE1]_(C#(/#C('(]'X,U>*#<*.'"U=P$AI$HA,&>=P+% 1A&H2^H\F(1 MA#SF@E.J:110Y,=FW@GT;AK%<%%.S\H=_$ W/W^VOP;,-D4CR5@HA:]$*'T_ MB36E LV&8!M3B7?E9:L,K$B[A9,HQJXKM@?8%76*6?_'D2W]W&YJ_$R!*70N@?3E*DOCR:['I/W=7@_U^V<#RLIV M^0,,M4.)^[]C>H%[(B6WJ*R.N?VX6IH):Y9Y +D8),^3(Y-U_QZ! 25S,\& PJE>%Q?7XY.T*S!PSTXNP5B&_A]KXK/)X0ELA82#!"F+>SF#IYUL-5.5)@]OB.LY^@;3;$3?\> MZN(J@F"Y3-J/_1%H/SG*@6K K58WQV/1MMM8 WEI==F<].=E79W"CIY:@F5< M BXD.:FFLV3CWKE;7.^+C-F,5L=LWMZPC8)7#QCHN4ROD[&A?*L T'K8V/M# MTW78--6U:4Z"-[F#%N[%SFJ07I#V-J"M90X7*QUWRV#AY[R6$1 M9X/A1K5D12LIWVKSI2A"A I-SPZ-G!H:A(()H0PM=2FOG'IM!#>TO!P4%X9SD>$A+[?3[Y_C M"$VZ8"^@;^R+E"9%UTC+"]!]9HK79,%N9=W 5\ ^+4?!L"[XED:XJ)).-V4^8>7E:^2RP3I31;WLZKO"F8& M1S"^+ VFO'A(;GMU 8P&_[MB**9&LFH/+M8&YJN8!7N$0%E.] Y$2:J;I6"!F8]J%WL(QJ?G;2;%B./TK1BD/PM6/'G)-U8LSLTE/&((?^/#RHA&>^5?7__^W^/V_I5?5? S.$P'YU+ M![A5KPAK5"!5,&B7_1%\1!,&GY5<7C?KN$2 D^6%-V2R*M#G4XE_^142L/GO M"C"<_U8M^_)BV9?%T=KY;W%0Y[]#0TBE ^CX_"^EKV>AZ;SP^BPT7LC8XM<& M VZ77 WRNM!("H2KM^2]"T_@0B/5K"_^ / ,"W;^>SR1E!LCE_S42<_!TIK_ M=M0K;YE@%LA0M1T$HPP_%B&Z1<\+^GP+ :F 8P8H?O8[(+;GO?Y%H2A'O>)S MEN;G('\S;KE"].T&$Y+P?E8%2(.$%>R^H./%9E2IS6T#@R)R^#V2I''7K$BJ-@N(;18X9^PC'.K-MX.7 (U; "N\71,:M5KH/2 MB<'=E1JP )W-Z*R9 ?(8K9OKV[%#-P/UA1:'/F &A100M !MZ_L!J#DI!QHU M]XE5=G,/?%ULB2E +ZDP,AW&!#D$M BD1%8^QHG[(A]"ZZ;B)7AI_J: 3)PT ME*5.QQ13ARO%X#TVP46AYGY*S(MA]RG[Y39E@IXJ8_MQ[>V6"U0=@2X4H#W] M1H519?T5A3>V2,D[8R!:O)XB;Y7C?34O_S-N,K5GTN11S^N;:EXM'6:\(1:\<03(_M:\S M>;NIF9F9PX5.V8?;B,O+XC6*H,^97>$8>'UI$#CO03_;8T(GIU/J=MK)+H=S M0YA;V6^-(S4+H)?5R^&R,KV2HUG5,R7VN-:FI%[:I2OS?L_B89D^!!5<;.PN M,CPTLW;_N!_7<+KBY7$L3!4(:Y?#T-AE6W+F8G^AX*-X$.5VP 8Z_,12SPSX M(ES7F3H'<0K& G:E!.S/T*+SH;BO@FRX'4,JG/V68^T\NEM-MMW:7NW/M[0V M2='A44UG<61CBG!C;\?$VOJ_"LL VS%Q-L)-;":FPI!L2S=PW#2.-'E&K06%HPYM+KC'$_Z;HW"1?.KB&[N7$Z&UNY, MH7B,XZC'J[=<@[-JRRK,:U7=!=Y_4:VU0@O!S[#"_@O-H9ZWUNZU9+" %KM' MAA(Q/:X@/69@HSW&" LW@+ECW7-VR.QZG$"'S:XR*$;L^B(+3(:\^< 4)T MS=#IHFV">S+&Z F[G'2H@^L0$/84'EU9N>.S>SUKP7\9SB9

?J^46JAK_:K:G-Z>*("#JT<-,0\-.M-J!:SN13018GFD'_1/"V#YO:EL1> M_.QCD S\F?:FZ[VB>CX!1EY/5^2UCL?#GO.G[!7:E$TE/',^[.T6FV4_Y^8( M9C'&+9&Q]U ZDZ1T8'1T1[T^CIFUX'Z:4NQPK_8$.MZ;"-^ULPAJL5@(E8.S MVKO[B3.&^)W-;JU4DSR\Z(.]!(I_B!%4E3WP6[EE:"T">W2HB#;T[.0SPNGO MN!,* WQ>*%#0Y@7[LTU&;C^)N M:@]SICWK7<6;LC%K0DVT^_7SX>==ESDS6[YE\Z#4BD!+:)+]OH4RN-\;1U;: MJ45W2K'U; 8XS1C7DIV;(KZRH&U7)=4NZ)[]_-O![N[O)46>XY;O1VBL0:,' MB$L8K>/L8MP*#-[[ [BIY!%55';II]*3,UI)"JP'0*R3H!Q:RID;8U5Q)91C MI!H584'5DGF0$$,?PP5O'-DE^WDX^:X--ES(Z A0C@V\>NLXCQ,6N5P8U@?\ M2G&,9QDTB)6D(A]>X2:&_B&' L*VKV P>H65_U=JU.G0]/*A27OS 23;L'0F MP&S14G90NE%NX;U/TSBU9MYO[]K[O\\AL\1(8:OA3\N0Y1E7;]HM+,X>!ES9 M$+E^[\1%SRN>I"R()3P$!O\"HY,M UFF&[J7JH_QRWW<(G*Z_016<0>6ZL&' M$ON@R7ZJ\];,*75K80#?M:$F-C$!" 4\ZS?9*:UZ&V@VV4BH])0L_,*_[SA_ M7%8C8./')P/3FB@ST!PC]).KRR'2:E.(E!SOI\48!5MX(+..&<$ESOY? ,(3 M]Z2][,C%F!/+>0K6C@-MS:!!'T\D[$R>*,'4FPQTQ]HK>-[E"G,X]74?>H(. M\4)RT6, [S7$+:0J#M'^#0H [(8=YY\)&VF5CC*[)."-T3F,(XES5#Z\A3)B M'7PVLT.WKVWVAK%R=7*XKX/G U-T4JA45R:DNAP_!^>P _9TQQ3;>%V#%GJ: M=VT3JFIL_,(H7#&>@[6>-3L\5BZJ+000+W1%5P$%0@> D%5,G9, F;_+"J'CH;]9#'NJ#TA.O]^BG 3$ 43M'<>^/=^)_XK>P I62+6>0PU*3 M.5Z6G9H1V/-]]$IGP].LN+DZ<5/HOC\EO)*ULDH'9X'KXS4XL(E(T% K34AX MZQ/@QJ4'.ZTLN 4EH$T7EH7=*X6F\Z$+@ZLZ,L\GCIS4+ITMY)SO5P"/-52G M7EQC"#4@A"H"MR3NCN#Y'1L$6=HF^?2^Q@1VIIR&4X!36)1R\&# M.V6D-F[AI(#S$PU@=[1+A_=$"8^LIP@-GPYTWQZ9O-QQOMA-U2K$TCKQ*G"S MIZ)6O'-)D9S32Y0'8$.6/MF_.ND .M=-02I!N\7&JB>K&_N6@HV&13_4:=:' MIP)?&,"G8?\7T.SA-A[:_*,*=+ >OORTW&FR=LED>=UFU[ZBI6L068S9MT'2 M:.W DZ=GY_7*L9PY2<3]I:-9?)5B8,_PM4O#1W#0+1]?NW?@OWDZ"V/VX!45 MQ<$K&&3TVZ(G#"<55KOUKU6^A6D"M-LJ32@1=&YF02#2R=16 M$;[%=FP5JPNHAS54X7>P%OIXE.BGZ8SY:R8'UE];!/Q.+FYF_$%G' ^RJ],^ MYCT!\[*#^JO0EEEZTKD$VZ/0:45ZM-G%;0-1FMEYE/6H,)Y'66_926>D M9.]A]:&P+7K9E7L3'V"IHM.NIGL4T,,#L )F>NA5/;PPD^0!1=@V.I$KM9,/ M,70"MVNKS;HJG]CXTJFS4[GLF.D0YUP"T[\PYGPUQ=ZBZ5]Q=@ 6=Q&@_>[P MG_T]ET;.WS!4@-SJ.;STRKT0&W[TLS(8T$Q'NP\-D33/1D7 UU0Y&'N(MAJ@ M03E XZBC*O9?&U!^B!>8++08V#+HNLJQ89T*Y9FYRH0<8GP"6'S3UTU)9;&' M.W/GU)YSZ4@MO1OE7N[$&UF%&)?$<[RK%!XIQ*G] M&Q2HJL*=ODSE]_USI$\F-LW[*O9H^\S[H\*G#*QA[/B^^^&7TMC+G5%>'/$_ M-]?$917A%,5Y_").J(QD+1+R%:=3\]R4@SR3"4N/LW.4CJ?BX/UPY0U5&&-U M5,%^46:*SB>9H::V.,?=*?)1%D'!N"DX%VX&@W::YFC&H/!@DUEJ*KK6[XU/ M>L]&&@[+4*_*A5+LWH.QA-(U"3I4::9&W>)49+DG-'6HJ7"*695I0TS115J> MF+1;L6<3*1U'*]OTS/@C9K(VJ\=X$NV"6TM *N0D3JUXE?)4Q0Z>\IF.Z<(P MMS*BJRKFD4_+0?%VD]"WF5B];,J+.!W/B6(Q69>#Z76Y(%-5?+NLLCYK@^3D/T-$OHVX7:1:>[9H"J"4@MH7.QR.KLZT+VFZ:]?J3C!Y%)&P^GK *OE>) MR100S1E*-LRP1)0R/]^\DMS"L9O?_JC"SJ\9IP)@NGV@VM/)["5Z LM590E/ MU<1X2%O34#.W)*NM\.%R37.+(Y48\9*7IT'SU6[?^9EH?!/W]TU\+M1E5; M)ZYQU3WD@&.-1IO;".S;Q@_^H$.]WT.;LI]=-L/\H!!BS\%>3ITJ:,;[81%D M8@PIE0&':7#D80=\QCDT;4,UX_Z0X_YE18GH9M0?5FL.P>[",^^EXZ#9('SX M(9]4-EUMB+[(D$RZB=15E'I-[JI;[;4NR39U6W.\)LE$"ZS16(O!]O^U]486 MYSRL*R]+\TGBUR-;E.^@;XORO;^VD.:28GU//S1KI-@:VA.QUA.<]+,R!];R M!%IW*#.ZK%+D3<-3XA(NJ:D!*]*"E[VM RS#[HP;ATYR,WKZL,;G6+@Z>7K MM&??WMXT?\P'VIRLV!U2K-IA!O_HJOWRYQW[TW^&>O$WG^Z$ 5_Y,]FA=_R- MAW=K];K.4K+C^7?MT'6_>2QL.NO[MVKV/U;$"C$#><658"MPS-*FU\2A5MZK M]NYR:;1P*1O\PHO?+*CQA3-P=@EN&I_"F[0-*>!I.?;B-O08.NXQ+#=<^H@3 M-+FT1#*K& ;#\O0.CO2;FDS=S4R!%$=EIIC9?5[W]F-6:HNY=I[1@))F0#]BSYVZ'U;VF18 J+'^6_KS.NDSA$M^RK4L8DR77OC^;Q M$XG3 IMW;K-"FC7NTL;8\)O;_YN71L?_E-1?,O\OZ$&7< M4PMKLM])2N<&87Y6UAD\XM1K22]'M'_-#]-:KSC]:C8A8JW>+0S%$SDY2>%G M14? ?<:W6G]KC',C[==-R?.0]E7B%C+*WFR]U(W;8.LIJZ426+]I E!ZNBG: M$$G=#E+P5ZHP[KDB!0_*6J^3U25C6#M97:Y .=DB_7F-J#X4DKT4Z5@^/YPT M,U3O&;H;)=C@-&W("*VUFCGJ%]G<[ZYD-DB(;N=GJYWX+E<_$=U"^^W6GLYM MX=A;*E(;TEG-K&[!K-[9IGK8:7T)6P)EB%3O9'S,]/53;P]L9GOP&??P%F3W M6<'#O6APS2#BNET:ML.\FL/%S,&OIR;+M1;EY918A-O'B+>4(=5:.IHM@"V> M)A$^DQV +5 X7TP':U^URNRWG>+@ONZFO=1F^DU_-AL#=]@8B%HL9%NDBAK7 M\R//#Z4MXO%FENH]2RQL,19M_?[ UFBCSR8W-KK?)CF=9/-L+*'U-P=:(>=; MI($:EOW8&HB#A'C-+-5[EGX3+4+8[XTI]/!#O=OM0V>NQGG)TOD;;?8IM0M=XH?[)3.LZ%,RW4.;04!W2*M MTW#JQ[9\6A%=5^\TD_38A@\5WC:;/;76,T5,KL)@ YN??B%(Z:E-G2V-KUEA M!-&6\((MTDB/$MK32-4]B7G0(M$=CY@T,UOKF14M[M_1ZMJ*<+Q:Z\:_^GE> M%M983&_81*/?7QW^YI&6)_C:Y*X>H-7,Z@J^COK()\VL/K-9Y2T1UFVMOK2= MJ7W,\V5RK&F%.:"?VCBKM1RO\ D&331>(QZK#\C=U9!JINC1-%% P]NKH?KM M0=5:P;3-T.F@W1.;I)^94L\4M09J:_O4GE*M-G]X0#='J9XC5Z[]W*ZBRWZ+ M!ALT@I[CW&[GQ(H6(QM>WV/1,D@X79J.A43=JGVTZ M']MP[,?W]CP-QVZFYW;[0D\8+?F2S*"G2(T]6V^!PRSI_@ACS]?J/K3SX]L9"D$MJXS[<4-L6EY7-7%XMLJQP<^MZ MGX_Z+M?7N9Q.0^M:L5^5C M/B\K'U.G][K56TP7P5DA"+VTLS$!P *K:4]E1N:%W VR%,8(WL\V7Q17Q?.F M_PH],2M_@V4]ABNEQI'$Q A%&=:_OO[]O\?M_2]3A5P_[.TZ<@ -_ 2I3WO. MG[(WDMFE[>N--5>W02:K3'E?9C+EU>F%;M5]F^C/N3"9[)E,IR$[10?AN+&0V-T=CAKN' MQ6BOVV5\O!757[ NAM ])_+^_2QD=)Q1:SOOY$Q=U>M_;O=WJ MU&'C\R1C8=/.L ^*-MKA8\1=4UR4K<]=-D3I#KU;0X#,:[V ZO=R^!K:*JN" MC['V]&#<&B3AW90*=?2T[%_(R?_6?6=$'N9\;PU6O/[U*R+B8^MO_ M%V?0Y)(.K2PT[@]F"HVO7G(U*S[N!3N1+QZD^/C=6KVV1':X$]RQIOD3==9K MZGEOQM-YZX+>MQS+>CGVUBZ+>V]!J7WEX/H6"W\.8T;663-K;1 &M5E4*S+7 MR@Y8T29O(;>$N4&V-I"7EL29[J#3OP2<*2-%'N0\\TWW;>?6Q'WW[-9[^;JX MFE><&HA:--JF&DO;=+SW>2Z?^^[L;>?R65%,JN4%ZZ9RWZ9CS%NA)O_.^HG) M\[3?DQTG,= P*DAH[&>JGCZXO];[CRLB*%L!W:9D'M?([A9L;-=:0%;!7NBM MFS-\@Y/THFR 4YD9-[9^9?0+FUY>I&\MW;9-@/C:\.:W?+%-V?.:*.3'CD)N ML>"9E$2H.[P5Z4 'H[B3JF+?JW=IL[;E+2>1*NVDP_'?:2\?9;@9BQ^3?M8M M@'!HU&D/NGMRV7+D7(+K0889;H:ER^2_H[2IM7#'%529;%5M34; M6OC8M#!:MY9,C4CAGGH+(57S,=QO., ]12Z=8M8W7Q@X$L;2P\O,G/W.K$BA;EP M@V?9L3&\110R]A6^AE$H'2OXQ50(_=#([I*0>]G)^XX>&6QB[DV244_9Q,/X M6SX:#/K9T+;:D?#+Z4(X_F!ADP_'4&*X?SJ$]X8VL*AF#B\-?_:&6- L+6+W M\=Z33'9A;##$>=09VF'.C,I&:?&Y8TXD6%0P1^<&#Z-,U>A,TIYM!#^//5#+ MM-K*-?-8@K;C?%AZ.*8U=_;@7VR'C"/*BP,:5G0*6:FBP4_!R 2!,3V8Q4Y? M59)P&RE=(D #6XBA.JU3S??4)-_^&%EMSC[,E'+=FY1R7?O PQ,!TZI2M,YO MG_^/[ [>[/T^D8;B^$ZT$\Z>(J-\ZIN'.<=3]N5.IQ-NC'MO@MR;(/R5V[BYLYO[SX?_F[)PO TS< 0D+B? MJZ A? -GF*']\9!%O9YG%&\3!#]Y:]'R^38Y*IL8^*=>/4T,_'2T,*'K[OPW M,?";UJ*5/D372J=P^VGTR*3Q"/5H$_)TAW@ ME5:H0EY>O0P44&:*/B7<1+V MV82VK KO)&P+3X'6B.<^&P%965">W?&@8T/E:G#BYZ5HZE54C@3;!&\-E7MT M>&-TW7+4#96[5_3ZU&F>@1S:B(U>;X3'?3"ZHPS)F!SG[N-!H8;9K;]G1=D: M.?<;7O78-J2_Q0<-FYCR>NS%/,?0U>5C$K5"SK>/R#4AY5NY+IN0\EOS9PX+ M<]W34358',\PI%R;25!X%3M9A(WK48:AP>OD+<>HSTX?_N.\^WPXB08=$_+; MQ&0XP_Z)L1=?I,-31\[T4-VP;U6<_9_*^H^]'\<1___M76MSVDJV_2NJS)T[ MSA3&2#R,DYJI(M@^QW,=VV,G-??;K49JC&Z$Q-'#A/GULQ_=D@"!P2:VL/7A MU'% M/JQ>^U'[[4[ES],D6$O08F 5X02;Q7 W\,[KDY[,%L2.BFR)FN&+2:4 MZIM5"U!]6'QE+H\:LU!D.';]]#>?,Z%,W2F M^9[>5\*#D/E!\'4EYE*B>>[^DE^39WZ^5:LUA7_S5(>YFT^")89/&,R$!T 9 M#&#N&4$4.0:?G(@H$O>20 4F>P7@426=U?_#B>UAT>,@>"?]>TDV0BS2? M/A=A^>\_=2WS^'-D](4O'!=DPY%^0,@'SPZ$_\,0M@U8 E"I&3Y&!*V[0\!S M/YY#>6HW;0=SZD-#W O7CYCS\[T.6U!_3E>#S,T;W=RQS=PILD[6 J@4ZJL! M*D 67+SA.G_[X#:DTQHT&BUY['1;7<Z'$K Y MEEPCVDN7[A^)Z[BJUDV?E9MQ*R/00?8^7K[1HSM9"O?>5 +\@U\C(B:OT!]8 MW@?PG:X,PKN&S':GWIE#D6@$N'^("AQDXD'J^X7HX1.S?IP^G+^ 8_U+K&.K MWMKX)58GI]E$;)Q*6XX',ER\MJ._\IUKW@ =SFWWD?1P"^2W%E@%*^=4<9B* MNI-.]S0(?Z#N5H83#:G9SE]/PE>,=8^S*5E V>H>D9R 6\WYZ=B;>T3*AQ7_ MDB3^CGP(8FU\C\7_!R'B(<@I8*"!E*CSMF4^(R;[71\'7\G^2*I6L[4_"9H%[D^@@N2VAS5+W[;XUO? M6-KZ ["0B:.Z%C('TG/E ]H3 #W817J%WC>&BQS:(6AOHL^BN9"@FX?/)6&( MGTW@+9$Q';GV2'E;Q.,EGRM'!LY(N7FG#!M"JU^;&RLG$&FX?C*$5MB1RK6L M[N1"+XVXO.3DJ;:Q3?KE-5:]Q >5_<]-A_ G=(<>6L0W(AC'A@=& M!)LI/HB[85K*%"MP&E9OI?3+ES8+[I1$XP"_1WS/&:J7UW=X'HUPY)Q^YF@F M8U1N_\9!:.D=>EC]:C<>0<4CK7BD+\HC?94#MHIYNF5&1TD.(W9$2=V)S+T= MWF7%52T)5_6Q7083]TIG6U@^+-S-DNG^;8^AB_E[R\H:K<#O'\O:;,K M +)S7+-:QU5B\UJVV>)VU'MJU)*W I;MFG6NJ;U>K;LI@R%-;D\Q3_JE"F)A[+> M5(Q=9^O,F;5/83!@-G&[66]G"6GYY%)*86ODM>$YUT_@H5Q>^G+*D4Y8@@ZA4'&Z$*;<@S0)W2 T9E*$M7Q*,$TF"(CG MZ:3<8=5>?DT M)WQUQF!I<]'FQ-@MB/<\58P[QW5K=8KJVC=R]FDN4W-K>47AV,E0LCKN6;(J M=<]LYX:'&3V3!'XM5,[2?"ZMYLC\5R>_>?G"3\!>AWX"P@6]T^//-: 2;+>; ML:URC!K,ZDD'*&)F-%&.$#)2\D,KSN?=5\G/G8WJU,K=@'@N=7I)^!]]*0%V M3E2>L@&6KC?)UC=/1&Z-6-Y[RWO9'ITTQ.P!!P P>774:8F.%05JU6:LA'J\%? MH>$$^+E*FL54?/H&U5V03I'.V(UHBD1NBE!ETETV# BP7R1(-"/512S'1K/1 M/! ?#UH?#USW(TK9K;Q//#83[@[_QP [5#)4W4E; V#/CC<&E%>2'UT(/ %S MX#IE^>RAR !.A#+'3_2#S,[A" *5TKI.WAE??IXFQ,.2*%L3G[DE,XX>N=:Y]!&]P?Q,EC)TM.?["=&.V)3UD<0V M-LP&R*56H&A7*IC5A!,C!=FG(V.KO,C(V[9N_#,18.S'?$D2SBA\X.E_XX)X M092$N%L'(!^HA/ VJELW^K%Z%[Q+XDQK?CHJXLS3&;C)W"5JMJ R@P&@4$+@ MHV]$0QE<9'XH-BDK.GM&#RGF)4PWV+'$MJ2/ZR3%2.Q0.(2*S0:UY^)]3@G9 M\KDO685- @_)*%%&I8&G$&0&@0CI&BC'#:4=!\ALPX' ,Z$ [S1<>)>B@H!S M*7_PJ%S?'<,L@2^-M1,DNM?04(2 A2_(*$& KJ=@X/ [_Z1][*9G7 ME_@P6@<<+$+*4T9E(XD5AB-FL$Z'\#]C($"+\W;(G$D#M?$0ME.@=V_T"-$L M[VX37PR[GXT)/M#(@%.Y^+Z(Z:HI%V7:(@;:\ M@ RP7WZ0CHR6&@QXM.CG^'+$0<\,H/P*S%&1ID$"(Q_ &PE2V$=%VW^>&W^/ M+B<6^0!;WW' 2,R.OM3$+@BKUN?:(BQ:W#>!4.=%:J64 ]N$D M.U18G$9&!7()]6..HI3&7(4#@YF->C.CTD=1,J9) H.&:XUH/89@@ J#ZD/[ M>,R5I$[6]P9Y_6CS_8%>VR!!U4+^@#:)M'B*,>-I- JF M\*9!@![,=ETLY;IN"4[]4()6WE-(0AU-> 0^)ED3V6#T;;Y4_8KB\Z3E5MH( MM?G*$_!$IGTCTJ$33]@RX^D6&AH$'5/4KGEV>H#:(^Q0R/%K?LL4+(81!YA4M0(;)!.L MU!"[CT-SP:N2#M/BI08N,$BP>$+JEX7R7H3,_E<_UZ-0DTFN5HS1*CDG;30# MZ2N+JF]M&O4Y+GG4IU4W**X9>+P6-W@ZX&"0IP3AV"W![PSV;6:A9/&J52/< M3X2$?0I8,Z$"AM).R.8.L"R&#-5%]/K[#);4]^!W8*#)D&JBE._#FA3:R6\X M)YL^.S]]DW3ZC ,Q%_R_35"OFDUQ:+8/)%^):;8=]2^EYL^T6=>SXX]<#X2/ ML0J+@M"^1@!!E] A1Z=F\,T3L,AT"B'31:]MVF]R\])!(PA(GW4.0KWK4T"% MQ"A$;:#.\092M\W@F41IZ2\*)F.[,.4>QLNA:P, EMQ11W[<"&&@CI!UZ-2X M8X"(\&=:0,)1*@O;I6,<%^&0#P,IET*=]*@D"9Y_Z@JM@3**QY&>];NS?DU! M+7J9R3AAVUX[M@G6N%3&/DYB%IM:K)!2)'V/2!TH8SPLAS](S7# "MN+ (31 MW!LF/BD/>%"H8-H$70$NVH8U-FC4>(P)PXU(C630GJY1MO+[!UU]=>R"9VA: MC2G4HJAA[LR#CRY@Y/L'7Z?;GJS7*-4V\'W)UD7JRZ5U>19",^)!@$A1]&0V M7WT53T(EQCB4V+OCB4<2#O_V87@Y?%!6B\(.2IQ3LA]0= M]HDCHC8:&D@_6 MR"S=R6 P7 7*X*D4(*B2 M6[)TO-0TC_&TIF9X[+=2MAE,"EG*PD\/#$&]X9WU\&V"P5-;)!SX YU"]7>I M6)^,8]:!NN2X0Z7:E0.5.Z#,"@]FE=6Q !Z>;.[?BG+^"T:_\YDON5QALL-4 M75!.VI0/N+1H@:8N0&X!8"U9B3T]/:39*?MN[JDS\O.]7??O9":IT>BM]LR$ M(,0"U\%R]^R&C;$9/$)3VX.MJ:4SAL(#?&5XXJ-JOW+R0Y(=/E"?ADF,WJIV M D'Z'!>:#O,&&/$$Z/?0-73,T,Y-SP?#7'5P.Q;*^*67U M^S-\.98=/?2"@ I11O!3E10XQA A.:%@'?Z3;4SH!D\KA?8HY2Q:E7&F+60^ M)5)S!UYT!-Z=8@W0*93KJ3,#Y8S"4+3['0*TX?D/&O@8_Z\;OP=3V-2*), I M(G/99_1"]6N& X[4!KXWTRDE$GL#;?44JT$=CS$2@N/*\5>*=L8J4IQE5CH2 M9(UC!^XX'7$0TINRQW[X>&@!SR7L D^EYU%LA!:)7Z># ;RR>7VT.!(U5>SS M>U'PF$CM2'Z>@7TG)<<^JVY\]T-YC[0 =*?NR/D#(3S[@RX$S.6QJC*F^*4R M>\H02%T+BU>!_XR2\RVKY(O7K -J#P4)[G4HFRV5+TFXPN/3HB/B9Q0/KAPM=FSNO+U M2T;T"N6@-&&^SI[FG*N%:,\7+6^7L69YM]XYV:RP]NM7 >]VZVUKLPZITBT+ M6\KBBA#%!26V*+OZW$4$#^.9C&08;Q)SJ$Q:>@3Z+09%#FSN=7[Z Q"N7P;Q]$,AD=XI%O MH]DT?\J?/YNF61_%,*E]G&OD NADJILTO>,L3?NX5DE'DR2,D#B(@:3<.77K M0'S$2!$=4],_"HF_G.E6K$;# EM8+-H@3\.72ML]&26L"B7>'DI8CZ)$EJ[TJU%B3 W?8GC4ZU[?=BVUO5MG^#V_ZY MED*U[=_TMJ]O=+O.='<3R)/AT=3:?3.O2S?A\\'/5">P1Z/#J2SKT( MCQP1BR.STVATK,81]-?L6%VKBS#1:#8ZC2,UI*8I<'' ,PA@),*[%V,&CY[Z M&/=MC[]0?)\%^S]+J'%]30\^2(^55.S5 *'3*3**A?Z7:%T66,HYN#OKTS=R M$"98[\)JY:YKQ2(:ZJY>Q\!D)^C"8);E)'VLP.;5P<:JP.;=@@W\>6)V.AIL M6M9@YHFI'UA4U8UPYLO,N!13XRJH&U;-H/U:36]0ZIF;O#[I*6H6D^4=-<*9C]4##-2L&\ M6P4#+S@^;J:@T+2490I[%^MCP+95UBQ_K N6QK2?O\P.4]6C35HFQVM\;2I; ML\B>+<"5/IO"BP9M%UD-U, BWJC7'%X@ M8?PF?@9^,)Z!WHBE3QS/.WLDQR+=+I68OIJ8]GN7)1'3=;;C:\IJ7WBVOD3@ MTO5_8!&@9LQ2J*3V9:6V]7X%MD_USF[P 6"HLPAXWL@2O^];]]OS^Y*7CWC)I?JS(7'J?2UOG1Z M,](4_Q!K6878%-9DP5(Q,?"PGANV))!X%5,S\T:(D>U0"HG52;S:[.[>IFO56T]IYJZUF_:2Y M^NLG6&HK=5ZGY#JON 1![_OMQ=5%S[CYO7?[M=<_^_[MHM^[O#,NKOKU3=RK MUK['"DIGA7P5,Z/#22A;F&+[,+(OLT_/&U$)[>6CZ(B+Q]](K"G_6RBE[TDQ M?(J'\ KU.'-D[5UM7Z&; M+W?O3(G!D!=GFNXD:;.3.VF22;)OGSHR"%M3+'F%2.+[ZZ\DP,86R$"VP?A_WW MHQ/'Z8>'@;A^=#@XD,4<:^ ,!];@(/2''D2'@Z&C0%_BD]@?HPD$XL9(?/(2 MG^Z-.9^>]'K/S\_[S^X^9:->W[:=WA]?KA]4T;VL;(3)MZ72+T,6Y>7=GOQY M"&.4%X?)=+Q4'"8,$PRG8\@F<-^GDYZ\9]MUG5Q$ F*#"DQB#HD_5T&227GI M@+,>GTU13Y1 #/MS 4IJR%!BS>4@YPP/$XXN*9M\0B%,(GZZEY"_$ACA$*- M-(@(2,2S'; MLAU+VC(E^)KZD*M6FY57-ZH)]5#$8_G-6D#LO\3!7J]^!9+8&D$X;5Z)HF!: MD>Q*\\H46J\S& QZ+[(Y5E9#;UJJO"4_6DZ_F=JJ-EI?M_AFY7*;J,/"%9O5 M(9=[91W*/:E.58J2-ZF@K,M UL4Y?%U=VM6C;2445(S\_1%]Z@4(KW6.N$I( M?JCT!T@(Y0I%7LFN3:>8A#2]("Y)5D]R:N]1F =;+9Z7^(_Z[P0RG]%HC;/U MIHQ.$>,8Q<6^0 &,&0I/]V2/8.4![FL$A_NB)GD13<%R^Y0_]X0(BJX7=Y++ M2JI.]V)!1H12V_S(-^[#J.F-"Q$_B13/?_O;#U#8]/:%B.@F_Q%W/V6HZ=T+ MD5CD%VW8E_*/XG> @].]"RH2V3LX$O63UW^]OUJ3BRCM"ZD<.@=?L/+1%@FC M^ /6(@&V@)($4O1#;U5@!2J)47!+/JK/J[>;"6=%#((K3E);;KEUE8IE%W-S M&HU, D2$L/@0TP@')Q0^NOA3/0XBA:^H*+!V%/-.#2F48!8_/FO M!//99MN)29&Y71S8]F&;=I%I!)B HLY_@U3KKA44R('Q^#*BSQON-A:P9H8/ M;?NH%<,"'R@%'2+SEHT@P?]3M1#Q[A.*?8:G\AL-SQ/A8*AA[U\+T$"@& 0Z M3CI.PK$?T3AA2'PIPJK 7 "6Y.70':+N',98N,5=X28:,54F;R9&_JT2HU D M T6<;K/P"7&(HV9N8X Q<>+9KJ<[2RDGX*<,L$L9RT,RF4 VH^$#'A$ENVOH1#J.&$5*7-MG=M8]=/0@6,,!/ M*4I'&WN;^%4B;HY- T]/+)8HZ&C (9RRI@E"452QBT?(W:1,+EPX:P&:0Y3KJ'GO)9XR6)#CJHDUA0PR:)!B[[A; M,G6+R-8 UASR/%?OX&OSV,6 6,?R;2)E$UQS"#WP].RA :4=#+!7HN9DA$53 M;A%,-6%SX#QTU'+22@>70W0O0*Z:KU6:5PIA#GQ';EFBL<)#%P/>GH?H-%H@UR-GU$IHW@6]UTV,K@4SLSCP:@3%SL]T MWJ4//L_N(BAM$\A'1:9R'H8@WC#7, 9NZ^^[=C'>G*1PKT'"E#E%G/(]T" M[DA2MFV5Z*^%,_9S?<I4];-F)*$S;'0->Q!ZNT* A0P.BP[5N$N0H(:K M4KNU8.88=N#5<);.IW:K1GY(IM/T)7<8%5]GN2(A%>RT?2SL%6K,+!]ZCEV' MY:+"Y==I0$'GK@DH;K)G3>0[ Y2D#RW+0IB,+FC,Y13AO;BZF7;03)>Y,1QY MCK9N7]X8Y@^Y+/3*;YEFH%2K#$ M"(SOX$RFN2)6BBLL04'!,(UHKP5H'A\-'#T9R&%!AJNB>H9<)'%'W9*E6PRE M&L :AU>N[>J3LG5I[.*HJX[AVW3,37"-0==U/$=;[*_/: >CZPTE?KH\WC:< MEB,8XZ?;=_3\6>!8&5!'PV6I)=OXDQ'([$"NYVB+QA7,=-)?+B%FO\$H05]$ M36R-U*[&&&OL2\?X%/;F401'-)T=Y&S$4/*F,V&^.O S''WR-'3 MR0PRV^RD KFJ#NVYJ9H-4]7$]/LGL>>HZ^=K>>NDSYW@[C*V 6=3&BZ M24RSE+,4P>Q= Z8UGNWJ2YJ5S'0Q MLRDU;:NAF@G(&.#$0,W19J\,).W"6FK<,\+Q)QPE9;[8?9S>'-C,JG M?>LS*G)*HO\(YAV4D%[2EQ6*0Z^LN M[9JC_8[DP3\H.'M"#([DJRK)1&WYURK!::O#3/R1U]=W?JKV[EP=R/2!@L(= M\W-+G461//L#!>4_9Z_%;JX5---G;A''7E_?'ZJZ1R?5P109T8 MY[\T?LET(6=.>0>./K662@,EWDUCO_+UPFH=H,BA+88$BV(Z45FG*.BRS__2]OC8+ M74U1)SU(3CMAM1^:6I-1VS,BTGC_4 .,V8M<1Y\76X!EJSD%N!TU+6@MGYV7?E\Z7T^>KI>=]JD(E4=[?;U&<8Q0=K(&&:6/ MH,M_'A&;8)+.@(F/>P .8\Y$;#K="V$DCPF3QP;*Q^CK A LET'EB6&<)?*8 M,7E>ZHD0Q#1X5,> !0G+IE+C1&C#/)'??F$TF9[NI<4Q1P(J/34LO9(+78E? M),SB>$'M9BO&%R)E$)'%%A 74^6"QVN[G<0S) M;3H\_ W%#V9Z9&@O":7))E(:74W-9B\%VX)F3\^D\<8/*&(JE>V"X:1SB\-^DBSZ9Q+ MRI0-XD>,& KNZ0Q&?"9^]-63'A4$;%S/&]E-@M=R ,JX],8+RJ;R@021^0_Y M8CGG"YH,$2M:(ZUEWAKK26_>8&\NYMDU5;?R75+ZK#I M5I5>B=7D9PU[+T?_]/FSLZ4'X H?"X\,JZ[C++-?5:O;$/@;]3X"7E2MAHWD M$392_R\)%$V (Q0L]OZ]D$=PRFW)^3H7;(JR=5=M+AO-,3-W&%"B4@AV6S3#G'Q9MY0@;QM5W@0&0=6O:(:%/BSQV>Z MIN(AULI/X'#6M7Q&6:4!&R T M:6O?TPC;')-M+>>L7[4?/A5-KVVJMRU'VWH/^ST&'S_8C$;MFFUYZN(W[,O] M]^&YS&OC\06-A.=@:.Z*UPAMO5_6$K1;@AJF= 6)[=].VU8Z?R.L\.B(2 %" M)&K(T+T8FFW>,^KHW+Q%&\T[95NFWZ<#N.Q;.C^?B(CVP)- +?%4F*:N^-\T M;;J7T>HV_#6>;YG>,GO2@5Z11 D5P=O9Y N.1/X@RF> MJRC>KEJCCOTQFL"/[_X/4$L#!!0 ( ,*!IE(LS6(GP!T #DR 0 5 M875P:"TR,#(Q,#,S,5]C86PN>&ULY7U9>MP MA*OLL%U=?9\86!(6IRA2UD\N0+=//Q;/K+4_83??H$IG&6QM//OSS]_=-K8I_^US_^]K>__PV3E[-X=@+3Q9,7'?@%I"=?QXOC)W\DF/_Y)'>SDR=_S+H_QU\\(?]8 M?NC%[/2\&W\^7CSAE+.;?^U^CE3D)*4F62L@TF=!O,N)9* 2A+#49OY_/O_, M&,\ZX>M&.U7>QHACP1&G<@S2@W:!+1N=C*=__ER^!#^')RC<=+[\]9>GQXO% MZ<_/GGW]^O6G;Z&;_#3K/C_CE(IGE^]^NGK[MUOO_RJ6[V;.N6?+OWY_ZWR\ M[HW8+'OV[U_??HS'<.+)>#I?^&DL'7$_N?$?YC5R^ MC927".-$L)^^S=/3?_SMR9,+=72S"7R _*1\__W#FVM=^K-N/!W[TV/?G?B? MXNSD67G7LQGD^^O'7>0?WGJSTZ/23$N%1<] M_^>/#S_[ 2+Z23R;+&5^B[^OFBB=]< #WQ8P39"N=K27M-C(= X)?YC/)N-4 MF/W<3XK1/AX#+.;[J>'>5BOJ9S<)OBNN +B$,)G%:V^:%([.NLM/3GR R?+5 MT=F$D3?96Q4%$<8:(C,^U3;D3#252@E/HTCANM)6 M@BU9G?T\+*F]:APISNDSF"SFEZ\4]5)"V8KA_[D6Q85.>X@4X^QLNI@?3=.[ MQ3%T'R "CEAA O/?8'$IJA,!K%6,*)=QV-+1$&PJ$:N444%IF9QM(NHVZ*ZK MX JQCKKX9-8EZ'"D?_KD*Y1Q>37H7T#U7;S%N.M#SNH=S^9G)R?+-LEX 2>7 MGR\S0"V&+&:M#7-!"92H+V?>=W#JQ^G5M]/R#%Y"L90F+P,.R#RCL,)(8B-S MA'/MHW%4&='D<5B+9AM.\$?'B?Z*K\:!EQ 6'R'B\+P8PW?A%$3.O=<$N-%$ M,BG09>&*T*"B\Q3=%\5;<& MFFTX(!X=!_HKOAH'7OCY,0Y/Y=NK_SG#P6D" M9];_\Y Q&.M@D.-H,?* $!R0@(7.-T*2E/L?HA&G!B:W0;<,1 M^>@X4M\PU3CS9OH%LZ,TAKI-9":ZD-)SP(')J=P9"?*L2)-LP\)XSX64O? M>0N,0_*@>_+F+C>ZMJ6J/2?O3J%#O4P_OP4_ATM4YY>8>#069$J$,Q.)-#82 M;W DX,P%R[/RFOH6[-D,:TCN=67"5+1'/8Z4 '"-G,X[&4!FDE5@.+!30X+W MBAC&F976&!]<$W*LQS,DA[LV*RI8H,74BN/9Q\4L_GD\FZ!ZY\7;6YR/>% I M1'0:;(Z)2/P545$4UT!PD:8$N6JJRCTW6)C=@&NCT6)\8M>Q2C2AKY O96E/B6F=4P6$R MP0A(D:R%LZ QVC6T!3_N&_X&,S_6IT5/*U1CPT4\/+2X0A:6PH2[6!UV4#&@3AH%8B+('7FEH%OLF2R M8=-I"#LN.]GX5HRXMX8K;JG,,.Y8G+^?^.D"'\CRU)R6<;6LWTB.8ZG$)R8Y M+G'*Q>"TK-L0$ PGV^2$5TU&L$V@AC3%5:! -?U78\3K\12E?CO^ NG-=.&G MG\=E^6(I:<$$G IGD*!1!$\D.F7$1O3%J.9@M; 19]T6G-@,:T@S7 565+1! MHXVWWV;3N!JWHK$Y82Q*$BM;0#$DXB65..$RSG'DRJY-.L)=@(:WM=*+"U7T MWFC5\$-1X;O\^_R"G",;DK(Z)<(\+3L'"@AZA:HNTRX&IY^\).A'^-S-H3R((ADP#!@YX)DRPUZW9IKUL3[78MF&Q+H M1T2"WAIO&?FBHRHX59$$0 C2E! N,$\2-2G3S&P*3?;;ZB_\E76&V739[G+O M^MW9HN28EK3=D65)F^0\ 5.D!'S>+!J0,"C]%->^%/QPL_N8)SQ)U'A\P(E-)F(B4^X3:P3#+^[C,+ MQD!L$C/?"VU(451EHE2V2SV^Q'AV4K0,%WF5".BT@V.8SM'-?S.-LQ-X.YL7 M__Y=_N2_C0"LDLHKP@-%D$X(8I.5A.7L(QC*$&>C[?M=< XI\JK-I(86JT:K M#[#PXRFD5[Z;XE@XOP+Z)>1Q'"]&QAG0/F82O4SH:$2..DB<@$:?$-T%DVV3 M8>A^:$,*U2J3I[)=6NSACHQ0*)X 0HU%#S2!QV#!4L)%2>R5 GW2)CD>=VYE M5LMBN>(4.TO1S6:"B*Q$R6;+Q+(2*T9"1"S):IS R(0^0P[38@/, V;;\!H8X!;A#B[\]N MJN@M_M[W;.+Z WWO?4%[#(LQ=G<=S];G$[=IN>89Q9TE:7G \^,"ORY3-69Y M-3_@7WU)V[CB3Q=/>D_M]NJR[='0?66O=&X40Y,?<H5)*(Y!T^<-$1 MKV0@6E%'(P0;0Y,%V6LH^I_CN&SI-0Y:%YD_9^AP_-#N<\BS;A6?85@&\U?? M%IW'\7,\]=WY&[3'3EH!71VQ? Y3#!(7HQ2"R-Q&PB@H M(J6R&")&]):]E]8DR3EMLK=Z!YX=757RJ.C43_N5J="&VR"L9H)1XKB(1&H5 MB0V:$6-10LU%RB8_Z@%N'W5?M'/1]=)='5$C+$3T<%T.!NWN%?$:!1/<D6EB&-WT-AYNW'MY\)ZR='7!F79,8 R01)I T6QR4C<5Q".2WST3DC MC+1-\B;78!G20L-0N=37A!5/'LR7N>VK*0E1>)NX=(+$J#21P6?B6.2$>\$S MB\F";;)><1-(_PV+.:!^RCGQE_ %)K-ENN.J]9$O*=E)*B*HIV4/)1"7<"Z/ M"0+C/"@J&NU5;$ UI$&X%R]N;U+4LD4UWO\3?:_.3\IYV72"9XZ!'&_"DVX'=XVO*Y* MD8KFJ.IAO.4 M;(CPDF$$7)*!'4)! 2W3Z-MYV8S0=\<+]SK/;0>UOB18Q^N]M5XQ!VSY7%U& MTIV/BS_&B^,79_,%"MF]^A8G9R51MDS(^"^59#4A%%#!$Y&&XI?$+;$N1!(8 M4\Y93ADT69?8 ^N0?.O:!&IMNIJ5$&XF/WY/?,1 , F5*3$AH8>G?2).!DV4 MCL8&!CRE)BE6&S!5\1_7M'_TQ8\GI:!3GG5S/X$?)[..TG^CT59'-Y<8WA>W M&%FZ6'3C<+8HG_HTN]B$'W&<2K-%%X<9+PIG/+',,G2*$U.*T\Q5DTHIC>4: MUDI)'<:N]64'0HUJC_?US;1H* <7$_IV$M ?-YP$PR@)+I;3A5:%-D=;-F0* M//222ALN[:_V@V1$]4EHJ9$W5:__H:3Y#" 'Z\6QGWZ&^7CZ$3\)UX_+M3#3 MIOX.9Y:MI3Z8&?S\^/5D]K5-UMN/U@^HXO42U'_"@NQE\N$E:#+2M&((BC496Z&;ZJ9J2%S+NN[%V%9\MEZ90CGS"&DG$F@4*Z" "NLU2$V2Y>^&]6@ M]M >C#G[FJDAXI]1XUV3-\#Y@.V[! M_47YT\-8O2E4HITUD#;6/2KCHTV&930YU0)G5J>)MQ+]L!1U%"IGSV\L6=V. MJO;J> Y?;\,;^-7C3T!9UD]5*,COJX5INU$@$#LA-42H[XL1+$9@7P @P$1U.ODPW M*EYQ%Z)MF./^(K-=7?,<*OD5J&'HV&&\C-/2.OP]R%]4Y5ASUT5@A:"I7%T4B V00QY(?A@/N+_M:N:1K--!68^:W] !."\B1PO+N357-32T9KT;/?SY%X:.--$K'<+ZDQ%O8Q$A^6YW,"-Z SUZ9)9OB]R(967N(@ MK*IJKG8LNH/@3 GC*/$Z^D+P1)R(DD1MG>%48C#=9KC:!MUCV$-LSJ;>9JO. MJ->S[N,L+[[Z#D;.22,TQL_&*DJD39Q8K1,QS(&.%ICB3=(4UF!Y#/N&K=BR MKTG:C387&PE7M[\3HZ%(J+T1I5B@(4YE06)P7BG'=&1-F7(GLL>P7]A\E.EE MKG8L6L9%J(QT5N3^ON["$Q0RA\P#+C^PI5WOH=N/$NW _;5 MH:Y7W^(R*_F#7\"KG"$N1NC21<\S)9'&LAJD&4[2J$O+/$[,D6?)FRS)'5;, M1JL,ZU9:2@43JZ0@5)?#4B[P Y^9&B[;UR3?MN# M@ZR$<4&C3)FH(!T.;*[<6 R!>&XABBQXP/",NE")VY0H/E$'Y.@:B(.JK_/H.=J7 P_! M442DC3% #/"(:I":!,DDR2P'50*2T.;4P[X<[;>C\&8^/RO%W=_E:W=;@1'> M.2!1BA*_HW_L%$)VAMELA9$B-JE=>B^R(;DYC3BU:<>@O[5JWOG]8R.CP'AW MNCRO^NH;='&,FAAY+81)LERHESB13N$\)%%\2#R[(%CBNDFMR7N1#0 2 M];=6$Q+]X;O.E[J1%XCF(YT9!(^T!E\JH@3NRFY%(,8Z&@3B\;M2\V\*[[[*>K7"E?JI'.8S=>$GV6GY_-QU/8[WJ0K=JM=D1Z=RDJ MG39_[N?C^2R_[V".'N1%8M4>VEK73#7EW(NQG2Y>ELOX)GL1:$-K+36S%G$E M!7TLHU1W/LL?QY^GXSR.."ZLDNAQ['D_FXQC<57W4-:6+5=3W#Z2'%2)[97Y M4$H=@')_*U-:V1_H\7COV=.!E;U9TDI*OUB56F[$[*/)JQ^OIIX[,=67^=/% M=FX_R3]=V1.N+/\Z?/6UT.-16M-*"SUL?@1Z'-AZ"6'Q(TEF=6WET31=N;(P M\A"R9$ 2+[>*&,N)]RZ3%$%#\<3ES:*9=YS4NK^O_HG^:WH8<2%BUCP0'KC M:()9XG-BA'*3!%.BW&O1)N-_#9HAK BUL/SM=/^^IJAX_.,JE"ORZ6PYHL$P MTRZ+M"]W'LH9W>A,9"9+UZ8@^EV AK#0TX-U^ISU)H3 MUF*J."NNVN_G&UQOI(7\C7V#52\]?8,;K;300PO?X,>QFXMNSLN%!9)#SDH8 M8EBY&H>E3'+,)\/K)"@,)_ MA)KE/=TI$5>.N(;@4J0HJ8A-:K^NAS,$'Z$W VZ?X.JM^8HG 5=87I?+?8XA M_7,V2_-1UD8Z58J8)U.*!IF2CL H,49I8$PJ*6U3%ER#,P1OH!T+]M=\^XG_ M>B&@4M+VHOSUM5.8>TP(6[5;;8K878I*L^_O7.S0^D%5V= =V:;['G[* M+LT?5*4M/9OK_1^MNK_H]S):]WJGL8H6)2PQ+%4?H"W6(\'T\_CP0WAG$NB$D:B,R,$X+!9_5;S^N*OZX.$O+^II*^>101*H= M0V 22' \$J^"Y3884,#NFW=VZ&](>2RM:-!*_74K=EV74W/!'8I*7$J&2(<# M5F#!$4:-SR%ERG.3N/F^"?'>HZR/DB&5#'&(E=,;-0[V6CU;5R>ASMK9)G35 MEA"O=])G-75M2\W4T71=]7I7'^,QI+,)S&X5"NNU[+IK)\U4N:-\E4*;LK2R M@+?C+R6]\GJW9?E& ,61)I?2V GGCL#0R?0\$Q:]H^A]VNB;1#6;8?6=G#:T M_L^NW%21P'H:M27\HJ*(*W<'!E\*C# O4XI,-"D *XDB90[Z[4W $T"Y=VA#JJR MT,-0JX81#^\NU0?+VWG>S4XR2S]]/?.D^E9.$IR55:HI3R5YK MH!O:J[CHN2WJ ZBISQ+\O:T>1&5-E]SO[K;74OO]S1Y$=6V7UJ_T>W2EWS+0 M!T$]M4X1PY(M!8 ]"50EHA)U0H"//#1:4[\;5(5C8>O;OO!L0J9,TAP)%PXG M&X;X/#6<>*&-ESI8T\9CV QK2'YG-<:L.0Q6RS+U2IG_\$FNUD3&GR>PU/_T MFJ]RIP@CRY(4,4D24KDS.2LH%>V0"28R[X!S$9N4S:DEP*#\TV84?!!SM_=9 ME]7/WH7)^/.RO;UFPUMM5)OZ-J.KY"/<[&1_A^J.EIJIHZ'C=+.K&K',O6TV M4]1!8IF;G7X\.T6EE&?>3Y[[2=D9_G@,Y=K5/.M.^I[M[-%;,S7O*W$EA_6N M>W& :IY-5$08739JN"8V>D6<D!$V12DEBN9]# M^E1N>"D9^(929IAG/(0#2CN@\S(U>7)K+Z^>4>IM]*['=.6@A@],).8UR3PP M@H 8L9 9"5Q"U. IA28WQMV+;$CY(@>DRYZF.;R;^/WH;[DA>C8M9QMGN;P) M17HQFR]*(F!)?J@ZP>W69<-9KH?LE::Z):;2V2APH"[K3(0'7V[E!N(9DL6[ M0$$ZPUQL,MQ_1]!WE/IXC%'3)^A.?LA$M:8>: GE2U&@% 4^6< (!0;<+21#FGSJ&+V?LALY)$L<+*,07B$.538,N;4FUK%Z3W4_@%?Q/<]F=3G1&%93*URY#[>F3[%3A^T\BOWEKN9/ MS.< =WBEER7N7YZ5V]2ER$%;C%Q40#X*38)2AN1L( A!#84F9^VW!=AWB-JV MG]]0\9^^PN0+_#J;+H[G(VZ43CX8$E501!INB0TA$(JC*M@L3;Z927U8Q=P$ M/"S/I@'[;HZ&![%LM:ER6[3_%WSWZ>MLQ'PTSN)4KDN0*$6@Q K\21F@&41T MRC9)B]L1Y[!%\.L^0%= 7CZ]E9-S+E#!-P0UPN M%XTS)HDS,1"F@\LI94>-O&\JWK/O87EI#0ET"-L\S&B%C("1SKD47@\DQ>R( MI&QYK44B*43%M+6,NB8G3G9&.J0#*<,;L7:VY8-0;OE@L*B=Y'O.-%;O]+.-C?N@-?4AG=B&,.L*B" M70YC6>6F[(=>6 DR!>J5)HIE3:36G#C'-!%:N^"ID*'-GL<@%E9^GR9\H$KA M8$BOOI6"4D1<0FX<(Z@UXI:H5D0S\H%BEEIF:606C;)C=P+[:-<4MF% M=SN-FE5LVCH78I098&#-@(0<#9%<*Q+0BR#4!>Y*C081FB1U;Y4;]$C61_I0 MJ(9=VL^JJZKFVWUT_)8UVL_[O[E)V?P*T:H9QWL?^BL I&-E>HN_I[FDW]AW*7"K;V>7FG8H\GL5[G;?7?7Q^U8K\ED.\8 M7X[G<3(K,$99)0DE"R<$X8F,O*3> B6<22>8IP%XDRO)[T14X\Z$U6UDZ^2U MG"J$P*U M,=8!-JS'L537Q4G@Q6R"))QU%W;YW,%RDMAK1_J^-NMM.>^$OE:A@7LZ[7- M8LNF#Z; EI[];[!X.YO/3Z%[,3LYF4T_XM]AK\AG;4/U0I[[<;;4R/Z>_:;F MVFJGH6>_MK\^8?.F]MIJZ> /U]%T,7XYGIR54BP_;HZLK;S-O;15Z0X2UKIO MO'2+$1*D^PRMWTV[7< M6'4'J?NT[#K<[/H]=,NB1\L:2/B&^5%$(./%>5^E[MY3727WE+0I<_]8QF^0 MCKY YS^70L9G)Z?+7-#J5+Z_J\;? M.H^$C'O7^KRSK6K:V0YM8]7TH-!]33975$LJE4AGO%RF7J[8E/O,/L,T[KF5 MOJ&U:EK:%G%S!?6@U/V-'D!=]])JM3A/@ 1YP" !4 !A=7!H+3(P,C$P,S,Q7V1E9BYX;6SMO5MS6SF2 M+OH^OZ)VS>M&%^Z7CNG9(;NJ^OB$RW;8[JF]GQ@)("%S%T7JD)3+GE]_$M3% M$D52B^0"*D_?OS7QU^9__%__>>__=M__ _&_O>+]Z]_^'F2+LYP//_AY11ACOF' M/X?S3S_\GG'VQP]E.CG[X??)](_A9V#L/Q=_]')R_G4Z//TT_T%R*99_._U[ MXJIDK2TKUB#34!2#4#(KR#4JY;DO\G^>_ET(66RFGSL;3/V88$'$P((I*6I M&Z)8/'0T'/_Q]_I/A!G^0,*-9XMO__'CI_G\_.\__?3GGW_^[4NKCW^Y]_D_U>+3(H3PT^*W-Q^=#5=]D!XK?OK?O[W^D#[A&;#A M>#:'(^+[S^X5[^0,AGTJ^-ZC>T"[>! [ MP[.(TSZAWGGN+9S7()<1UD?"Q70X'L+Y)YB>P=_2Y.RG!<:7$YJ,W\$I/HP/ M+LX_L3JK0U?7OUA/JN/>#@ESF.,^8??QCF?_PX M++IP$7WQ/ AM;?;@%S"JL^N' M3XCSV6YJ>_"I_>ES.P&6%.V"\"(;-#$E;77TZ+DM3D>A@ >C!]N)LIL%5C_W M'4S)+?B$\V&"#HO!2BMT>7*/EMA:D"5KJ&*2X])B%$&33P+".D0=$Y=H=<;! M]B+U-28^S.G?ZJ?-)N4MK50+!V(&8_K0V?D4/]6I]3.^GLSZ&S!;O++I:-I5 M].6AIB%[D%YZ8[0-"63(N2@C18DQ>K5ZJ&WQ\JJ#:RV,)ND.EE%U^28W:]0( M(HX6/QUR.9]R6P6( ;'X7)3K<0;1G(7<&^BWBE:^Q MHS-2(ZA>[3R?]*C92_.1 #_^,)EFG/[C1]Z3I7\EN6D8+2#]3@'ERXO9?'*& MTU^^I-%%C45/9C.D_^6/\&4@::+E*@*3A(YIH00#'3ES', [8Q)$T9 ,VV ] M/%_V,_!JMC2SSGU"B7T)=37ICD]_^7)>9^=OBE!>20,A,6NK(K1-+$KOF,FJ MQ Q&@9,M:+,6T9.?3/K1=0,2O)S,YF_+%7L'J"+%)]RS' 5G.@9#(CI"%'C2 M/"2AI[QJX_S3SB]$?S5.)&;>R7^&YP/K,2B$FJ:P3 R;8VE MEB[4Z%'Y]ZEA^O I9S2?78L\ /0<-"\LY^HYY^B8 M%RDP@^@4>(W6-B'#,I#G8OZ]%'S?X+:W2/*2B77/;A#)V85$#FY2TE.TY"FX ME28RFK; I.(A<-\TAOR&Y?E$CSOJMX''2,L13G$VOT2TF(\&$HT' 8HY)8G2 M"33S7$B&J>X/1X]RS4<7Q IOVW>O\ RF>+E MYS["%YS]\H4F.WK_< S3KPNEO)G0;\=STNQHP>=+*0>6:V4BMZR 2DP7"I$! M#+#$#12+N43?9+9H*-,SH.#CL'<#Y_4&\M4*^H+"\S*<#X))SBKRE+30-*D& MB;0H:Z!87*B@4U'<-]D%68/GF5!H/STW<%#)1[Z]DH;DC F!853 M-&.Q4*! M5*A+J14"=+ MC'X'Q9,W]>XZ;>&0UO7RSCGR-VP$]&TA2KZKT34I>#Z?#N/% M'"BR_CBYS#:X<=)]Y-E;;YFQ,9-?G30+20H6G+01M1?"FF91[/[XGSRICF'' M^W1TK>AX\AF&HPJ8EM$9C/ #IHLI68C"Q/Q_+V;SJL@.8@Z2-!ISU"P[(\@Q MI)DT)%(Q!7[)BJ)#T$WVX1K+=81P_1A\Z\CY8Y"ER8'C/0:K_%.M#L5G*TF:?:"VF)S^%]J7O^U3P^U+A%YB.*2B8O>XIN+JIRW90'U[<6\%HC43)IEU#%J)\%[YCG4 MNI=8PPG0S%H3H0"%ET*U8,MN<)\\B0Y@I16KS]Y9=#=:^%@7Q8%-I3B1#,OH M)-,EN[I& TMH8P 7:";,31-!%S!Z),.M\J+F%-A#EZL9_ M_#B?7N"W'T[&<_PR_V6T>.$_?ISAZ=D]%[$['6;3^>#==)(OTOSM] -./P\3 MGGP9S@;2I9BBSBS%$(F?9+KH"C">C7<2-=?0)>*CY]\B WVW3(1U 'JDPH:J MK@W4V,&6DQYUVJ/'>0M//2R[0C3[>3%==@(U6"HMZ\G@]]'TN1JLJXO[9O-^ M#'7?ZCUI^6 40.LP!Q2L(%"4IGQB0(:_+9RB@?"*HQ&<.>=)/ R+.^@.)S+UZ-E M)GVIM4%%Q)6(5V!LRNC!+._]S^2(K_NY9S<"ZV4\:HHJ4$XX"58;K,*PF4# M9=^*OX,6?;[\!.-3G W'B]CUTV1$S)W]\O]=#.=?FS!CT_L.QH3.0B\7\F)1 MWH(M LE=T"D*H;/5V<18I-?Y8G/OA9Y1EB(\K4N0#<4Q#BW%,28P#M)G M50(8;++P]U_H^6J32XB+ M\3>[M5@$NIB:9 YLC?2[I%I/AFN0"+QQ;% $<]7N\6VY_'I>Z^^^)=X,2D)O MI!!,@@U,AYI&(U R;U4-BI7VODE_C?U@?Y<<;&'2!JG)"_0GX_P[3*= \?*: MP?2.R(33:8VL[WY^@&AX+HK7)B::_ 2)A%\*AMK8S(.FZ+U))<6^P+\#4A[* MK T2JK^E&,X^3DYR7I@&1N]@F%^-7\+Y< ZCQ0BK/5,7^WDXGBWV]]XC*7(V MG./5#O6EM.\Q34XO#;P0?)"2MQ;L M>=/Z4='B@(G;M_.!!TJ3DTSQ.&&L+@S/A@7!28$V"YYYTZ]W M\S1(SMOK10AM&8"/S0"N[1H,\-]FB[[[=VLNF8=!22(R")>35=2F1Q#2" M61ETR2G8TJ83P$.;AGLGCWJ13 1?F/61%B>C#/.Q)((B!(:(P4&3_/1'DSRZ MS[G)'KH\=O+H/1$NV547HLFX^D*+E"HG:'J1,C.5N:,YK*94"9&8@")C59-N MW&-V%:I'DEZZE;77$6=OK3TK$)UV)S3!M9;KFKI M3?4'XX64,3E/SDVPBZS+:!@HZYFO]P((3$G')I'# ?FP)A'U6'381N-MBA^O M/:^K]#J3E2:WJ#JDP3/M.2VFIE@&0@>!/G*,K8_<#YVYV*.%UI^F[Z#>!MD6 M:[9$KL"E6!LX9:F*-) MC]XYR8KYNGKW.@<_%B6!B&RE"(1JT3DX*H;H(@&+4?,FD\AJ.,^!$3TH>FU. MQ!$2X5_"[-.OH\F?;:ZO^?;TPZ4NKQ9H*5'9%\.#]U%ZZ73T+O(@HO/6&"6# MC*Y#HO(JT7:PT-OI*8RO^OA"[?(\2]/A(@]B4EYR&6 M[ %U;5491>!%)P-!UGQQ'FI' >D !]N*LX,E:C$Z&?;=%&=DXL6;=E'\JL?T MI><'(2[GXWL#MDAA*#BB $D!!, DBD (&HT?/ "V'RW^7*?,T4XLWO"TACI= M"7A9M281/65)SCDMH_;.JQ)+T25R)>Q*U:Z OH.&/UR^]<^]R MWW.X;3^ $Y1# 3FDJ,S3&EOF!:%,^!.,:E\5HX6+<%7 M7]B[]R;B>E"'CP1[YL?]S<6>+-!BG_%R[-5"\,4FQGM,./Q;D870/_!GB0@PPZV,QRJI<-V&19J.G1W$N9!(D0;9,\]V[PGA]U M^K=*JY*PI50?JZQ8]/4.&>B?A(SP&1:!7$/%HP5L5P]QY/K QIS84]LMJK32 M)\P7(WQ;UHI^F>V!G%MGT+%L:YN8E *+,4C&DRX;+8'USD"B2:^;1'Q8Q0EB9#KIE7 M,K&,/M+_%QMD%Q^X4S.O+H".EFG5A 63AM;HN=_;0_BN3HBZ(.R[_U\W:(=O M!MB_2;?@RQ[V.!)SM)$N*,6$536?69'+;@K!#<;J5&(FM_TY,&9##\%'09@M MS'!@HGPKB[HZ._92N,B]8:DH4=NI[G\5I"=QA6]:U M,.XVB],^EFF2('930$>QWAO\\]8NZG0RIB_3Y7'T8D1!<4J:Z,C#I]5:RR)8 MX X8T'@"4?O]A2;;FUNA?):.3WM[-0C0/]+GOE'_BO!=,+7,15\%ZCBIZ UM M.6EDB 8[@*NQ*6%C_>N\YD=)6A"%N0+I@B:K1"DWZ"2Z=B+[Y615R6;_ 0#=3S,*RW/!JI&;ET MEHD4C1"@$G==O-[]CR6_87K6SDE?MFBP5WP/6@5V7:+5 5I+CV0#MN,X)KW9 M\2%^[&F$)@52ZR&JXHU.A*X(2$P'[QC-?(YPAJA,SD'Q1N7R!^;' [[),>BQ MC>Y;T(*.0^Y30+,9ER' M=T)ZL^$R-WHTP&&\D!$XG-G>93D@9;8Q18L^ZC#"V7O\ MC..+>O7NU8JI%*;,C6'6UX,'5_L^91=9]N 46).<:+)[LA+-(W!4]C+:IQU*_P?^=3*]]J,L]0P^)UE9RQ&J18FW^11Y3O7T3>,$8D.#(+LVC M.AT)WG_]L_0[>M!TCQU]*YHW<$:BWL%T1>\NH/I./UF+YO 9)_N::=)*QSUG M"JP'ERC@BL[2K,;KW>M@:F-"D1ERPP&\5N"Z'+$\1L-O2!PYB-VW46V/]JZ5 M88,/YYB&,*)Y;5&FE;Z^'5_WC\@*MK#5[ MX!V'S>7HR0*3_M77X_*]&M;'/R?7YR\^VQ*<9M+7#D-2<>:!_O.^ZCS70EHJWC31!.4B M+P:D+B7XDI,1P:6DI5=2#]: VT]+"Z]M7UU=/:2!QE;!6]);$9K^C^<8: T2 M5@=O@HQ)!I--*GA';_>![J>]/:J/5SRE@?ZZ5 V'B$8EBT58U (P(G'0.Z$E M3=&(?M%UK]1N$@/NG.!Q^N;6@H;("B+D>*]0O%>=8L"ISA".6%=$$K; M-MER&U'MNYGP,\;YM\=>5Q$FH^MU38:!%375UB06LP,*F;PH*1"!19.ZJY5H M#K^9T!\/EG<2]E=W@]..NZ#>3,;I"E?@H(N0F>E MM+)>!:*M0R5D"7'8E5L M<@O6.D#/EPD[*KWO:&,E/4_&^18\IXLFL27CBPNVN/<,DD!FHN):">&YZN:? M/ORNYV#N%FIMD-K[:CS'*2VFMZJ!%9<)Y_)CZJP?IU,Z[;WO\93A-'POS'_DQ2WN +#9FF, ME99QSFFUJM%S])DB+IFE]#:'$&3[5>%AH,^)-DV-U. H?)4F+C?B0RS>I$@S MFU[2^10"V3L:Y$)*M$VRKM8B.E2U=CMR]*/L8U=F7TOSZW ,X[J]\VH\ MH_?51R[V=25H)4.IUQ1K9!IHF027.8N(16E5BFO3V7P-GF.=>/5D[$G_2F]1 M3#*%\:S4G?UQOKS8;3@^?5M6H)W5Q+39ZE]=]_#M($O32J4>A3E.IDXO+%FN M5SFVB1\[;95TTD$-!;RK)1]!DZ,(@0E7 )Q7W.HF\][CI^L#24*/GJW;6+;O M2+\VHZZKQC\OH%X(BYB_[::^K+<8UR:,<[QN5EZ?*C!(0NA9$8A MJE19H8NZ6]2_W7N/4'5U- -/#F.=WH\R/TVF\X\X/7LYF9Y/IH3J;JQRG2SE M"X4?-5G<>,VT*84%F2G<]1B@&*X@\$X$ZO:^[Y4X#:S1)-GU[(P\WF&]3X5< MW^NCV]HZP6G+G#:>0E8O61#@:NLJK96):+')OL)*--\A@?JS3H,-RG]]^%AO M>KV8?GTQ'(WN$=IAU!CKU:= $+7WP )P9$EQHQT:X7R3>HS-L+YC$O5HKP9[ MGK?03:JBEM"%6#,=7&*Y*.)ZE)8%+(*!%F"5ES15-G&Y-\/ZBTU]V*O'S<[% MBOM_8/P'8H5U?:U3J1D>)"=XFAYKRUU:6V7MP.NAU$T^T=%57G[R=VC__37< M8P+VM_7QRK5:R45C$#W7B2'%F$Q+Z6F=M)IE29%F0.Z#;'([]494WR%U^K?6 M?2K9ENF"8V+ACG=_W/[S/I.W5D):SMI",* CSS()[:4"*!SHVX@J60U^L ;< M?EK:+UWP[D,::*Q#NB!W*OC"I;.":QV%%UIH&8,WSDHERF CT/VTMV>ZX-)3 M&NBO4[J@Q$"1:T')O4[*T,P@4TA12IERC':P&>H.&GPWQ7,8YE^^G-=[WV9P MU9C_.K]C-L/=LGT[/;,EDM"$D)81.-H N$;+*D1<15 R#;<5I M9(G=IX@MGGY(JW285*(H-"J2,&A!(^65QYR]TT8'I2'I[.A_X&KZ#_!.1NIG1GLUGL/X=$CVWGWVNO>, M_M:#3>"6E$H>" J/BD(!J961,>NBBD;8/:@N7TL"KHJUTJGM6@14@_S5BXMDW:>K1!=SA]PQZY\R*+*=^;=*@&&.# M$OXYK9F=RDE"XA/+HK8R5TDS$"4SKHT%L*%NCAUXT"R ?5=\V<$6#FR=3WFD[/)='YU$?8 2KT02"L6=U)'Q/HM.*S=AE-L4]*S/=3OBT]] MV*O!L>L&Q&]P/BA&R"@RLJ)JH^J@ P-O!4LZ@H<2R4MLLMF]&=;WQ9QM[=#@ M./5;%YX-."^3E"F(<(5'PV*J1W6USBW0BLJX2PESBJ U;\&8[A /50_0G#.- MK/*(Z@36"?7BZV6[B1',+GO"I)#!YGHAJDBN7JP2< MRTY8(3AG3F%D&B4-2D]Q""@BB76T-LA#[YP:E]L$3MX$T_%>"$4*H%@>Z@>%2.^OXVF_2E\ ;;2K7N M?#3"-+^ T76KS"MDR1FWN#+> J\R9L>"5IR)+)5+BBN*)UI083VDY\V+GDS1 M)B___&*.TP^3,O\3IKBDBBN0W BO;!0LRSIQ6DC,.PH['7*?(*F29),MI$[H MGC=U^C?0VCVC%DEM2QL7,)TNKM;L\?SNWC-;'==M!K]T.D>VR-+7\^@0-&3O M@Q51YF*%M-+I=.]T;I,8.R5?W.J-#+=Z(X]QOHO6-SZOO_2*KJ"7,^F2]L9Z ME;CGFD/Q2D1P*LN,"HOQ@Z[P>];T/@E(#S[U$%KODBI@O=;)0,F!:RU\-$+; MR+F4BNR0TD;=]Y1HM/X%>R48/?S80]B@RW1CM DZ^)BS\SKF$KR"9# 7'DR0 M>O, Z.?X?VTW]F];FSPH'G6]VC(XR72TEH6H#0O9 2U9T9CE1K<]12 /0ML[ MTEKWALM#0U\<9I4*XQ:0(DV-M#RC9>"B4R98FJ2:'.!NAG5XQZEGCMP+O_JS M0H-X[-9YW\]X/JW]C!?7E2/-10NUC^^< ZX59F! ^B259BEJ7F\$-;7V*;)@ MT'>^.8MD6^T7K@-4#QP16*<3$>*YEXS845A,NF75"0+967]G#3<]X'_@FAW#LY8&#"N:*Z9+2BR:8)@15A [EA83(BT0F,JW( M.D?) E>..9.$<=H;D[MHQ=5Z4(_(<=[5BO-X$.P-=>;5FE#!/>"'P%2GLIN'>Z)ER&&OH5!@(=\=>3],IZ$YO2%KFC1,L)R%%0!]MFX+)-7B>'QOZ4/S: M_9?^4RH6D]G;.!J>+K:)=CK9O/>,OHXQ-X-;;H*@093@,^>1TT(+GLY M>%]^:!_I/0\^LY66MTKO\2 #@O:@;-39\YBM$D&9#%X#&'Y/W_>>OJ]/.9LA M+E[R,\[2='A^I87KG4;@I?8U9SI%FA"+3% SS+COFD4MOK4^E38WK.D"'7R;[ M9,2]\\T^U-X@LGI+*&A0C4\78K\?GGZ:ORW_FEUFU U*B#%1Y,="3KHZ!8&< M I'H*PS&!=2ES>6=&U$]+V+T9X 6L=4=<*^'$(>C(9$V6:^41&39QMJ(. <& M5DJ&PA*+,:94FF0AK<'SG!FQF](;1%=W8?V.E:F83S[33T_QY^$L32[&\_=U M:L-IJID8UD!-I:88T').T:"Q])4)--%)8\%;KCBV)\G#0)\S>WHV4X-#\DM= M+,V"6-5X_5V]F&%@ G,1%0!T$6/35)GNL%[7A1J8)*^ M^X>O@OCFHJKL;?FEQAGUX.7M0B>S06WPI13Y5)H7O+HE,"]2"'Q4M8.L"@_& M5%N_]7E0HJVR&[097\W=,?X)HP5I4T&*ZKUB6?E:C>\$@QPBLSIG*:.C2:_) M_;P/X'H>;&EAA+7]PWN<.6[FM.%XL=5P"1*CS2X LRE*TH+G+ I'M@6C3. I M"V%VGC56O?%Y<*"=DN\SP>U?W?UU<9+UZV1* 7E"S+-?24L?<5PWRD>CR9\P M3C@HVM%Z9B6SQM&A))%VT8$5+ N(T9SX$9$5$H8L2PO(FATLW")Z7^7=3['T+AQ:.Q$TL?DW2 MGR]PX 0)JU$P)U1BVI;(*#27A-/(;$NP!1KN$S\,\+GQHX%95NR<]=&1M$Y4 M"X#OIL-Q&I[7J^$N 0Z$CU8%Z5GM-$Q!-]3;5$$S$6-"$S!H:-5::SVJY\64 M_@RP@AY]M"ZZ0;>2OS8HJ14"BZ9V/I$N,$*F&>%RM2>*]:E5KZ*-P)XO2?8V MPPJ>[+WKNEKXRY1TK:+W.M&<9C10&(7(*+KFS,B *9A%PLWA3B@/6BG2?HG9 M7^7'K@R93>>##_6L<5&^BY/3*9Q_&B88+1**C30D0A$4@_- [E6]'4R6Q$*2 M6E H>#_$6H"XI=!O25;Y7%U!; M%'-TX\$Z-(ZLX+M6=KMGBW/B:PWF,/=IATD2)/2;P+)"]GZ0_/@]' M(_P-IE]'<'/7JW9/VH;BU M8[5]QO*'B_/S2R\11B]@5$.8#Y\0YZ_&94)_>-DYH[?\T2W>UBJS=%>!E_.E M4B\6/CLC:DY*S:V?C&LX.BGU0\/Q M:=T>K??9O:>?]FKF[5[9SM9[B+YD< K>K8\9M2Y9"P#( DP06C@C,$9<8?"= ME="'U6_N%_L-YE=W+E^^_F9W8K^+9_=[83.+[R[V.'J M96X8A9$0H=RW]ZX*V,':)VF1?#5[!U]KI$E,HI],+S#?>M,N1NWTW+YLM[T0 MRW46/(@H.'>!?.L@' COA"Y@"T8:I':PK3B-++%[;0HQ;2&DW>E#.JB$ZVZ:4NILN+]I@'MWG\(6W498ZC: -RRG7]\IK7 M&[N#QCK;U;WH$+L-H'YFM#>3<;J\3W?/*6SU@_K2? >82SI&ETM.PA9>8KV\ MU3OE:D]03BX$9J4&#P+N2YM[D'SC\YKJMM/-\X;3*N %4+BE??#DC;D"WJ"- MJ4!PJU7<#V]_A>'TOV!T@;_10G\QO2QGWT7%JQ_4EVX[P%R>P$-0Q0>E?$#- M/4:3C+ V$8FQS75;(<%TGFA/1BAI'+:(9'6B4A$P M&&]6Z[>7%7'EDR\;G],,?VN(7/T^3\;P'NL(HM#E!04P^TPE_;V\J07W5\?R M#=$\J1!Y$89\5*\B35.F6!FP!)^ PVI[[P1CSWR":QRW=RG^.9U]?# M+FQU@Z)6R(PFU5(G<3:?0IH/1$PF*(W,"B5J)I%BH>:V)U./ T!2Y-)$,P\B M.\*M'8=DV;T2VEXMU:"6]B7,/IV,<_U/[83Q&4:+1-;[@ 4.)4U,TZ#B]M7X,\[F9^O0Z2R*,9JS M#+DP[6)D(&-@+ELAA,P8VA!G,ZSGQI8>C="@$'>M[ -58U:)BKEH'-,43#&H M=U\CEUHG)TJT38J;UB)Z;L3H1_4-JFB_+9'![!-KX_>!NV1+H]N8/9US&IFLZ,3S]2_-=?Q9D]3--@D6@5-7D&SH5AAE&4VUZ(T MH! S>(I#$ MF98(( K09'LPEJCODR6[F*)%P^N5NYJ+5=I\)WP-XRPMH'_'$"KKZ( M,#FR%1NL9WO)X'2.7KG$"@+-WM8)%HJVC-/Z'$-R*D"74M5GP, '(K+'2,!M MC-> >#_C&8SKE;*3V? &4PI9D3YJNV6IF?;U'J6D-4W^*FLKG2FYR>*X"LSA M7:?#F?/>W9Q[VJ)!./;;9(Q??X/I'SC_]6*(VH)/I M%,:GE^>ID_'B%/[CY!U.:PGEKY/IV_DGG-XZ897>4#BN9&U(#77#N%XE%AT3 MUM1&YP*D;=)ML0_P/?C)NV*H!8MDXH59?X'I&',]JY:8T3 9,3$-SE)4ZQ/+ M1:+/3B>MFIRW]BK%41:_P[)XA<-])!;TWJ!@=TFNOJ\;-M_J-=]-:-J;#V'T MGIXVOL"3LUKI1"+*>D\*N1@JD;)=P>H9"(:\B.Q$!)[30]/^ ?%^1Y1^K"SH MN]'*'B)^'.(4\_O)5QC-OU[?RA",R=FA9-Y*P;2A>3:"0"92D"444[3LUIJE M9V!_4?=P=FVR([P8,+6C\C7PWX?S3R\O9O/)&4Y_^9)&%WDX/JV)CO2__!&^ M#()'1,DU+?3UYGOC PLN219)! ZAN%*:9$#L@/4[8N>A+-H@6?6ZYT*]#VWW MT;4XMR&\TBL-K"@9ZVT3P*+VG&49DL_>69*T!3?[$^%0B:]')^J1K/Y84F3W M$/K%UWI/[V(;G[2?U% M=3LRH,U!WLX:_';9=!+9]5]H1798;)AMH; MG/S[VD!0@31%)@=)-7%#'C&/'SBJ?BXTWL;R#>A[M:U_LXU?+U6Z/C,SJ"%D M*9GB]0*54 H+4"1+QCHN"B=_3;0@Y09,3RH^V]7*R^WD>S)1CUNSM:GJR[IE MAM-SF,Z_OH&SR_&D0C!2:L=*C)QIYPWS/A,RWB\GK^?7_;.A8*> 822/8*-MC?SW7GS@1??774_Z4-Q/:^EO\&76T" M%<]T4;0NU#M.DY,ABV MU[W=X7;GS4_0@CLK[H#IY&]P_GHRFY&3\7)R=C89 M?Z#?+WEE'3L_KWQ0;RV?'X:YE)X[>EGC3XYIJMD-;XIQRS@) >H\4)$9O9%(4-485N#0(J_7;2UOBE4_>IVGY MIN "O8XP"M DJBJ*25):GI$UQ9;6B>VJVO^K1)^/Y\.?AB *^ MS_BA]A7>NVG\]F]I:I4M!%RRE:<0";-/1O&L= \N.4;%)U^VQK:4YS+[2%93$ZV:!920J:5 M20RR"XQ+I;)QSI&+U38)L@\Q#I4(^2AH?$0&/):$R#T%?_%U]0,6^S3"D?NK MO&=H5:P)SHY%QRU#;P.X %*7)H5O#64Z_C;VX9G:[]S?&V,:Y/&L1G;K8*@+ MOI89DP\!/$XRY*-A1">F[FG.8]"N:&UC4H')6+MSV)KZ[S P$;0G&:*EP/'Y MT.V!G,4GR[9MK-B 9;^+ANK7_?.$T5*JVHO3$C"%P"*O M??D*+Z!#]B(TH==:1(\EJMK5>),6FF\0 ?T.]?1[?KVI7^]:2:$P'A*1/QO# M0.;,./ LZ@>&:FWUW#!SSPN)P7@6*.VWT+=MFV7/.DOK8FNP!= MOGKFT=U//38^KZUV.YQ[(.?2F%0B MTI#@8+T3):0B,]B4))@U.N[EX&/UH]_485<']!Y;\!V?W%;[FP59LH/-7"A% M?,_H-?DM,?&"AKZ#K%72?HT=[KUCSVVUE2^YE6?UXNNWC[R#KXLLK#]AFK_M MZ21M/0 GYZMX2^=R_ARR.0ZB@LWC1[-9M= M8!X VJ*TT"QSQYDN'EDTTK(@(TJ9G5%M*JS7X#G\*GU@5MWK+MR#75K<=;@, MZ^W%?#:'<6TU,.#<:U<@,^.4J]OK-=%"*5:0AY)2S%PV.5C9!.HOXNQJH081 MX7-1=?ZV7$IT\IE6C;J6_SJ9_K-ZNP,7E9$\ J,@ACQF;04+P7CF/+G1 M2DG4NLD]&ZT$^NY8^RB8T:#QSLYRU?:J\Z^OQK/Y]&)QR<$B,?SC)QA?QO.S MA7BS5^-W.!U.\L!DG[4E;8,4BB(]BN[!%\^$33P;(91U38X^#B7@7R/B,3"G M15>@ \GY.PY//\TQGWS&*9SBXI<_PQQO[HD8<&\1)'!F00#3D;ZBP%(SGK,7 M12%Y74TN_'XT&OAKC#T)[MT?A'KO Z'1XC.85VODER_U2QP@+U;G1-%&JJ6) M3@$#XQ,37G%T2F N35H+=(/WW=&W@=7N<\OT=@R$T\_#>@O/RBVAR>+N;1HB M53VSCY-YK6/\]ON7D]G\S63^?W#^'M/D=#S\;Y+ZV^G&;!" Z[8_;CX\S]@6$?[<"X7'0H!+KZ4?V<& !ZS56] MAK/4G2-!@GI7*"9RZ'-P4NKRM$;(2C'_&BJ/AT7WQXSK+X7V0;7/UNG],B.- M.ZYY+(5Y8Q+3,@+S4CB&)%@46MG<*&#N2X)#)VT<_BL4?3;;L OYUW[/@ M+"9A#'&KWC8)%BEH5\@2?>V2#'V$]?JXAO M8HSSNQ&,;V6?=)&I9VW:@XE*&?"HEM1"LU%A8TIR%NLF"^ M!,.B%%)'4Z]$:3)3/AWR/I3T^KBYNXU]&W#VUO4DEP=/5_EV2L]J&D&0*@:&M+<"T(R$S#TR9I(LUHEC?)1[IU-1C)8+OTZ_KQR ]-^&\!ZA> M[?$>1PM]S#X-SS].?AG/A_/K>^Z[0.V[O]:6& _?@ZL'JV[B2 .3]-SV:5O( MJ1X(\.!9YHJB=!G\=ESS;6*)GTKPM99AP M>K5*RFBYMMPQ9XPE@4UF@?/"-%-_^3;TFP.\IZ%)"?)&.9@(RG^9!HPLQ)2ZU MLX:;@.CB8,=W'CU!GBMMP23/K$7B:N22Q9PY\R!(O*QE2DTZSQP_0;Y=CLC- MH;30L>##,N4AQC]31^2>V_#S9 M-/+G-)SV8-F3*LKXKX4];N1<7(R:A6"V:,ZT=S1K6),8B2FED\DF:-+GXE " M_C6:CC*:]F#9DRK@("L4'-X6E2L?7 3%3$RT#/,2&/C 6;+*%>X$+S+^-::.,J;VXUJ#DHS#^;:E8!20%+,.!-/H,^:0G0I&S[2#%4 M=U,L;EAJ/8V?C',MU$CTY<=)_=&M>NTK QF5>)"DP% ,&:A(FN!33597.2CI MDHA:/;37^DAD>4*SVWX;/X]$WUMQI^];W]J)_\L7G*;AK)[Z7\F9("]B<9JM M=3V:\Y8%'I&A",9$GEV*X2N*4 M6W+/M-&%>5T*/BD(M7NZA@DJZ,SQ3%C M,-1;Q*H.@F QWR1]6A**8P;DD&<12 MVP&HP+P'QUSPHEAG'&"3XHU'HX&_1O3C'-$MB?RDW.RK3?J+*UH)7(2)8 M1>$_UIVO.L-9(B?WY=GN73W2W?>'#Q^6)+O:H,5WTV'"@5-]KW] GO4X>Q[NL&.C],7FB"%Q M)L!%ID5$%J37++L0?3SVH7%'4?X:3H^7.0WZ1?97#ZXX*E^\9R$F\J%\ MAGK=KV$6 W!;@(O$_VKQ]0B.J8YB\3R*\,\2L=$7ES= M8$3@3;HT/K,67UL186.+KVT,\E2Z(W61Z:\67]NW^-J**X=HD[2+H9\*B0'K MQH!-C'.H;HJ,+'JMF(M2)*/!9SQ.2?*C(>]6+;X>'7>WL>\!6WR%X&VT7E3O M.#,MA6:^*,X9PAQK-0!%Z0$TRSD$6204E%T.4YX.>[9N\74H\FQCB:8MOA"R%(C(I*R] MIVR=44V=44NJ=6Z2B_[Z3CZA%E];V6=MBZ]ME'OH%E_W5N&E3>&3V>SB['+G MN/=+K1]^5=M;KK<4]7Z7+XX<12@A:XLZ:A%2S$XA%UG*===>;R5T;U;M=DE4 M[Q;>[K5MK;V'"I8L+U.R8(RQ5H/F/H<<05A$G8HQ,MEUP=%6 ([>[,V!!.DR M,F-5[?8==.V-'%G6"H)/:(1L* D"69ZAJR?+B18'",A92BZ! M$R*@UDTVZ9_O/7C;<&['>_"VL5J+IFB]!<'9*.#5C4!>=15JQVO@B3GID]=& MY49G1-_CN>8^O#R.Q1_+N>:K,2W+^&%. [,^[G7]@RITC;)**CZX9%E.UE7O M.K/@BV8N!J]2%L;9)INH&S ]_;VQK4@R:6.L!AOQ:Z!=Q6E=P+4\RMR([CAG MDKW9LAM']C#$P=DBBLM9TL#4J6:IJ%KF%$QB@J-U* V-ER:.VQ%8\L#AWW%( MLHW^&Y#C/Y#-2]6P^)>D_XUV0)DNK ME!(L^TR#)9IZ-1;II'C.04M2@VF2AM )W7-B3/_F:++\?":I)]/AS2ETEIX+ MI3+#*"33R"GJU*:PH*(W6FLN=][9&NA;2TUYF]SBFX7*1QI#Z:AX77:!) L1)#'*P!MY^6WL#T>0/!\9(+MW+0$?P.6EZ<=M7 <3K_^I&" MRAFDQ>G#+BI>^ZR^]-L-[))R(_ HM M''[HD:WUW(7+1&3KR"N+IH!.18(G9@4\I1RG6JKN?DXXU3_^V=V=23!)T MI.5 &Z:-B QXH37!**RKIK6N2;?@AX#M'\:L?/[)V>2BEOV46S\;")^SXK00 MZHR>:5&;KI.):%W,*-!IITR3G;8M,![>,>F5.?W\)([ M]?)B.JW;BN/\9C).E]\,I')1YR(8Q)H,(9)F/I&_EDMP0GKK>6QR*T1'?,^, M0"VLTF0S9:4.KL*QV:^DM-MS_DV^S=6?#'A)I PG64(@[CNA&.14TW,S%$$. MO"U-KN[9$_]3-Z+(U%MYG/=D)[J,/2IC1K;Z?'G+%'<>S9C! =_;)M#7.XI?3Z9*T#N)9'G!O1'>>(LS=;=N/( M'H8X.%LDUQ!UK9!)'I@NJ3;\+YD9C4F$E+-OT_;L""QYX(CS."391O]]7[CP MVW"$L_EDC%?)(==9Z%PJ$5R]<2<1I"P\\Z@%,^"CE%PEDY?Z8*QI!;/Z^8_& M(][% I-^U==CD+Z ]!I/8?0KWAQS6%VL@%"/1!WY8%AERU"K%) "OF0EB-S) ME$L/?C8VW$=AAYNKEYR;RP)L\J^=\9F)4*U]Q7[,U"(!OX[EN^M !T:'\Q4?H).YMQ U?*V3>9NY++6OSA09% MK8Z/G# :R8N42:?"F]SU=BA.[.82'H 2VRB^YWK/DU*&HV$%=%GA>)TQH;($ M<#7A0B=6B]B8C_1M\8IKK\![TX4*G0H_5T,XKM.QBV$FO6JUYZ83O\$8+A/% MK['8#)P<'*92#H0%2;00#'/*R*AELCV6]BZ__$G;=B]--IC(7\#HLKL)XMU, M7>V,DECO*"W1DH]3KZ7W""R+C-9ZY,(V"?;7 ?I^/,1>3-*@^?XJ7-=>20=D M+?W"]=".XQ_V8\(.O-A#_P>:3*X[FFA3@3_'H(D?R9^:V,6N>+J>D%4L=<*Q^!^8*18 M10&1I0Q&Y1AI[EPBP9H#K%L//6PGL48ZG_2@L .V$'LY.3L;SJOP,,XO)^/Y M<'R*XS3&UL[+U[<^2X[;[?& M9QT=-RKPE.@I5\9]02BD\B+[+UZI]_"/[B_^")%5OS;'7[SS_\=O,.H!_^Q[_\PS_\T_\%P/]^ M]>6#]V;-'N_%JO1>YX*4@GM_9.6=]SCG]ND?FL>_'SS_1U0]'6",?Z[^NGFTR(X] MJ)H-?O[?OW[XRN[$/0'9JBC)BFD!1?;7HOKEAS4C987Y6;V\DT_H?X'V,:!_ M!8(01,%?OA?\AW_Y!\^KXB5O=LY]%GJWY MUY+DY0="Q5)I7[56/C^(?_ZAR.X?EJ+]W5TNY/%FEWF^TZK6$FLM@T1K^8^G MA/U\@?J.]"T/=76@7&7N1U*B9LN= MIKV,__,/ZJ?%8P%N"7E87*L)[Y/\(LCRK:+S4GS.UP\B+Y\7?N!S2GFDIJ4H M 1"C%"#*(L DYX11@F,8+\K-M[T0*_#;UU:-2I:9H!\L+"U/C-A<%.O'G&WG MNOOEL0E,S5UZMD,_K\B]*!Y(\X+25KL%M0'_HO7TUM)[:/3S?LQ67O&?LOSI MGW[>VG8!L,O)X%I.@Y16TJNU]%HU3V*U9COZ++7#L,[W@5@S8R!V!F(%@B0% MK:QHFE"(A/[/8ED6[6^ _@WP@\:I^,>SLGX^Z._KO#6$Y.Q,9S1/_,S6REUZ M*,%.OVCWTL[BGW_(%9% MY=E=Y[GZ!H1VEE\];Q_Y3)[UKZ[_(#E_^Y^/6?G\7KF'>>54%Y_*.Y'?W)'5 MIP?=1/&+:J(LWJ_J*6:!I,!!DE(0X0@JNA$2D 0S@'":)C%)B&(<&Z:92O&Y M,5>EG>!V-#59+PM,5%_Z,0A2F0+(U)Q(I/IGRFE,<1A1FHJ%6K+1]9^YG[L& MC-[3]=2D32PL)Z?)>MULLIMC3XX\>5;V +W"Y5[7:*]CM4>?O>YSC>5>9?J5 M5QOO=:SW*O.]4MGO-0!<>34$GOI4:A#<3J[4:\N6$K"A# &!*$A@ (% %-?J.DI9!RF,(ZBT,3UV&]X;J[! M9G]3*VAAOUU48BRN%[Q#QFAV3(K M,U'4O_L@U'_$-54<0%BY",($)I)@$".H',98Q %E "24H003>,$IR9C\P(= MYC:,:QW-QN\ET/_E*F?S[(@JY[].$@X 0 MI#P^$JIE%DS4U"PEA@D3H9GO-TS\W*:6CO8>6>DU:4=_N\T%RWXPVR(8#]V1 MYYE>8+VM[MXWK;U7J7]Z:K%>HP_#S>5*VU*#2=?+P]#97_4.;&48RWT1R^IX MEN3E\XU:%!>*./4"^=5S]R_7W[-BX2L*BZ#O QK%:G6+: S4XE8"&''FAS 2 MF!,;AC,7/3=V:_3S*@65"Z=4-'3?!L!N1FCC@#DRF5GA:,U5]I"XY"D+Z9-R ME#TJ^_PTH(5AW/1&T/*K8(]Y[>(]D4S]=2G>K?.O9"E^6^6"++/_$OP7DJT^ MK(MB02/E9NGX AIS'T 84T 2F8(P(H%,B( BL HRL%5@;CRUU="[52H6WGKE MD=8*(-'[%&>H1/(FBWBIZO]+>B!+Q*\E_%Z46 M6$=!=!R4%7\M\E(Y(VK9IB\OU;OFQW91DS#P8Q$'0,8ZO$XD:DV%I03*80@( M931)?6SG,XRCZ-R\BHZ=MH[#2#UIZEJ\?/^,[GQL3-1.1[54TRRY-;,-@=L: MZOU8[;'7MGJ-LM_I77*NZ16G-/?!WV;S6T?0*Z\US[M9>XV!GK*PGBO5_-CTP$;7^#] MZN%1QU@KC:)?Q3T5^8(ETI<\B0"-]/FRP!(@01, 8QS#*(X13ZWNVO?(FML, M6^GF17:+WSXLS9:CCA :>7+;+L2NO%I1?;&B LS[5FOK<)O4 !.7BZ8^<9,N M8PSLWE]8F+PR\(0U7S,A>/%.J:FC7ZJ-S%)O7#Y_DMLMS>UFY@('08 B!7&$ M0J'(@S& 8L4E(0L)0S)&B%F1A[4&.X:GXF)B/?5:^ [?6OCD/JO77J'?.AKZ>#Y*T/T,?BI[3DW5K):8];Q^* MT<$I_."&G-ZL>/M=[^>(2HUN]/3?LO*N^\I"42"):() F@040)A0@",B 0F# M* P032FW"F:^4)^YD66K=SUZ\^8FP0/IRQ8V2C^9$>6$Z(^^<=&]M-%1^LK; M[9.N/74&W)U71[_H88OM!+<_C%6:PY406_P,[XE8-WNY/_HWHM?.Y=OF)+-8 M$,1C'R.U9-5IE&&4"H#31/F?/A1^$E-$I=6I87 MN)8'0-M[D9? -ZG#V"CJ;30=QR\\A<=8+N"!O!?S]DY9WN?8G7S'CD2*O%Q\ MT;MMS=Y,S'D8,<$ 9!@"&$,$,*8^".(X9B2$$<;,A"_VVIT;-7S5^^%%F3&R M]'X51$<45;O5W]ZL[TFV,KSCN@]>/P=< ,G840Y#T3 >[R=L[QG:ZHW.L%;_ MVA_2^TU.,GI/V-$.U%-_'C:Q=[-^K/C7M'(@T@A2%@ M+ @ ) $'2(0A2%/""*;_O0G$L9ORC;O M;/H? ]B1N6$?TR:<:8R+%K;HN'0,C&5/ZB38(K+O,%B_/W$0[8=L)=Z7XKY8 MA+$?AE6J.BG4.H6D#- D%$"PE"10K54B*2>)?MVH-#=RNS@4T?NF;?,JXRR3 M>#CH8#."G+;;QG:KINFQZ0(]#T">183F5JL_1VCE 8K.8B(/6[9/\]N<"CR_ M_<[NM+R/Z@-?H#0F ?0Y\*G>1:*) @FZB<>1R1*H RCQ#3=[S$!L^/:1D>O M5=+36IKG_ST*8C\#NH!F;#ZS0\4J,7"?Z166[Z'@/2S)>Y$)Z1!_,V76RMGO/D/#WFNW0; MCHF9U _HL7-_8N][].(MHM>/>:[#DB.&XB#6<4:$)0 &@024$P:@&N%"2B8E ME#:C_%#$W 9Y51'.8[5RPS/:','2>E=G $+3[=]<>8UZHVS9[)D^TN9,*^6E MMF'VK.S9<-E_?=0!/%?3> M/DL#$3$(2%A5 *(0H#1F((12Q!&)4^A;D<\).7.CFXZ:]0Z>;33)"3C-J,4! M2".3R2$^(UR(. .#T]"1$Z*FC1KIM_<@8.3,XT,#SL0#R7@3WK9AG2I#RV85 MHI8A+(T18***Z8T(P"(6 ,5A1*5/(>.)S2K$0.;FZ2OW0 MKE6(15TB&_0-.<0MIF/S20-GHVZ%9IU(HRUHXWQU8P&0VR"U\V(GCE4SQN$P M9,W\U;EE2Y.7(A]@.3;-A@'T#1]R]?"R+4C% MKH]G\@)>*_$;;9:Z8(D $0@#J-3]F# ,)0PY1(!&+4?/=O5WQO^>OKC5O-M_<6SW; M_WU];69NQ1Q4G9'?,ET*L0T\?T^YP^S[?!9!*2[M^G.$M8S0D],E"QN@F_-: MBPM?\C!-F%"3N0[C%I*KGV*U<"88IQ3Q((%68=P]LN:VF;9?[(_M%/O[\>-: M\5: +.?,/JS-IC)'"(X\PPPK0>FR(N(8U-LG;BZU#D\1E5 MAVT/&Y\;JBO>*!^-^@F2:>*#A,=,D4C@ YHH=!&+TC 6/H?0J@;..8%S8Y)? MLU5V_WCOR5IO;UF586F# IYU$9QZI/ >_V<8]&:D8\4QN\W/C5&NOWY]>_/5CBOV #-CAN$PC!T74%>2'^/. MUW&;70[P/0F3#N?CUNT/WA-/#=P.9W>"/R[%)_DYUS&OB@947^IJ"WH15.57 MO-$A 8M4IB02! *91AA YJO51L(PX"%7#4.9\LAJM6$J>&[#N]5636I:W\TE MQSI]Z;=*9]OK4J9]8+BA-@*RHQ_670*J_?:3)4).MXA,94^[C6.)R,%6B^W[ M QV+.E1)K8ZJ$"5]3]5RSCS9P(Q&PU9)K]5RG,GT+!A.)];3TJ:=9,]:?3#A MGG_#_N+<6]5@^7S-N?IR"IU10WS*U=AYRI01BTBF5+G%& 2)SJT"PT1YS%B M.(@H\I,HM+A UR=H;I-KK:O7*'OE5>HJ2+U68?,[=;WX]I.%2]1&IHKA@%E= MMS-!XX)K=[W-3W;]SL3([C4\H^?G%J2R6^9D$06$AY'@(&)0 I@(M3272( H M)7$(R]50.O""?#-H[A9=Y*> M=BY98LD2/TT@8&D8 8@X L@/4A"$S">!I%0RJ_LCIT7-S3M6FGKE>C>E\U4; M'&XWO?3@:S8AN$%M9 IO .MF5Q[G7NMY-%PR8X^T2;GLO-7[[&/PQD4;0T53 M4;XM*"]XYX;ML2+@OA AC7D"&(D3 %E$ !5" B19%$82BSBF5D=3P_28&]-L M;G8V=E0;LHTEWH>A-^:'=I+5UMZ8T$^S[W<6]?'KJU^(Y0C;AM:JO,2>XE"\ M3FPX#F[NPGIFK\BRO@(H1/E+OGY\R%:W=<1 1I;51D=5:XW4?M^'3:U15][&+&]C ME]<:=D%&QHO[UHR#I^RQD7*0YW(8(G*\A=VN[0 MJDHE44WQMR37-]<*-6,\WC]6GO8;(3.6E8L8)40&6 *N/GE=BA("'"FZANKW MB<0Q@]2W*YQT3N3<&+BCH<=K%6UK(IU%V8PIW6(W,A>VRGJMMMZ/720;A1TF M@S-'QVUMHK-2)RX_9(K"884AXS.J=0#:PD>==:! 1D;^K$UHQ=GB(W, M+-NTDDW0^ 8]I6R=J6&$%)-]H(R2;/*HP)=).]EG^\D$E+TO#4Q%*50C8E?" ML5#TCVIU>_.'6#Z)7]>K\JY8I!CI)%$2I!R& ,HTTLGK," IY8C+$,7,RHL9 MJLC<>$=]@Z%E!LNA76#&05, .S(]U29<>03HO+2]@2% !]57WJ_8\I%748AY=6A;EGE& M'ZOBO#?KCPH=)5W-NU9L;EW[]U^LO;__UTX[]106S!?\%3ZJNM]1@&,D&)Z'#$@(2%J8!R_> .Y6W]X")!S](.U#=,[POOHO80#O-%AEH[O/D)#'=Z# M=BZ]@;HY06ENN*ZZY]U-H5G^:?5%E[_)E6:O2)$5U;6R;:Q($*1)Y,, )&G M 50_ ^S'*> B9#Z-,/>1572@4^WF1HVM<3KQ7/>\L[G K<-/NF$GK9&>\K$V M9GJ5G4,OO+KH=8CMZ1N^ M+H7831GD\>%N] AV?6?Y^X-@^J[06O^JD\AS+]U;>\_GL\[AN?!I$J4\$2!. M @2@B"A /,$@X2C NEPM(I')U#-K*^[8GJ['S.DJK.ND/. M3'^SUGU.T^C4M[VJ%!>=+U;_6BVPCB8-;K.RMN!Y%7I_#Q\O7[.JW4J?O_^/ M>,?<__]C-OF8C3W-/\5'4GNL6E7MAP9^U'BA\U9^$F]VWA#L><5_#F7MO.LB M+Q>_DO]8YZ\?BW)]KYRWZ^]9L0@A0HPB#JC>5H&!% SC@"!28 C!"D-C-S: MX\W/S9]LE?.^:>T,H^Q/(-?OF5V.Q\@ND2D4Q@S=;W'/8EZ]V%G(JW_M+^)/ MM#P);_5;U1+&F:>&G@TI9GF]+LH%$C$)"&,@XD(""%,"2!(D $H?02$P93*V M._1I6I[;^*R+]]99>IG2S[9H[P8Q2?T8$RR B# 'D"/%:!*%(!$A@Y@IW.+( MJN[Q(,0F*W=X:Z/6IJ&Y_X#&G/ MIL/#H?T'!@:0:X]'NTVYN%/?9/8DMD7./XKRD[PAWX\>MG\F^E/>A,1(&/LB MA0C$R,< )JFO[VYSX*.4P22&V ^D5:BY&[WF1IOUVHUU[?*6RJ2_6H:F.^HU M,R9Y@;X8F8?J;M@QR:MM\G[45OUTY2G#]):E,NWJ9$!3;=\H\4N.,7<:3>]( MM6GC[MWB>1"A[[CY"\B\@;9\ZW*K]@#:/8XOI$' 1(@4H&H25#.>#S"A' 0QC''@ MJW5!0!=/(J?K:1'NBORS8VPQ6UV,VR034$?+J@SWK35Z%]#R_6J_X5QW3T\3Y MW%.1+QC#(>2I! $+4P #[ .2"H6PSS&2/$Y)8A5NV2]N;E32ZNII9>VXXPRN M9N3A#JV1V>.WK]X.5MY65^];K:W#-:P9+"X9Y(S$22G$S/I]#C%\:V!V1OX? MCT5=W_!F??7Z\_O75\?#>+91"-45R;PZ,9/KO#H$\3HV.IUNR;&,9B M[U=/:C2N\^>/HESX/@N@3%,0XT MO$.L"_=$ 1 IHRA"-.$^MJ&I;N-SXZ%6 MMVJ[>M63$

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�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end